



GOLD KIDNEY HEALTH PLAN

Gold Kidney Health Plan **2025 Formulary**

List of Covered Drugs or “Drug List”

PLEASE READ

This document contains information about the drugs we cover in this plan.

Formulary ID: 25216

H4869-001 Gold Kidney of Arizona Gold Heart & Diabetes (HMO-POS C-SNP)

H4869-003 Gold Kidney of Arizona Gold Dialysis (HMO-POS C-SNP)

H4869-011 Gold Kidney of Arizona Gold Heart & Diabetes (HMO-POS C-SNP)

H4869-013 Gold Kidney of Arizona Gold Dialysis (HMO-POS C-SNP)

This formulary was updated on 10/01/2025. For more recent information or other questions, please contact Gold Kidney Health Plan Member Services at **1 (844) 294-6535 (TTY users should call 711)**. Our office hours are 8 a.m. to 8 p.m., local time, 7 days a week from October 1 – March 31 (except holidays), and 8 a.m. to 8 p.m., local time, Monday through Friday, April 1 – September 30 (except holidays), or visit www.goldkidney.com.

Note to existing members – This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to “we,” “us”, or “our,” it means Gold Kidney Health Plan. When it refers to “plan” or “our plan,” it means Gold Kidney Health Plan.

This document includes Drug List (formulary) for our plan which is current as of 10/01/2025. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2025, and from time to time during the year.

What is the Gold Kidney Health Plan Formulary?

In this document, we use the terms Drug List and formulary to mean the same thing. A formulary is a list of covered drugs selected by Gold Kidney Health Plan in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Gold Kidney Health Plan will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at a Gold Kidney Health Plan network pharmacy, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the Formulary change?

Most changes in drug coverage happen on January 1, but Gold Kidney Health Plan may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow the Medicare rules in making these changes.

Changes that can affect you this year – In the below cases, you will be affected by coverage changes during the year:

-  **Immediate substitutions of certain new versions of brand name drugs and biological products.** We may immediately remove a brand-name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost-sharing tier and with the same or fewer restrictions. When we add a new version of a drug to our formulary, we may decide to keep the brand-name drug or original biological product on our formulary, but immediately move it to a different cost- sharing tier or add new restrictions.

We can make these immediate changes only if we are adding a new generic version of a brand name drug, or adding certain new biosimilar versions of an original biological product, that was

already on the formulary (for example, adding an interchangeable biosimilar that can be substituted for an original biological product by a pharmacy without a new prescription).

If you are currently taking the brand name drug or original biological product, we may not tell you in advance before we make an immediate change, but we will later provide you with information about the specific change(s) we have made.

- If we make such a change, you or your prescriber can ask us to make an exception and continue to cover for you the drug that is being changed. For more information, see the section below titled “How do I request an exception to the Gold Kidney Health Plan’s Formulary?”
- Some of these drug types may be new to you. For more information, see the section below titled “What are original biological products and how are they related to biosimilars?”

✓ Drugs removed from the market. If a drug is withdrawn from sale by the manufacturer or the Food and Drug Administration determines to be withdrawn for safety or effectiveness reasons, we may immediately remove the drug from our formulary and later provide notice to members who take the drug.

✓ **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may remove a brand name drug from the formulary when adding a generic equivalent or remove an original biological product when adding a biosimilar. We may also apply new restrictions to the brand name drug or original biological product, or move it to a different cost-sharing tier, or both. We may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective. Alternatively, when a member requests a refill of the drug, they may receive a 30-day supply of the drug and notice of the change.

- If we make these other changes, you or your prescriber can ask us to make an exception for you and continue to cover the drug you have been taking. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Gold Kidney Health Plan’s Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2025 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2025 coverage year except as described above. This means these drugs will remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year. You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of 10/01/2025. To get updated information about the drugs covered by Gold Kidney Health Plan please contact us. Our contact information appears on the front

and back cover pages. If non-maintenance changes are made to the formulary during the plan year, changes to the Gold Kidney Health Plan formulary are posted on our website at www.goldkidney.com.

How do I use the formulary?

There are two ways to find your drug within the formulary:

MEDICAL CONDITION

The formulary begins on page 1. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, Cardiovascular Agents. If you know what your drug is used for, look for the category name in the list that begins on page 1. Then look under the category name for your drug.

ALPHABETICAL LISTING

If you are not sure what category to look under, you should look for your drug in the Index that begins on page I-1. The Index provides an alphabetical list of all of the drugs included in this document. Both brand-name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Gold Kidney Health Plan covers both brand-name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand-name drug. Generally, generic drugs work just as well as and usually cost less than brand name drugs. There are generic drug substitutes available for many brand name drugs. Generic drugs usually can be substituted for the brand name drug at the pharmacy without needing a new prescription, depending on state laws.

What are original biological products and how are they related to biosimilars?

On the formulary, when we refer to drugs, this could mean a drug or a biological product. Biological products are drugs that are more complex than typical drugs. Since biological products are more complex than typical drugs, instead of having a generic form, they have alternatives that are called biosimilars. Generally, biosimilars work just as well as the original biological product and may cost less. There are biosimilar alternatives for some original biological products. Some biosimilars are interchangeable biosimilars and, depending on state laws, may be substituted for the original biological product at the pharmacy without needing a new prescription, just like generic drugs can be substituted for brand name drugs.

- ✓ For discussion of drug types, please see the Evidence of Coverage, Chapter 5, Section 3.1, “The ‘Drug List’ tells which Part D drugs are covered.”

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- ✓ **Prior Authorization.** Gold Kidney Health Plan requires you or your prescriber to get prior authorization for certain drugs. This means that you will need to get approval from Gold Kidney Health Plan before you fill your prescriptions. If you don't get approval, Gold Kidney Health Plan may not cover the drug.
- ✓ **Quantity Limits.** For certain drugs, Gold Kidney Health Plan limits the amount of the drug that Gold Kidney Health Plan will cover. For example, Gold Kidney Health Plan provides 30 per prescription for Farxiga 10mg tablets. This may be in addition to a standard one-month or three-month supply.
- ✓ **Step Therapy.** In some cases, Gold Kidney Health Plan requires you to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, Gold Kidney Health Plan may not cover Drug B unless you try Drug A first. If Drug A does not work for you, Gold Kidney Health Plan will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 1. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online documents that explain our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask Gold Kidney Health Plan to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Gold Kidney Health Plan's formulary?" on page vi for information about how to request an exception.

What if my drug is not on the formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Member Services and ask if your drug is covered.

If you learn that Gold Kidney Health Plan does not cover your drug, you have two options:

- ✓ You can ask Member Services for a list of similar drugs that are covered by Gold Kidney Health Plan. When you receive the list, show it to your doctor and ask them to prescribe a similar drug that is covered by Gold Kidney Health Plan.
- ✓ You can ask Gold Kidney Health Plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Gold Kidney Health Plan's formulary?

You can ask Gold Kidney Health Plan to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- ✓ You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- ✓ You can ask us to cover a formulary drug at lower cost-sharing level unless the drug is on the specialty tier. If approved, this would lower the amount you must pay for your drug.
- ✓ You can ask us to waive a coverage restriction including prior authorization, step therapy, or a quantity limit on your drug. For example, for certain drugs, Gold Kidney Health Plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, Gold Kidney Health Plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug, or additional utilization restrictions would not be as effective for you and/or would cause you to have adverse effects.

You or your prescriber should contact us to ask us for an initial coverage decision for a tiering or formulary exception, including an exception to a coverage restriction. **When you request an exception, your prescriber will need to explain the medical reasons why you need the exception.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can ask for an expedited (fast) exception if you believe, and we agree, that your health could be seriously harmed by waiting up to 72 hours for a decision. If we agree, or if your prescriber asks for a fast decision, we must give you a decision no later than 24 hours after we get your prescriber's supporting statement.

What can I do if my drug is not on the formulary or has a restriction?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or, you may be taking a drug that is on our formulary but has a coverage restriction, such as prior authorization. You should talk to your prescriber about requesting a coverage decision to show that you meet the criteria for approval, switching to an alternative drug that we cover, or requesting a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 30-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 30-day supply of medication. If coverage is not approved, after your first 30-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care (LTC) facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

For members with a level-of-care change, we provide an emergency 30-day supply as follows:

- ✓ Current members that need a one-time emergency fill or that are prescribed a non-formulary drug as a result of a level-of-care change can be placed in transition through a pharmacy submitted clarification code. Gold Kidney Health Plan has authorized its Pharmacy Benefit Manager to process a one-time fill in this situation through a manual override at the pharmacy point-of-sale.
- ✓ When a new claim transaction is received from the pharmacy for a member's admission or readmission into a long-term care (LTC) facility, our claims system will recognize the current member as being eligible to receive transition supplies and will apply the point-of-sale approval.

For more information

For more detailed information about your Gold Kidney Health Plan prescription drug coverage, please review your Evidence of Coverage and other plan materials. If you have questions about Gold Kidney Health Plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day/7 days a week. TTY users should call 1-877-486-2048. Or, visit <http://www.medicare.gov>.

Gold Kidney Health Plan

Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by Gold Kidney Health Plan. If you have trouble finding your drug in the list, turn to the Index that begins on page I-1.

The first column of the chart lists the drug name. Brand-name drugs are capitalized (e.g., FARXIGA) and generic drugs are listed in lower-case italics (e.g., *simvastatin*).

The information in the Requirements/Limits column tells you if Gold Kidney Health Plan has any special requirements for coverage of your drug.

Drug List Legend

| REQUIREMENTS SYMBOL | NAME | DESCRIPTION |
|------------------------|--|--|
| BvD | Medicare Part B vs. Medicare Part D | Some drugs may require Part B or Part D coverage determination, based on Medicare coverage rules. |
| EX | Excluded Drug | This prescription drug is not normally covered in a Medicare Prescription Drug Plan. The amount you pay when you fill a prescription for this drug does not count towards your total drug costs (that is, the amount you pay does not help you qualify for catastrophic coverage). In addition, if you are receiving extra help to pay for your prescriptions, you will not get any extra help to pay for this drug. |
| LA | Limited Access | This prescription may be available only at certain pharmacies. For more information, consult your Pharmacy Directory or call Member Services at 1 (844) 294-6535 (TTY: 711), 8 a.m. to 8 p.m., seven days a week, from October 1 through March 31 (except holidays), and 8 a.m. to 8 p.m., weekdays, from April 1 through September 30 (except holidays), or visit goldkidney.com. |
| NDS | Non-Extended Days Supply | This drug can only be obtained for a one-month supply or less. |
| NM | Not Available by Mail | This drug is not available through the mail order pharmacy. |
| NSO | New Start Only | If you have not taken this drug before you or your physician are required to get prior authorization. |
| PA | Prior Authorization | Coverage for this prescription requires prior authorization. |
| QL | Quantity Limit | This medication has a dosing or prescription quantity limit. |
| ST | Step Therapy | Coverage for this prescription is provided when other first-line or preferred drug therapies have been tried. |

2025 Dosage Form Abbreviations

| Dosage Form Abbreviation | Definition |
|--------------------------|---------------------------|
| 8 hr | 8 hour |
| 12 hr | 12 hour |
| 24 hr | 24 hour |
| 72 hr | 72 hour |
| act | activated |
| aero | aerosol |
| admin | administration |
| ampul | ampule |
| app | applicator |
| appl | applicator |
| auto | automatic |
| cap | capsule |
| chew | chewable |
| CT | count |
| comb | combo |
| del | delayed |
| delayed | delayed |
| disinteg | disintegrating |
| disintegrat | disintegrating |
| dose | dosage |
| DR | delayed release |
| EC | Enteric-Coated |
| emolnt | emollient |
| ENFit | enteral feeding connector |
| er | extended release |
| ER | extended release |
| ext | extended |
| extnd | extended |
| extend | extended |
| gast | gastric |

| Dosage Form Abbreviation | Definition |
|--------------------------|-----------------------------------|
| HFA | hydrofluoroalkane |
| hi | high |
| IR | immediate release |
| liqd | liquid |
| loz | lozenge |
| lozeng | lozenge |
| mini lozenge | miniature lozenge |
| misc | miscellaneous |
| MP | Metered Pump |
| muco | mucous |
| pak | packet |
| Pack | packet |
| PCA | Patient Controlled Administration |
| pell | pellet |
| pk | package |
| Powdr | powder |
| pt | patient |
| recon | reconstituted |
| rel | release |
| releas | release |
| soln | solution |
| sprinkl | sprinkle |
| susp | suspension |
| suspen | suspension |
| syring | syringe |
| tab | tablet |
| TD | transdermal |
| var | variable |
| w/ | with |

Drug Cost Shares (Table 1)

H4869-001 Gold Kidney of Arizona Gold Heart & Diabetes (HMO-POS C-SNP)

H4869-011 Gold Kidney of Arizona Gold Heart & Diabetes (HMO-POS C-SNP)

Initial Coverage

You stay in the Initial Coverage Stage until you have paid \$2,000 out of pocket for Part D drugs, you will move to the next stage (the Catastrophic Coverage Stage).

| Deductible | Pharmacy Type/ Days Supply | Tier 1 Preferred Generic | Tier 2 Generics | Tier 3 Preferred Brand | Tier 4 Non-Preferred Brand | Tier 5 Specialty Tier | Tier 6 Select Diabetic Drugs |
|------------|------------------------------|--------------------------|-----------------|------------------------|----------------------------|-----------------------|------------------------------|
| | Standard Retail | \$0 | \$0 | \$40 | \$100 | 33% | \$0 |
| | 30-day supply | | | | | | |
| | Long-term | \$0 | \$0 | \$40 | \$100 | 33% | \$0 |
| | Care 31-day supply | | | | | | |
| \$0 | | | | | | | |
| | Out-of-network 30-day supply | \$0 | \$0 | \$40 | \$100 | 33% | \$0 |
| | | | | | | | |
| | Insulins | N/A | N/A | N/A | N/A | N/A | \$0 |
| | Retail | \$0 | \$0 | \$100 | \$250 | N/A | \$0 |
| \$0 | 100-day supply | | | | | | |
| | Insulins | N/A | N/A | N/A | N/A | N/A | \$0 |
| | Mail order | \$0 | \$0 | \$40 | \$250 | N/A | \$0 |
| \$0 | 100-day supply | | | | | | |
| | Insulins | N/A | N/A | N/A | N/A | N/A | \$0 |

Catastrophic Coverage Stage

You enter the Catastrophic Coverage Stage when your out-of-pocket costs have reached the \$2,000 limit for the calendar year. Once you are in the Catastrophic Coverage Stage, you will stay in this payment stage until the end of the calendar year. During this stage, you pay nothing for Part D drugs.

Drug Cost Shares (Table 2)

H4869-003 Gold Kidney of Arizona Gold Dialysis (HMO-POS C-SNP)

H4869-013 Gold Kidney of Arizona Gold Dialysis (HMO-POS C-SNP)

Initial Coverage

You stay in the Initial Coverage Stage until you have paid \$2,000 out of pocket for Part D drugs, you will move to the next stage (the Catastrophic Coverage Stage).

| Deductible | Pharmacy Type/ Days Supply | Tier 1 Preferred Generic | Tier 2 Generics | Tier 3 Preferred Brand | Tier 4 Non-Preferred Brand | Tier 5 Specialty Tier | Tier 6 Select Diabetic Drugs |
|------------|----------------------------|--------------------------|-----------------|------------------------|----------------------------|-----------------------|------------------------------|
| | Standard | \$0 | \$5 | \$47 | \$100 | 33% | \$0 |
| | Retail | | | | | | |
| | 30-day supply | | | | | | |
| | Long-term | \$0 | \$5 | \$47 | \$100 | 33% | \$0 |
| \$0 | Care | | | | | | |
| | 31-day supply | | | | | | |
| | Out-of-network | \$0 | \$5 | \$47 | \$100 | 33% | \$0 |
| | 30-day supply | | | | | | |
| | Insulins | N/A | N/A | N/A | N/A | N/A | \$0 |
| | Retail | \$0 | \$12 | \$117 | \$250 | N/A | \$0 |
| \$0 | 100-day supply | | | | | | |
| | Insulins | N/A | N/A | N/A | N/A | N/A | \$0 |
| | Mail order | \$0 | \$5 | \$40 | \$250 | N/A | \$0 |
| \$0 | 100-day supply | | | | | | |
| | Insulins | N/A | N/A | N/A | N/A | N/A | \$0 |

Catastrophic Coverage Stage

You enter the Catastrophic Coverage Stage when your out-of-pocket costs have reached the \$2,000 limit for the calendar year. Once you are in the Catastrophic Coverage Stage, you will stay in this payment stage until the end of the calendar year. During this stage, you pay nothing for Part D drugs.

Notice of Non-Discrimination

Gold Kidney Health Plan complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex (including pregnancy, sexual orientation, and gender identity). Gold Kidney Health Plan does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex (including pregnancy, sexual orientation, and gender identity).

GOLD KIDNEY HEALTH PLAN

- Provides free aids and services to people with disabilities to communicate effectively with us, such as:
 - Qualified sign language interpreters
 - Written information in other formats (large print, audio, accessible electronic formats, other formats)
- Provides free language services to people whose primary language is not English, such as:
 - Qualified interpreters
 - Information written in other languages

If you need these services, contact Customer Service at 1 (844) 294-6535 (TTY 711)

If you believe that Gold Kidney Health Plan has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex (including pregnancy, sexual orientation, and gender identity), you can file a grievance with:

Gold Kidney Health Plan — Appeals & Grievances
P.O. Box 285, Portsmouth, NH, 03802
1 (844) 294-6535 (TTY 711)

Fax: 1 (888) 991-0047
Attention: Gold Kidney Appeals & Grievances Department

You can file a grievance in person, by mail, or fax. If you need help filing a grievance, call 1 (844) 294-6535 (TTY 711).

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at <https://ocrportal.hhs.gov/ocr/portal/lobby.jsf>, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1 (800) 368-1019, 1 (800) 537-7697 (TDD)

Complaint forms are available at <https://www.hhs.gov/ocr/index.html>

**Multi-Language Insert
Multi-language Interpreter Services**

English: We have free interpreter services to answer any questions you may have about our health or drug plan. To get an interpreter, just call us at **1 (844) 294-6535**. Someone who speaks English can help you. This is a free service.

Spanish: Tenemos servicios de intérprete sin costo alguno para responder cualquier pregunta que pueda tener sobre nuestro plan de salud o medicamentos. Para hablar con un intérprete, por favor llame al **1 (844) 294-6535**. Alguien que hable español le podrá ayudar. Este es un servicio gratuito.

Chinese Mandarin: 我们提供免费的翻译服务，帮助您解答关于健康或药物保险的任何疑问。如果您需要此翻译服务，请致电 **1 (844) 294-6535**。我们的中文工作人员很乐意帮助您。这是一项免费服务。

Chinese Cantonese: 您對我們的健康或藥物保險可能存有疑問，為此我們提供免費的翻譯服務。如需翻譯服務，請致電 **1 (844) 294-6535**。我們講中文的人員將樂意為您提供幫助。這是一項免費服務。

Tagalog: Mayroon kaming libreng serbisyo sa pagsasaling-wika upang masagot ang anumang mga katanungan ninyo hinggil sa aming planong pangkalusugan o panggamot. Upang makakuha ng tagasaling-wika, tawagan lamang kami sa **1 (844) 294-6535**. Maaari kayong tulungan ng isang nakakapagsalita ng Tagalog. Ito ay libreng serbisyo.

French: Nous proposons des services gratuits d'interprétation pour répondre à toutes vos questions relatives à notre régime de santé ou d'assurance-médicaments. Pour accéder au service d'interprétation, il vous suffit de nous appeler au **1 (844) 294-6535**. Un interlocuteur parlant Français pourra vous aider. Ce service est gratuit.

Vietnamese: Chúng tôi có dịch vụ thông dịch miễn phí để trả lời các câu hỏi về chương sức khỏe và chương trình thuốc men. Nếu quý vị cần thông dịch viên xin gọi **1 (844) 294-6535** sẽ có nhân viên nói tiếng Việt giúp đỡ quý vị. Đây là dịch vụ miễn phí.

German: Unser kostenloser Dolmetscherservice beantwortet Ihren Fragen zu unserem Gesundheits- und Arzneimittelplan. Unsere Dolmetscher erreichen Sie unter **1 (844) 294-6535**. Man wird Ihnen dort auf Deutsch weiterhelfen. Dieser Service ist kostenlos.

Korean: 당사는 의료 보험 또는 약품 보험에 관한 질문에 답해 드리고자 무료 통역 서비스를 제공하고 있습니다. 통역 서비스를 이용하려면 전화 **1 (844) 294-6535** 번으로 문의해 주십시오. 한국어를 하는 담당자가 도와 드릴 것입니다. 이 서비스는 무료로 운영됩니다.

Russian: Если у вас возникнут вопросы относительно страхового или медикаментного плана, вы можете воспользоваться нашими бесплатными услугами переводчиков. Чтобы воспользоваться услугами переводчика, позвоните нам по телефону **1 (844) 294-6535**. Вам окажет помощь сотрудник, который говорит по-русски. Данная услуга бесплатная.

Arabic: إننا نقدم خدمات المترجم الفوري المجانية للإجابة عن أي أسئلة تتعلق بالصحة أو جدول الأدوية لدينا. للحصول على مترجم فوري، ليس عليك سوى الاتصال بنا على **1 (844) 294-6535**. سيقوم شخص ما يتحدث العربية بمساعدتك. هذه خدمة مجانية.

Hindi: हमारे स्वास्थ्य या दवा की योजना के बारे में आपके किसी भी प्रश्न के जवाब देने के लिए हमारे पास मुफ्त दुभाषिया सेवाएँ उपलब्ध हैं। एक दुभाषिया प्राप्त करने के लिए, बस हमें **1 (844) 294-6535** पर फोन करें। कोई व्यक्ति जो हिन्दी बोलता है आपकी मदद कर सकता है। यह एक मुफ्त सेवा है।

Italian: È disponibile un servizio di interpretariato gratuito per rispondere a eventuali domande sul nostro piano sanitario e farmaceutico. Per un interprete, contattare il numero **1 (844) 294-6535**. Un nostro incaricato che parla Italiano fornirà l'assistenza necessaria. È un servizio gratuito.

Portuguese: Dispomos de serviços de interpretação gratuitos para responder a qualquer questão que tenha acerca do nosso plano de saúde ou de medicação. Para obter um intérprete, contacte-nos através do número **1 (844) 294-6535**. Irá encontrar alguém que fale o idioma Português para o ajudar. Este serviço é gratuito.

French Creole: Nou genyen sèvis entèprèt gratis pou reponn tout kesyon ou ta genyen konsènan plan medikal oswa dwòg nou an. Pou jwenn yon entèprèt, jis rele nou nan **1 (844) 294-6535**. Yon moun ki pale Kreyòl kapab ede w. Sa a se yon sèvis ki gratis.

Polish: Umożliwiamy bezpłatne skorzystanie z usług tłumacza ustnego, który pomoże w uzyskaniu odpowiedzi na temat planu zdrowotnego lub dawkowania leków. Aby skorzystać z pomocy tłumacza znającego język polski, należy zadzwonić pod numer **1 (844) 294-6535**. Ta usługa jest bezpłatna.

Japanese: 当社の健康 健康保険と薬品 処方薬プランに関するご質問にお答えするため、無料の通訳サービスがありますございます。通訳をご用命になるには、**1 (844) 294-6535** にお電話ください。日本語を話す人 者が支援いたします。これは無料のサービスです。

Table of Contents

| | |
|--|-----|
| Analgesics | 3 |
| Anesthetics | 8 |
| Anti-Addiction/Substance Abuse Treatment Agents | 8 |
| Antianxiety Agents | 9 |
| Antibacterials | 11 |
| Anticancer Agents | 20 |
| Anticonvulsants | 40 |
| Antidementia Agents | 46 |
| Antidepressants | 47 |
| Antidiabetic Agents | 51 |
| Antifungals | 57 |
| Antigout Agents | 59 |
| Antihistamines | 59 |
| Anti-Infectives (Skin And Mucous Membrane) | 60 |
| Antimigraine Agents | 60 |
| Antimycobacterials | 62 |
| Antinausea Agents | 63 |
| Antiparasite Agents | 64 |
| Antiparkinsonian Agents | 65 |
| Antipsychotic Agents | 67 |
| Antivirals (Systemic) | 74 |
| Blood Products/Modifiers/Volume Expanders | 82 |
| Caloric Agents | 86 |
| Cardiovascular Agents | 87 |
| Central Nervous System Agents | 100 |
| Contraceptives | 105 |
| Dental And Oral Agents | 116 |
| Dermatological Agents | 117 |
| Devices | 123 |
| Enzyme Cofactors/Chaperones | 171 |
| Enzyme Replacement/Modifiers | 171 |
| Eye, Ear, Nose, Throat Agents | 173 |
| Gastrointestinal Agents | 177 |
| Genitourinary Agents | 182 |
| Heavy Metal Antagonists | 183 |
| Hormonal Agents, Stimulant/Replacement/Modifying | 183 |
| Immunological Agents | 190 |
| Inflammatory Bowel Disease Agents | 204 |

| | |
|---------------------------------------|-----|
| Metabolic Bone Disease Agents..... | 205 |
| Miscellaneous Therapeutic Agents..... | 206 |
| Ophthalmic Agents..... | 209 |
| Replacement Preparations..... | 210 |
| Respiratory Tract Agents..... | 212 |
| Skeletal Muscle Relaxants..... | 217 |
| Sleep Disorder Agents..... | 218 |
| Vasodilating Agents..... | 218 |
| Vitamins And Minerals..... | 219 |

| Drug Name | Drug Tier | Requirements/Limits | |
|---|-------------------------------|----------------------------|----------------------|
| Analgesics | | | |
| Analgesics, Miscellaneous | | | |
| <i>acetaminophen-codeine 120-12 mg/5 ml cup inner 120 mg-12 mg /5 ml (5 ml)</i> | 1 | QL (4500 per 30 days) | |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 1 | QL (4500 per 30 days) | |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 2 | QL (360 per 30 days) | |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 2 | QL (180 per 30 days) | |
| <i>ascomp with codeine oral capsule 30-50-325-40 mg</i> | (codeine-butalbital-asa-caff) | 2 | QL (180 per 30 days) |
| <i>buprenorphine transdermal patch weekly 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour</i> | (Butrans) | 2 | QL (4 per 28 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg</i> | (Fioricet with Codeine) | 2 | QL (180 per 30 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | | 2 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i> | (Tencon) | 2 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral capsule 50-300-40 mg</i> | (Fioricet) | 2 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral capsule 50-325-40 mg</i> | | 2 | QL (180 per 30 days) |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | | 2 | QL (180 per 30 days) |
| <i>butalbital-aspirin-caffeine oral capsule 50-325-40 mg</i> | | 2 | QL (180 per 30 days) |
| <i>butorphanol nasal spray,non-aerosol 10 mg/ml</i> | | 2 | QL (5 per 28 days) |
| <i>codeine sulfate oral tablet 15 mg, 60 mg</i> | 4 | QL (180 per 30 days) | |
| <i>codeine sulfate oral tablet 30 mg</i> | | 2 | QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|---------------------------------|------------------|-----------------------------------|
| <i>codeine-butalbital-asa-caff oral capsule 30-50-325-40 mg</i> | (Ascomp with Codeine) | 2 | QL (180 per 30 days) |
| <i>endocet oral tablet 10-325 mg</i> | (oxycodone-acetaminophen) | 2 | QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> | (oxycodone-acetaminophen) | 2 | QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> | (oxycodone-acetaminophen) | 2 | QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | | 5 | PA; NM; NDS; QL (120 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | | 2 | PA; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | | 2 | QL (10 per 30 days) |
| <i>fioricet oral capsule 50-300-40 mg</i> | (butalbital-acetaminophen-caff) | 2 | QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 10-300 mg/15 ml, 10-325 mg/15 ml, 7.5-325 mg/15 ml</i> | | 2 | QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 7.5-300 mg, 7.5-325 mg</i> | | 2 | QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-300 mg, 5-325 mg</i> | | 2 | QL (240 per 30 days) |
| <i>hydrocodone-ibuprofen oral tablet 10-200 mg, 5-200 mg, 7.5-200 mg</i> | | 2 | QL (150 per 30 days) |
| <i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i> | | 2 | |
| <i>hydromorphone oral liquid 1 mg/ml</i> | (Dilaudid) | 2 | QL (1200 per 30 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> | (Dilaudid) | 2 | QL (180 per 30 days) |
| <i>methadone oral solution 10 mg/5 ml</i> | | 2 | QL (600 per 30 days) |
| <i>methadone oral solution 5 mg/5 ml</i> | | 2 | QL (1200 per 30 days) |
| <i>methadone oral tablet 10 mg</i> | | 2 | QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>methadone oral tablet 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 2 | PA; QL (180 per 30 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | 2 | QL (700 per 30 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | QL (300 per 30 days) |
| MORPHINE ORAL TABLET 15 MG | 4 | QL (180 per 30 days) |
| MORPHINE ORAL TABLET 30 MG | 4 | QL (120 per 30 days) |
| <i>morphine oral tablet extended release 100 mg, 200 mg</i> | 2 | QL (60 per 30 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg</i> | (MS Contin) 2 | QL (90 per 30 days) |
| <i>morphine oral tablet extended release 60 mg</i> | (MS Contin) 2 | QL (60 per 30 days) |
| <i>oxycodone oral capsule 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone oral concentrate 20 mg/ml</i> | 2 | PA; QL (120 per 30 days) |
| <i>oxycodone oral solution 5 mg/5 ml</i> | 2 | QL (1300 per 30 days) |
| <i>oxycodone oral tablet 10 mg, 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone oral tablet 15 mg, 30 mg</i> | (Roxicodone) 2 | QL (120 per 30 days) |
| <i>oxycodone oral tablet 20 mg</i> | 2 | QL (120 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet (Endocet) 10-325 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet (Endocet) 2.5-325 mg, 5-325 mg</i> | 2 | QL (360 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet (Endocet) 7.5-325 mg</i> | 2 | QL (240 per 30 days) |
| <i>oxymorphone oral tablet 10 mg</i> | 2 | QL (120 per 30 days) |
| <i>oxymorphone oral tablet 5 mg</i> | 2 | QL (180 per 30 days) |
| <i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg</i> | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|---------------------------------|------------------|-----------------------------------|
| <i>tencon oral tablet 50-325 mg</i> | (butalbital-acetaminophen) | 2 | QL (180 per 30 days) |
| <i>tramadol oral tablet 50 mg</i> | | 1 | QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet 37.5-325 mg</i> | | 2 | QL (300 per 30 days) |
| <i>zebutal oral capsule 50-325-40 mg</i> | (butalbital-acetaminophen-caff) | 2 | QL (180 per 30 days) |
| Nonsteroidal Anti-Inflammatory Agents | | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> | (Celebrex) | 2 | QL (60 per 30 days) |
| <i>diclofenac epolamine transdermal patch 12 hour 1.3 %</i> | (Flector) | 4 | PA; QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> | | 2 | |
| <i>diclofenac sodium oral tablet,delayed release (dr/ec) 25 mg</i> | | 2 | |
| <i>diclofenac sodium oral tablet,delayed release (dr/ec) 50 mg</i> | | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet,delayed release (dr/ec) 75 mg</i> | | 2 | QL (60 per 30 days) |
| <i>diclofenac sodium topical drops 1.5 %</i> | | 2 | QL (300 per 30 days) |
| <i>diclofenac sodium topical gel 1 %</i> | (Arthritis Pain (diclofenac)) | 2 | QL (1000 per 30 days) |
| <i>diclofenac sodium topical gel 3 %</i> | | 2 | PA; QL (100 per 28 days) |
| <i>diclofenac sodium topical solution in metered-dose pump 20 mg/gram /actuation(2 %)</i> | (Pennsaid) | 5 | PA; NM; NDS; QL (224 per 28 days) |
| <i>diclofenac-misoprostol oral tablet,ir,delayed rel,biphasic 50-200 mg-mcg</i> | (Arthrotec 50) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------|------------------|----------------------------|
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 75-200 mg-mcg</i> | (Arthrotec 75) | 2 | |
| <i>disflunisal oral tablet 500 mg</i> | | 2 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | | 2 | |
| <i>etodolac oral tablet 400 mg</i> | (Lodine) | 2 | |
| <i>etodolac oral tablet 500 mg</i> | | 2 | |
| <i>fenoprofen oral tablet 600 mg</i> | (Nalfon) | 2 | |
| <i>flurbiprofen oral tablet 100 mg</i> | (Lurbiro) | 2 | |
| <i>ibu oral tablet 400 mg</i> | (ibuprofen) | 1 | QL (240 per 30 days) |
| <i>ibu oral tablet 600 mg, 800 mg</i> | (ibuprofen) | 1 | |
| <i>ibuprofen oral suspension 100 mg/5 ml</i> | (Children's Advil) | 2 | |
| <i>ibuprofen oral tablet 400 mg</i> | (IBU) | 1 | QL (240 per 30 days) |
| <i>ibuprofen oral tablet 600 mg, 800 mg</i> | (IBU) | 1 | |
| <i>ibuprofen-famotidine oral tablet 800-26.6 mg</i> | | 2 | PA; QL (90 per 30 days) |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | | 2 | |
| <i>indomethacin oral capsule, extended release 75 mg</i> | | 2 | |
| <i>ketoprofen oral capsule, ext rel. pellets 24 hr 200 mg</i> | | 2 | |
| <i>ketorolac oral tablet 10 mg</i> | | 2 | QL (20 per 30 days) |
| <i>mefenamic acid oral capsule 250 mg</i> | | 2 | |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | | 1 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | | 2 | |
| <i>naproxen oral tablet 250 mg, 375 mg</i> | | 1 | |
| <i>naproxen oral tablet 500 mg</i> | (Naprosyn) | 1 | |
| <i>naproxen oral tablet, delayed release (dr/ec) 375 mg, 500 mg</i> | (EC-Naprosyn) | 2 | |
| <i>piroxicam oral capsule 10 mg</i> | | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------|------------------|----------------------------|
| <i>piroxicam oral capsule 20 mg</i> | (Feldene) | 2 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | | 2 | |
| Anesthetics | | | |
| Local Anesthetics | | | |
| <i>dermacinx lidocan 5% patch outer</i> | (lidocaine) | 2 | PA; QL (90 per 30 days) |
| <i>glydo mucous membrane jelly in applicator 2 %</i> | (lidocaine hcl) | 2 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane jelly in applicator 2 %</i> | (Glydo) | 2 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | | 2 | PA |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> | (DermacinRx Lidocan) | 2 | PA; QL (90 per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | | 2 | PA; QL (240 per 30 days) |
| <i>lidocaine viscous mucous membrane solution 2 %</i> | (lidocaine hcl) | 2 | |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | | 2 | PA; QL (30 per 30 days) |
| <i>lidocan iii topical adhesive patch,medicated 5 %</i> | (lidocaine) | 2 | PA; QL (90 per 30 days) |
| ZTLIDO TOPICAL ADHESIVE PATCH,MEDICATED 1.8 % | | 3 | PA; QL (90 per 30 days) |
| Anti-Addiction/Substance Abuse Treatment Agents | | | |
| Anti-Addiction/Substance Abuse Treatment Agents | | | |
| <i>acamprosate oral tablet,delayed release (dr/ec) 333 mg</i> | | 2 | |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | | 2 | QL (90 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 12-3 mg</i> | (Suboxone) | 2 | QL (60 per 30 days) |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg, 4-1 mg, 8-2 mg</i> | (Suboxone) | 2 | QL (90 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 2 | QL (90 per 30 days) |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 2 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 2 | |
| KLOXXADO NASAL SPRAY, NON-AEROSOL 8 MG/ACTUATION | 3 | QL (4 per 30 days) |
| <i>naloxone injection solution 0.4 mg/ml</i> | 2 | |
| <i>naloxone injection syringe 0.4 mg/ml, 0.4 mg/ml (prefilled syringe), 1 mg/ml</i> | 2 | |
| <i>naloxone nasal spray, non-aerosol 4 mg/actuation (Narcan)</i> | 2 | QL (4 per 30 days) |
| <i>naltrexone oral tablet 50 mg</i> | 2 | |
| NICOTROL INHALATION CARTRIDGE 10 MG | 4 | |
| NICOTROL NS NASAL SPRAY, NON-AEROSOL 10 MG/ML | 4 | QL (240 per 180 days) |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg (Chantix)</i> | 2 | QL (336 per 365 days) |
| <i>varenicline tartrate oral tablet 1 mg (56 pack)</i> | 2 | QL (336 per 365 days) |
| <i>varenicline tartrate oral tablets, dose pack 0.5 mg (11)- 1 mg (42) (Chantix Starting Month Box)</i> | 2 | |
| Antianxiety Agents | | |
| Benzodiazepines | | |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg (Xanax)</i> | 1 | QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg (Xanax)</i> | 1 | QL (150 per 30 days) |
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg (Xanax XR)</i> | 2 | QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------|------------------|----------------------------|
| <i>alprazolam oral tablet extended release 24 hr 3 mg</i> | (Xanax XR) | 2 | QL (90 per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | | 1 | QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> | (Klonopin) | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> | (Klonopin) | 1 | QL (300 per 30 days) |
| <i>clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | | 2 | QL (90 per 30 days) |
| <i>clonazepam oral tablet,disintegrating 2 mg</i> | | 2 | QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | | 2 | QL (180 per 30 days) |
| <i>diazepam injection solution 5 mg/ml</i> | | 2 | QL (10 per 28 days) |
| <i>diazepam injection syringe 5 mg/ml</i> | | 2 | |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> | (diazepam) | 2 | QL (1200 per 30 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | | 2 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> | (Valium) | 1 | QL (120 per 30 days) |
| <i>estazolam oral tablet 1 mg</i> | | 2 | QL (60 per 30 days) |
| <i>estazolam oral tablet 2 mg</i> | | 2 | QL (30 per 30 days) |
| <i>flurazepam oral capsule 15 mg</i> | | 2 | QL (60 per 30 days) |
| <i>flurazepam oral capsule 30 mg</i> | | 2 | QL (30 per 30 days) |
| <i>lorazepam 2 mg/ml oral concnet</i> | (Lorazepam Intensol) | 2 | QL (150 per 30 days) |
| <i>lorazepam 4 mg/ml vial inner</i> | (Ativan) | 1 | |
| <i>lorazepam injection solution 2 mg/ml</i> | (Ativan) | 1 | QL (2 per 30 days) |
| <i>lorazepam injection solution 4 mg/ml</i> | (Ativan) | 4 | QL (2 per 30 days) |
| <i>lorazepam injection syringe 2 mg/ml</i> | | 1 | QL (2 per 30 days) |
| <i>lorazepam intensol oral concentrate 2 mg/ml</i> | (lorazepam) | 2 | QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> | (Ativan) | 1 | QL (90 per 30 days) |
| <i>lorazepam oral tablet 2 mg</i> | (Ativan) | 1 | QL (150 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------------|
| <i>oxazepam oral capsule 10 mg, 15 mg, 30 mg</i> | 2 | QL (120 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> (Restoril) | 1 | QL (30 per 30 days) |
| <i>temazepam oral capsule 22.5 mg</i> (Restoril) | 2 | QL (30 per 30 days) |
| <i>temazepam oral capsule 7.5 mg</i> (Restoril) | 2 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.125 mg</i> | 2 | QL (120 per 30 days) |
| <i>triazolam oral tablet 0.25 mg</i> (Halcion) | 2 | QL (60 per 30 days) |
| Antibacterials | | |
| Aminoglycosides | | |
| <i>amikacin injection solution 500 mg/2 ml</i> | 2 | |
| <i>ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML</i> | 5 | PA; NM; NDS; QL (235.2 per 28 days) |
| <i>gentamicin injection solution 40 mg/ml</i> | 2 | |
| <i>gentamicin sulfate (ped) (pf) injection solution 20 mg/2 ml</i> | 2 | |
| <i>gentamicin sulfate (pf) intravenous solution 100 mg/10 ml, 60 mg/6 ml</i> | 2 | |
| <i>neomycin oral tablet 500 mg</i> | 2 | |
| <i>streptomycin intramuscular recon soln 1 gram</i> | 5 | NM; NDS |
| <i>TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE 28 MG</i> | 5 | NM; NDS; QL (224 per 28 days) |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> (Tobi) | 5 | PA BvD; NM; NDS |
| <i>tobramycin inhalation solution for nebulization 300 mg/4 ml</i> (Bethkis) | 5 | PA BvD; NM; NDS |
| <i>tobramycin sulfate injection solution 10 mg/ml, 40 mg/ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| Antibacterials, Miscellaneous | | |
| <i>clindamycin hcl oral capsule 150 mg, (Cleocin HCl) 300 mg, 75 mg</i> | 2 | |
| <i>clindamycin pediatric oral recon soln (clindamycin palmitate hcl) 75 mg/5 ml</i> | 2 | |
| <i>clindamycin phosphate injection solution 150 (mg/ml) (4 ml), 150 (mg/ml) (6 ml)</i> | 2 | |
| <i>clindamycin phosphate injection (Cleocin) solution 150 mg/ml</i> | 2 | |
| <i>colistin (colistimethate na) injection (Coly-Mycin M recon soln 150 mg Parenteral)</i> | 5 | NM; NDS |
| <i>daptomycin intravenous recon soln 350 mg, 500 mg</i> | 5 | NM; NDS |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i> | 2 | |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> | 5 | NM; NDS |
| <i>linezolid oral tablet 600 mg (Zyvox)</i> | 2 | |
| <i>methenamine hippurate oral tablet 1 gram</i> | 2 | |
| <i>metronidazole in nacl (iso-os) intravenous piggyback 500 mg/100 ml</i> | 2 | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i> | 2 | QL (60 per 30 days) |
| <i>polymyxin b sulfate injection recon soln 500,000 unit</i> | 2 | |
| <i>SYNERCID INTRAVENOUS RECON SOLN 500 MG</i> | 5 | NM; NDS |
| <i>trimethoprim oral tablet 100 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------------|
| <i>vancomycin intravenous recon soln 1,000 mg, 1.25 gram, 10 gram, 5 gram, 500 mg, 750 mg</i> | 2 | |
| <i>vancomycin oral capsule 125 mg (Vancocin)</i> | 2 | QL (56 per 14 days) |
| <i>vancomycin oral capsule 250 mg (Vancocin)</i> | 2 | QL (112 per 14 days) |
| <i>vancomycin oral recon soln 25 mg/ml (Firvanq)</i> | 2 | |
| XIFAXAN ORAL TABLET 200 MG | 3 | PA; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| Cephalosporins | | |
| <i>cefaclor oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cefaclor oral tablet extended release 12 hr 500 mg</i> | 2 | |
| <i>cefadroxil oral capsule 500 mg</i> | 2 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | 2 | |
| <i>cefadroxil oral tablet 1 gram</i> | 2 | |
| <i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i> | 2 | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 2 | |
| <i>cefixime oral capsule 400 mg</i> | 2 | |
| <i>cefixime oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> | 2 | |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>cefpodoxime oral suspension for reconstitution 100 mg/5 ml, 50 mg/5 ml</i> | 2 | |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i> | 2 | |
| <i>ceftazidime injection recon soln 1 gram, 2 gram, 6 gram</i> | 2 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 2 | |
| <i>cefuroxime sodium intravenous recon soln 1.5 gram, 7.5 gram</i> | 2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cephalexin oral capsule 750 mg</i> | 2 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cephalexin oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>tazicef injection recon soln 1 gram, 2 gram, 6 gram</i> | 2 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG | 5 | NM; NDS |
| Macrolides | | |
| <i>azithromycin intravenous recon soln (Zithromax) 500 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml, 200 mg/5 ml</i> (Zithromax) | 2 | |
| <i>azithromycin oral tablet 250 mg (6 pack), 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>azithromycin oral tablet 250 mg, 500 mg</i> (Zithromax) | 1 | |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>clarithromycin oral tablet extended release 24 hr 500 mg</i> | 2 | |
| DIFICID ORAL SUSPENSION FOR RECONSTITUTION 40 MG/ML | 5 | NM; NDS; QL (136 per 10 days) |
| DIFICID ORAL TABLET 200 MG (fidaxomicin) | 5 | NM; NDS; QL (20 per 10 days) |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml</i> (E.E.S. Granules) | 2 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml</i> (EryPed 400) | 2 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>fidaxomicin oral tablet 200 mg</i> (Difidid) | 5 | NM; NDS; QL (20 per 10 days) |
| Miscellaneous B-Lactam Antibiotics | | |
| <i>aztreonam injection recon soln 1 gram, 2 gram</i> (Azactam) | 2 | |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 5 | PA; NM; LA; NDS |
| <i>ertapenem injection recon soln 1 gram</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|--------------------|----------------------------|
| <i>imipenem-cilastatin intravenous recon soln 250 mg</i> | 2 | |
| <i>imipenem-cilastatin intravenous (Primaxin IV) recon soln 500 mg</i> | 2 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | 2 | |
| <i>meropenem intravenous recon soln 2 gram</i> | 4 | |
| Penicillins | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 400-57 mg/5 ml</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 250-62.5 mg/5 ml</i> | (Augmentin) | 2 |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 600-42.9 mg/5 ml</i> | (Augmentin ES-600) | 2 |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 875-125 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 500-125 mg</i> | (Augmentin) | 2 |
| <i>amoxicillin-pot clavulanate oral tablet extended release 12 hr 1,000-62.5 mg</i> | (Augmentin XR) | 2 |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 2 | |
| <i>ampicillin oral capsule 500 mg</i> | 2 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i> | 2 | |
| <i>ampicillin-sulbactam injection recon (Unasyn) soln 1.5 gram, 15 gram, 3 gram</i> | 2 | |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 4 | |
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 2 | |
| EXTENCILLINE INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT, 2.4 MILLION UNIT | 4 | |
| LETOCILIN S INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT | 4 | |
| <i>nafcillin injection recon soln 1 gram, 10 gram, 2 gram</i> | 2 | |
| <i>penicillin g potassium injection recon (Pfizerpen-G) soln 20 million unit</i> | 2 | |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml, 600,000 unit/ml</i> | 2 | |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| Quinolones | | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>ciprofloxacin hcl oral tablet 750 mg</i> | 1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |
| <i>levofloxacin in d5w intravenous piggyback 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml</i> | 2 | |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 2 | |
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>moxifloxacin 400 mg/250 ml bag suv, p/f, inner</i> | 2 | |
| <i>moxifloxacin oral tablet 400 mg</i> | 2 | |
| <i>moxifloxacin-sod.chloride(iso) intravenous piggyback 400 mg/250 ml</i> | 2 | |
| Sulfonamides | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg</i> | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 800-160 mg</i> | 1 | |
| Tetracyclines | | |
| <i>demeclocycline oral tablet 150 mg, 300 mg</i> | 2 | |
| <i>doxy-100 intravenous recon soln 100 mg</i> | 2 | |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>doxycycline hyclate oral capsule 100 mg</i> | 2 | |
| <i>doxycycline hyclate oral capsule 50 mg (Morgidox)</i> | 2 | |
| <i>doxycycline hyclate oral tablet 100 mg, 150 mg, 20 mg, 75 mg</i> | 2 | |
| <i>doxycycline hyclate oral tablet 50 mg (Targadox)</i> | 2 | |
| <i>doxycycline hyclate oral tablet,delayed release (dr/ec) 100 mg, 150 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxycycline hyclate oral tablet,delayed release (dr/ec) 200 mg (Doryx)</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 100 mg (Mondoxyne NL)</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 150 mg</i> | 2 | QL (60 per 30 days) |
| <i>doxycycline monohydrate oral capsule 50 mg</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 75 mg (Mondoxyne NL)</i> | 2 | QL (60 per 30 days) |
| <i>doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml</i> | 2 | |
| <i>doxycycline monohydrate oral tablet 100 mg (Avidoxy)</i> | 2 | |
| <i>doxycycline monohydrate oral tablet 150 mg, 50 mg, 75 mg</i> | 2 | |
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | |
| <i>minocycline oral tablet 100 mg, 50 mg, 75 mg</i> | 2 | |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>tigecycline intravenous recon soln 50 mg (Tygacil)</i> | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| Anticancer Agents | | |
| Anticancer Agents | | |
| <i>abiraterone oral tablet 250 mg</i> (Abirtega) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>abiraterone oral tablet 500 mg</i> (Zytiga) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>abirtega oral tablet 250 mg</i> (abiraterone) | 2 | PA NSO; QL (120 per 30 days) |
| <i>adrucil intravenous solution 2.5 gram/50 ml</i> (fluorouracil) | 2 | PA BvD |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)-180 MG (23) | 5 | PA NSO; NM; NDS |
| <i>anastrozole oral tablet 1 mg</i> (Arimidex) | 1 | |
| ANKTIVA INTRAVESICAL SOLUTION 400 MCG/0.4 ML | 5 | PA NSO; NM; NDS; QL (1.6 per 28 days) |
| AUGTYRO ORAL CAPSULE 160 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| AUGTYRO ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| AVMAPKI ORAL CAPSULE 0.8 MG | 5 | PA NSO; NM; NDS; QL (24 per 28 days) |
| AVMAPKI-FAKZYNJA ORAL COMBO PACK 0.8-200 MG | 5 | PA NSO; NM; NDS; QL (66 per 28 days) |
| AXTLE INTRAVENOUS RECON SOLN 100 MG, 500 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>azacitidine injection recon soln 100 mg</i> (Vidaza) | 5 | NM; NDS |
| BALVERSA ORAL TABLET 3 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| BALVERSA ORAL TABLET 4 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| <i>bendamustine intravenous recon soln 100 mg, 25 mg</i> (Treanda) | 5 | PA NSO; NM; NDS |
| BENDAMUSTINE INTRAVENOUS SOLUTION 25 MG/ML (Bendeka) | 5 | PA NSO; NM; NDS |
| BENDEKA INTRAVENOUS SOLUTION 25 MG/ML (bendamustine) | 5 | PA NSO; NM; NDS |
| <i>bexarotene oral capsule 75 mg</i> (Targretin) | 5 | PA NSO; NM; NDS |
| <i>bexarotene topical gel 1 %</i> (Targretin) | 5 | PA NSO; NM; NDS |
| <i>bicalutamide oral tablet 50 mg</i> (Casodex) | 2 | |
| BIZENGRI INTRAVENOUS SOLUTION 375 MG/18.75 ML (20 MG/ML) | 5 | PA NSO; NM; NDS; QL (75 per 28 days) |
| <i>bleomycin injection recon soln 15 unit, 30 unit</i> | 2 | |
| <i>bortezomib injection recon soln 1 mg, 2.5 mg</i> | 4 | PA NSO |
| <i>bortezomib injection recon soln 3.5 mg</i> (Velcade) | 4 | PA NSO |
| BORUZU INJECTION SOLUTION 2.5 MG/ML | 4 | PA NSO |
| BOSULIF ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| BOSULIF ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| BRUKINSA ORAL TABLET 160 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 100 MG (vandetanib) | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 MG (vandetanib) | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>carboplatin intravenous solution 10 mg/ml</i> | 2 | |
| <i>cladribine intravenous solution 10 mg/10 ml</i> | 2 | PA BvD |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 60 MG/DAY (20 MG X 3/DAY) | 5 | PA NSO; NM; NDS |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA NSO; NM; LA; NDS; QL (63 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg | 5 | PA BvD; NM; NDS |
| cyclophosphamide intravenous solution 100 mg/ml, 200 mg/ml | 5 | PA BvD; NM; NDS |
| cyclophosphamide intravenous solution 500 mg/ml (Frindovyx) | 5 | PA BvD; NM; NDS |
| cyclophosphamide oral capsule 25 mg, 50 mg | 2 | PA BvD; ST |
| cyclophosphamide oral tablet 25 mg, 50 mg | 3 | PA BvD; ST |
| DANYELZA INTRAVENOUS SOLUTION 4 MG/ML | 5 | PA NSO; NM; NDS; QL (120 per 28 days) |
| DANZITEN ORAL TABLET 71 MG, 95 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| DARZALEX FASPRO SUBCUTANEOUS SOLUTION 1,800 MG-30,000 UNIT/15 ML | 5 | PA NSO; NM; NDS |
| DARZALEX INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; LA; NDS |
| dasatinib oral tablet 100 mg, 140 mg, (Sprycel) 50 mg, 70 mg, 80 mg | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| dasatinib oral tablet 20 mg (Sprycel) | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| DATROWAY INTRAVENOUS RECON SOLN 100 MG | 5 | PA NSO; NM; NDS |
| DAURISMO ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| decitabine intravenous recon soln 50 mg | 5 | NM; NDS |
| doxorubicin, peg-liposomal intravenous suspension 2 mg/ml (Caelyx) | 5 | PA BvD; NM; NDS |
| ELAHERE INTRAVENOUS SOLUTION 5 MG/ML | 5 | PA NSO; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 4 | PA NSO |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 4 | PA NSO |
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 4 | PA NSO |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 4 | PA NSO |
| ELREXFIO 44 MG/1.1 ML VIAL INNER, SUV, P/F 40 MG/ML | 5 | PA NSO; NM; NDS |
| ELREXFIO SUBCUTANEOUS SOLUTION 40 MG/ML | 5 | PA NSO; NM; NDS; QL (9.5 per 28 days) |
| EMCYT ORAL CAPSULE 140 MG | 5 | NM; NDS |
| EMRELIS INTRAVENOUS RECON SOLN 100 MG, 20 MG | 5 | PA NSO; NM; NDS |
| EPKINLY SUBCUTANEOUS SOLUTION 4 MG/0.8 ML, 48 MG/0.8 ML | 5 | PA NSO; NM; NDS |
| ERBITUX INTRAVENOUS SOLUTION 100 MG/50 ML, 200 MG/100 ML | 5 | PA NSO; NM; NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| ERLEADA ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| <i>erlotinib oral tablet 100 mg, 25 mg</i> | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>erlotinib oral tablet 150 mg</i> | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------|------------------|---------------------------------------|
| <i>etoposide intravenous solution 20 mg/ml</i> | | 2 | |
| EULEXIN ORAL CAPSULE 125 MG | (flutamide) | 5 | NM; NDS |
| <i>everolimus (antineoplastic) oral tablet 10 mg</i> | (Torpenz) | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | (Torpenz) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> | (Afinitor Disperz) | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| <i>exemestane oral tablet 25 mg</i> | (Aromasin) | 2 | |
| FAKZYNJA ORAL TABLET 200 MG | | 5 | PA NSO; NM; NDS; QL (42 per 28 days) |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | | 5 | PA BvD; NM; NDS |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | | 3 | PA BvD |
| <i>flouxuridine injection recon soln 0.5 gram</i> | | 2 | PA BvD |
| <i>fluorouracil intravenous solution 1 gram/20 ml, 5 gram/100 ml, 500 mg/10 ml</i> | | 2 | PA BvD |
| <i>flutamide oral capsule 125 mg</i> | (Eulexin) | 2 | |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| <i>fulvestrant intramuscular syringe 250 mg/5 ml</i> | (Faslodex) | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-------------|------------------|---------------------------------------|
| FYARRO INTRAVENOUS SUSPENSION FOR RECONSTITUTION 100 MG | | 5 | PA NSO; NM; NDS |
| GAVRETO ORAL CAPSULE 100 MG | | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> (Iressa) | | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>gemcitabine intravenous recon soln 1 gram, 2 gram, 200 mg</i> | | 2 | PA BvD |
| <i>gemcitabine intravenous solution 1 gram/26.3 ml (38 mg/ml), 2 gram/52.6 ml (38 mg/ml)</i> | | 2 | PA BvD |
| <i>gemcitabine intravenous solution 200 mg/5.26 ml (38 mg/ml)</i> | | 2 | PA BvD |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| GLEOSTINE ORAL CAPSULE 10 MG | (lomustine) | 4 | |
| GLEOSTINE ORAL CAPSULE 100 MG, 40 MG | (lomustine) | 5 | NM; NDS |
| GOMEKLI ORAL CAPSULE 1 MG | | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| GOMEKLI ORAL CAPSULE 2 MG | | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| GOMEKLI ORAL TABLET FOR SUSPENSION 1 MG | | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| HERCEPTIN HYLECTA SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML | | 5 | PA NSO; NM; NDS; QL (5 per 21 days) |
| HERNEXEOS ORAL TABLET 60 MG | | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| HERZUMA INTRAVENOUS RECON SOLN 150 MG, 420 MG | | 5 | PA NSO; NM; NDS |
| <i>hydroxyurea oral capsule 500 mg</i> (Hydrea) | | 2 | |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| IBTROZI ORAL CAPSULE 200 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>ifosfamide intravenous recon soln 1 gram</i> | 2 | |
| <i>ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml</i> | 2 | |
| <i>imatinib oral tablet 100 mg</i> (Gleevec) | 2 | PA NSO; QL (180 per 30 days) |
| <i>imatinib oral tablet 400 mg</i> (Gleevec) | 2 | PA NSO; QL (60 per 30 days) |
| IMBRUVIDA ORAL CAPSULE 140 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| IMBRUVIDA ORAL CAPSULE 70 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| IMBRUVIDA ORAL SUSPENSION 70 MG/ML | 5 | PA NSO; NM; NDS; QL (216 per 30 days) |
| IMBRUVIDA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| IMDELLTRA INTRAVENOUS RECON SOLN 1 MG, 10 MG | 5 | PA NSO; NM; NDS |
| IMJUDO INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS |
| IMKELDI ORAL SOLUTION 80 MG/ML | 5 | PA NSO; NM; NDS; QL (280 per 28 days) |
| INLYTA ORAL TABLET 1 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA NSO; NM; NDS; QL (5 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| INREBIC ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>irinotecan intravenous solution 100 mg/5 ml, 300 mg/15 ml, 40 mg/2 ml</i> | 2 | |
| <i>irinotecan intravenous solution 500 mg/25 ml</i> | 2 | |
| ITOVEBI ORAL TABLET 3 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ITOVEBI ORAL TABLET 9 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| IWILFIN ORAL TABLET 192 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| JEMPERLI INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS |
| JYLAMVO ORAL SOLUTION 2 MG/ML | 4 | PA BvD; ST |
| KANJINTI INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |
| KEYTRUDA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| KIMMTRAK INTRAVENOUS SOLUTION 100 MCG/0.5 ML | 5 | PA NSO; NM; NDS; QL (2 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 5 | PA NSO; NM; NDS; QL (49 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 5 | PA NSO; NM; NDS; QL (70 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 5 | PA NSO; NM; NDS; QL (91 per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 5 | PA NSO; NM; NDS; QL (42 per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 5 | PA NSO; NM; NDS; QL (63 per 28 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| KRAZATI ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>lapatinib oral tablet 250 mg</i> (Tykerb) | 5 | PA NSO; NM; NDS |
| LAZCLUZE ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| LAZCLUZE ORAL TABLET 80 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> (Revlimid) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2) | 5 | PA NSO; NM; NDS |
| <i>letrozole oral tablet 2.5 mg</i> (Femara) | 2 | |
| LEUKERAN ORAL TABLET 2 MG | 5 | NM; NDS |
| <i>leuprolide (3 month) intramuscular suspension for reconstitution 22.5 mg</i> (Lutrate Depot (3 month)) | 4 | PA NSO |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 2 | PA NSO |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| LONSURF ORAL TABLET 15-6.14 MG | 5 | PA NSO; NM; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20-8.19 MG | 5 | PA NSO; NM; NDS; QL (80 per 28 days) |
| LOQTORZI INTRAVENOUS SOLUTION 240 MG/6 ML (40 MG/ML) | 5 | PA NSO; NM; NDS |
| LORBRENA ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| LUMAKRAS ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| LUNSUMIO INTRAVENOUS SOLUTION 1 MG/ML | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG | 5 | PA NSO; NM; NDS |
| LYNOZYFIC INTRAVENOUS SOLUTION 2 MG/ML | 5 | PA NSO; NM; NDS; QL (15 per 8 days) |
| LYNOZYFIC INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS; QL (40 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5 | NM; NDS |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) | 5 | PA NSO; NM; NDS; QL (140 per 28 days) |
| MARGENZA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| MATULANE ORAL CAPSULE 50 MG | 5 | NM; NDS |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 2 | |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML | 5 | PA NSO; NM; NDS; QL (1260 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>mercaptopurine oral suspension 20 mg/ml (Purixan)</i> | 5 | NM; NDS |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | |
| <i>methotrexate sodium (pf) injection recon soln 1 gram</i> | 2 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 2 | |
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 2 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | PA BvD; ST |
| <i>mitoxantrone intravenous concentrate 2 mg/ml</i> | 2 | |
| MODEYSO ORAL CAPSULE 125 MG | 5 | PA NSO; NM; NDS; QL (20 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| MVASI INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| NERLYNX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> (Nilandron) | 5 | NM; NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA NSO; NM; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA NSO; NM; LA; NDS |
| OGIVRI INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| OGSIVEO ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML | 5 | PA NSO; NM; NDS; QL (96 per 28 days) |
| OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) | 5 | PA NSO; NM; NDS; QL (24 per 28 days) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ONTRUZANT INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |
| ONUREG ORAL TABLET 200 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (14 per 28 days) |
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10 ML, 120 MG/12 ML, 240 MG/24 ML, 40 MG/4 ML | 5 | PA NSO; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| OPDIVO QVANTIG SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML | 5 | PA NSO; NM; NDS |
| OPDUALAG INTRAVENOUS SOLUTION 240-80 MG/20 ML | 5 | PA NSO; NM; NDS |
| ORSERDU ORAL TABLET 345 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| <i>oxaliplatin intravenous recon soln 100 mg, 50 mg</i> | 2 | |
| <i>oxaliplatin intravenous solution 100 mg/20 ml, 200 mg/40 ml, 50 mg/10 ml (5 mg/ml)</i> | 2 | |
| <i>paclitaxel intravenous concentrate 6 mg/ml</i> | 2 | PA BvD |
| <i>paclitaxel protein-bound intravenous suspension for reconstitution 100 mg</i> (Abraxane) | 5 | PA BvD; NM; NDS |
| <i>pazopanib oral tablet 200 mg</i> (Votrient) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>pemetrexed disodium intravenous recon soln 1,000 mg, 750 mg</i> | 5 | NM; NDS |
| <i>pemetrexed disodium intravenous recon soln 100 mg, 500 mg</i> (Alimta) | 5 | NM; NDS |
| <i>pemetrexed disodium intravenous solution 25 mg/ml</i> | 5 | NM; NDS |
| PEMRYDI RTU INTRAVENOUS SOLUTION 10 MG/ML | 5 | NM; NDS |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| QINLOCK ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| RETEVMO ORAL TABLET 120 MG, 160 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| RETEVMO ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| RETEVMO ORAL TABLET 80 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| REVUFORJ ORAL TABLET 110 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| REVUFORJ ORAL TABLET 160 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| REVUFORJ ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| RIABNI INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NM; NDS |
| RITUXAN HYCELA SUBCUTANEOUS SOLUTION 1400 MG/11.7 ML (120 MG/ML), 1600 MG/13.4 ML (120 MG/ML) | 5 | PA NSO; NM; NDS |
| ROMVIMZA ORAL CAPSULE 14 MG, 20 MG, 30 MG | 5 | PA NSO; NM; NDS; QL (8 per 28 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG | 5 | PA NSO; NM; NDS; QL (360 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| RUXIENCE INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NM; NDS |
| RYBREVANT INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| RYTELO INTRAVENOUS RECON SOLN 188 MG, 47 MG | 5 | PA NSO; NM; NDS |
| SCEMBLIX ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| SCEMBLIX ORAL TABLET 20 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| SCEMBLIX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 5 | NM; NDS |
| <i>sorafenib oral tablet 200 mg</i> (Nexavar) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> (Sutent) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| SYNRIBO SUBCUTANEOUS RECON SOLN 3.5 MG | 5 | PA NSO; NM; NDS |
| TABLOID ORAL TABLET 40 MG (thioguanine) | 4 | |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG | 5 | PA NSO; NM; NDS; QL (900 per 30 days) |
| TAGRISSO ORAL TABLET 40 MG, 80 MG | 5 | PA NSO; NM; LA; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| TALVEY SUBCUTANEOUS SOLUTION 2 MG/ML, 40 MG/ML | 5 | PA NSO; NM; NDS |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 2 | |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| TECENTRIQ HYBREZA SUBCUTANEOUS SOLUTION 1,875 MG-30,000 UNIT/15 ML | 5 | PA NSO; NM; NDS |
| TECENTRIQ INTRAVENOUS SOLUTION 1,200 MG/20 ML (60 MG/ML), 840 MG/14 ML (60 MG/ML) | 5 | PA NSO; NM; NDS |
| TECVAYLI SUBCUTANEOUS SOLUTION 10 MG/ML, 90 MG/ML | 5 | PA NSO; NM; NDS |
| TEPMETKO ORAL TABLET 225 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| TEVIMBRA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NM; NDS |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION 50 MG | 4 | |
| TIVDAK INTRAVENOUS RECON SOLN 40 MG | 5 | PA NSO; NM; NDS; QL (5 per 21 days) |
| <i>toposar intravenous solution 20 mg/ml</i> | 2 | |
| <i>toremifene oral tablet 60 mg</i> | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|------------------|---|
| <i>torpenz oral tablet 10 mg</i> | (everolimus (antineoplastic)) | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>torpenz oral tablet 2.5 mg, 5 mg, 7.5 mg</i> | (everolimus (antineoplastic)) | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| TRAZIMERA INTRAVENOUS RECON SOLN 150 MG, 420 MG | | 5 | PA NSO; NM; NDS |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG, 22.5 MG, 3.75 MG | | 4 | PA NSO |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | | 5 | NM; NDS |
| TRUQAP ORAL TABLET 160 MG, 200 MG | | 5 | PA NSO; NM; NDS; QL (64 per 28 days) |
| TRUXIMA INTRAVENOUS SOLUTION 10 MG/ML | | 5 | PA NSO; NM; NDS |
| TUKYSA ORAL TABLET 150 MG | | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| TURALIO ORAL CAPSULE 125 MG, 200 MG | | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | | 5 | PA NSO; NM; NDS |
| VEGZELMA INTRAVENOUS SOLUTION 25 MG/ML | | 5 | PA NSO; NM; NDS |
| VENCLEXTA ORAL TABLET 10 MG | | 3 | PA NSO; LA; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | | 5 | PA NSO; NM; LA; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | | 5 | PA NSO; NM; LA; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 5 | PA NSO; NM; LA; NDS |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| <i>vinblastine intravenous solution 1 mg/ml</i> | 2 | PA BvD |
| <i>vincasar pfs intravenous solution 1 (vincristine) mg/ml, 2 mg/2 ml</i> | 2 | PA BvD |
| <i>vincristine intravenous solution 1 (Vincasar PFS) mg/ml, 2 mg/2 ml</i> | 2 | PA BvD |
| <i>vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml</i> | 2 | |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| VIVIMUSTA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| VORANIGO ORAL TABLET 10 MG, 40 MG | 5 | PA NSO; NM; NDS |
| VYLOY INTRAVENOUS RECON SOLN 100 MG, 300 MG | 5 | PA NSO; NM; NDS |
| WELIREG ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XALKORI ORAL PELLET 150 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| XALKORI ORAL PELLET 20 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| XALKORI ORAL PELLET 50 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | PA BvD; ST |
| XOSPATA ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) | 5 | PA NSO; NM; NDS; QL (8 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (10 MG X 4) | 5 | PA NSO; NM; NDS; QL (16 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | 5 | PA NSO; NM; NDS; QL (4 per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 5 | PA NSO; NM; NDS; QL (24 per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 5 | PA NSO; NM; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| YEROVY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) | 5 | PA NSO; NM; NDS |
| YONSA ORAL TABLET 125 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------------|
| ZELBORAF ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| ZIIHERA INTRAVENOUS RECON SOLN 300 MG | 5 | PA NSO; NM; NDS |
| ZIRABEV INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG | 4 | PA NSO |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | NM; NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| ZYNLONTA INTRAVENOUS RECON SOLN 10 MG | 5 | PA NSO; NM; NDS |
| ZYNYZ INTRAVENOUS SOLUTION 500 MG/20 ML | 5 | PA NSO; NM; NDS; QL (20 per 28 days) |
| Anticonvulsants | | |
| Anticonvulsants | | |
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5 ML | 3 | QL (80 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | 3 | QL (600 per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | 3 | QL (60 per 30 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> | (Carbatrol) | 2 |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | (Tegretol) | 2 |
| <i>carbamazepine oral tablet 200 mg</i> | (Tegretol) | 2 |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> | (Tegretol XR) | 2 |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|----------------------|---------------------------------------|
| <i>carbamazepine oral tablet, chewable 100 mg, 200 mg</i> | 2 | |
| <i>clobazam oral suspension 2.5 mg/ml (Onfi)</i> | 2 | QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg (Onfi)</i> | 2 | QL (60 per 30 days) |
| DIACOMIT ORAL CAPSULE 250 MG | 5 | PA NSO; NM; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 250 MG | 5 | PA NSO; NM; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 2.5 mg, 5-7.5-10 mg</i> | 4 | |
| DILANTIN ORAL CAPSULE 30 MG | 4 | |
| <i>divalproex oral capsule, delayed release 125 mg</i> | (Depakote Sprinkles) | 2 |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> | (Depakote ER) | 2 |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> | (Depakote) | 2 |
| ELEPSIA XR ORAL TABLET EXTENDED RELEASE 24 HR 1,000 MG | 5 | ST; NM; NDS; QL (90 per 30 days) |
| ELEPSIA XR ORAL TABLET EXTENDED RELEASE 24 HR 1,500 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 5 | PA NSO; NM; NDS |
| <i>epitol oral tablet 200 mg</i> | (carbamazepine) | 2 |
| EPRONTIA ORAL SOLUTION 25 MG/ML | (topiramate) | 4 |
| <i>eslicarbazepine oral tablet 200 mg, 400 mg</i> | (Aptiom) | 5 |
| | | ST; NM; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|---------------------------------|------------------|-----------------------------------|
| <i>eslicarbazepine oral tablet 600 mg, 800 mg</i> | (Aptiom) | 5 | ST; NM; NDS; QL (60 per 30 days) |
| <i>ethosuximide oral capsule 250 mg</i> | (Zarontin) | 2 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> | (Zarontin) | 2 | |
| <i>felbamate oral suspension 600 mg/5 ml</i> | | 2 | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> | (Felbatol) | 2 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | | 5 | PA NSO; NM; NDS |
| <i>fosphenytoin injection solution 100 mg pe/2 ml, 500 mg pe/10 ml</i> | (Cerebyx) | 2 | |
| FYCOMPA ORAL SUSPENSION 0.5 MG/ML | | 5 | ST; NM; NDS; QL (720 per 30 days) |
| <i> gabapentin oral capsule 100 mg, 300 mg</i> | (Neurontin) | 2 | QL (360 per 30 days) |
| <i> gabapentin oral capsule 400 mg</i> | (Neurontin) | 2 | QL (270 per 30 days) |
| <i> gabapentin oral solution 250 mg/5 ml</i> | (Neurontin) | 2 | QL (2160 per 30 days) |
| <i> gabapentin oral tablet 600 mg</i> | (Neurontin) | 2 | QL (180 per 30 days) |
| <i> gabapentin oral tablet 800 mg</i> | (Neurontin) | 2 | QL (120 per 30 days) |
| <i> lacosamide intravenous solution 200 mg/20 ml</i> | (Vimpat) | 2 | QL (200 per 5 days) |
| <i> lacosamide oral solution 10 mg/ml</i> | (Vimpat) | 2 | QL (1200 per 30 days) |
| <i> lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | (Vimpat) | 2 | QL (60 per 30 days) |
| <i> lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> | (Subvenite) | 1 | |
| <i> lamotrigine oral tablet disintegrating, dose pk 25 mg (21) - 50 mg (7)</i> | (Lamictal ODT Starter (Blue)) | 2 | |
| <i> lamotrigine oral tablet disintegrating, dose pk 25 mg(14)-50 mg (14)-100 mg (7)</i> | (Lamictal ODT Starter (Orange)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|--------------------------------|------------------|----------------------------------|
| <i>lamotrigine oral tablet disintegrating, dose pk 50 mg (42) - 100 mg (14)</i> | (Lamictal ODT Starter (Green)) | 2 | |
| <i>lamotrigine oral tablet extended release 24hr 100 mg, 200 mg, 25 mg, 250 mg, 300 mg, 50 mg</i> | (Lamictal XR) | 2 | |
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> | (Lamictal) | 2 | |
| <i>lamotrigine oral tablet,disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> | (Lamictal ODT) | 2 | |
| <i>levetiracetam intravenous solution 500 mg/5 ml</i> | (Keppra) | 2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> | (Keppra) | 2 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> | (Keppra) | 2 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> | (Keppra XR) | 2 | |
| <i>levetiracetam oral tablet for suspension 250 mg</i> | (Spritam) | 2 | ST |
| <i>LIBERVANT BUCCAL FILM 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG</i> | | 4 | QL (10 per 30 days) |
| <i>methsuximide oral capsule 300 mg</i> | (Celontin) | 2 | |
| <i>NAYZILAM NASAL SPRAY,NON-AEROSOL 5 MG/SPRAY (0.1 ML)</i> | | 4 | QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> | (Trileptal) | 2 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> | (Trileptal) | 2 | |
| <i>perampanel oral tablet 10 mg, 12 mg, 8 mg</i> | (Fycompa) | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>perampanel oral tablet 2 mg</i> | (Fycompa) | 2 | ST; QL (30 per 30 days) |
| <i>perampanel oral tablet 4 mg, 6 mg</i> | (Fycompa) | 5 | ST; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 2 | |
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 2 | |
| <i>PHENYTEK ORAL CAPSULE 200 MG, 300 MG</i> (phenytoin sodium extended) | 4 | |
| <i>phenytoin oral suspension 125 mg/5 ml</i> (Dilantin-125) | 2 | |
| <i>phenytoin oral tablet, chewable 50 mg</i> (Dilantin Infatabs) | 2 | |
| <i>phenytoin sodium extended oral capsule 100 mg</i> (Dilantin Extended) | 2 | |
| <i>phenytoin sodium extended oral capsule 200 mg, 300 mg</i> (Phenytek) | 2 | |
| <i>phenytoin sodium intravenous solution 50 mg/ml</i> | 2 | |
| <i>phenytoin sodium intravenous syringe 50 mg/ml</i> | 2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> (Lyrica) | 2 | QL (90 per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> (Lyrica) | 2 | QL (60 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> (Lyrica) | 2 | QL (900 per 30 days) |
| <i>primidone oral tablet 125 mg</i> | 2 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> (Mysoline) | 2 | |
| <i>rufinamide oral suspension 40 mg/ml</i> (Banzel) | 5 | ST; NM; NDS |
| <i>rufinamide oral tablet 200 mg</i> (Banzel) | 2 | ST |
| <i>rufinamide oral tablet 400 mg</i> (Banzel) | 5 | ST; NM; NDS |
| <i>SEZABY INTRAVENOUS RECON SOLN 100 MG</i> | 5 | PA BvD; NM; NDS |
| <i>SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG, 500 MG, 750 MG</i> | 4 | ST |
| <i>SPRITAM ORAL TABLET FOR SUSPENSION 250 MG</i> (levetiracetam) | 4 | ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| <i>subvenite oral tablet 100 mg, 150 mg, (lamotrigine) 200 mg, 25 mg</i> | 1 | |
| <i>SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG</i> | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 2 | |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> | 2 | |
| <i>topiramate oral capsule, sprinkle 50 mg</i> | 2 | |
| <i>topiramate oral solution 25 mg/ml (Eprontia)</i> | 2 | ST |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> | 1 | |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | 2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | 2 | |
| <i>valproic acid oral capsule 250 mg</i> | 2 | |
| <i>VALTOCO NASAL SPRAY, NON-AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML)</i> | 5 | NM; NDS; QL (10 per 30 days) |
| <i>vigabatrin oral powder in packet 500 mg (Vigadron)</i> | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigabatrin oral tablet 500 mg (Vigadron)</i> | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigadron oral powder in packet 500 mg (vigabatrin)</i> | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigadron oral tablet 500 mg (vigabatrin)</i> | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigpoder oral powder in packet 500 mg (vigabatrin)</i> | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 3 | QL (56 per 28 days) |
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | QL (30 per 30 days) |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 3 | QL (60 per 30 days) |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14), 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 3 | |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML | 4 | |
| <i>zonisamide oral capsule 100 mg, 25 mg</i> (Zonegran) | 2 | |
| <i>zonisamide oral capsule 50 mg</i> | 2 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 5 | PA NSO; NM; NDS; QL (1080 per 30 days) |

Antidementia Agents

Antidementia Agents

| | | |
|---|---|-------------------------|
| <i>donepezil oral tablet 10 mg, 5 mg</i> (Aricept) | 1 | QL (30 per 30 days) |
| <i>donepezil oral tablet 23 mg</i> (Aricept) | 2 | QL (30 per 30 days) |
| <i>donepezil oral tablet,disintegrating 10 mg</i> | 2 | |
| <i>donepezil oral tablet,disintegrating 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>ergoloid oral tablet 1 mg</i> | 2 | |
| <i>galantamine oral capsule,ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | 2 | QL (30 per 30 days) |
| <i>galantamine oral solution 4 mg/ml</i> | 2 | QL (200 per 30 days) |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | QL (60 per 30 days) |
| <i>memantine oral capsule,sprinkle,er 24hr 14 mg, 21 mg, 28 mg</i> | 2 | ST; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------|------------------|----------------------------|
| <i>memantine oral capsule,sprinkle,er 24hr 7 mg</i> | (Namenda XR) | 2 | ST; QL (30 per 30 days) |
| <i>memantine oral solution 2 mg/ml</i> | | 2 | QL (300 per 30 days) |
| <i>memantine oral tablet 10 mg, 5 mg</i> | | 2 | QL (60 per 30 days) |
| <i>memantine-donepezil oral capsule,sprinkle,er 24hr 14-10 mg, 21-10 mg, 28-10 mg</i> | (Namzaric) | 2 | ST; QL (30 per 30 days) |
| NAMZARIC ORAL CAP,SPRINKLE,ER 24HR DOSE PACK 7/14/21/28 MG-10 MG | | 4 | ST |
| NAMZARIC ORAL CAPSULE,SPRINKLE,ER 24HR 7-10 MG | | 4 | ST; QL (30 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | | 2 | |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> | (Exelon Patch) | 2 | QL (30 per 30 days) |
| Antidepressants | | | |
| Antidepressants | | | |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | | 2 | |
| <i>amitriptyline-chlordiazepoxide oral tablet 12.5-5 mg, 25-10 mg</i> | | 2 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | | 2 | |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG | | 5 | ST; NM; NDS |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | | 2 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg</i> | (Wellbutrin XL) | 2 | |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> | (Wellbutrin SR) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| citalopram oral solution 10 mg/5 ml | 2 | |
| citalopram oral tablet 10 mg (Celexa) | 1 | QL (120 per 30 days) |
| citalopram oral tablet 20 mg, 40 mg (Celexa) | 1 | QL (30 per 30 days) |
| clomipramine oral capsule 25 mg, 50 mg, 75 mg (Anafranil) | 2 | |
| desipramine oral tablet 10 mg, 25 mg (Norpramin) | 2 | |
| desipramine oral tablet 100 mg, 150 mg, 50 mg, 75 mg | 2 | |
| desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg (Pristiq) | 2 | QL (30 per 30 days) |
| doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg | 2 | |
| doxepin oral concentrate 10 mg/ml | 2 | |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 60 MG | 4 | ST; QL (60 per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG | 4 | ST; QL (30 per 30 days) |
| duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 60 mg | 2 | QL (60 per 30 days) |
| duloxetine oral capsule, delayed release(dr/ec) 40 mg | 2 | QL (30 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 5 | ST; NM; NDS; QL (30 per 30 days) |
| escitalopram oxalate oral solution 5 mg/5 ml | 2 | |
| escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg (Lexapro) | 1 | |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)-40 MG (26) | 4 | ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 4 | ST; QL (30 per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg (Prozac)</i> | 1 | |
| <i>fluoxetine oral capsule 40 mg</i> | 1 | |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine pamoate oral capsule 100 mg, 125 mg, 150 mg, 75 mg</i> | 2 | |
| MARPLAN ORAL TABLET 10 MG | 4 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg (Remeron)</i> | 2 | |
| <i>mirtazapine oral tablet 45 mg, 7.5 mg</i> | 2 | |
| <i>mirtazapine oral tablet,disintegrating (Remeron SolTab) 15 mg, 30 mg, 45 mg</i> | 2 | |
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | |
| <i>nortriptyline oral capsule 10 mg, 25 (Pamelor) mg, 50 mg, 75 mg</i> | 1 | |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | 2 | |
| <i>paroxetine hcl oral suspension 10 (Paxil) mg/5 ml</i> | 2 | |
| <i>paroxetine hcl oral tablet 10 mg, 20 (Paxil) mg, 30 mg, 40 mg</i> | 1 | |
| <i>paroxetine hcl oral tablet extended release 24 hr 12.5 mg, 25 mg, 37.5 mg</i> | 2 | |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4- 25 mg, 4-50 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------------|
| <i>phenelzine oral tablet 15 mg</i> (Nardil) | 2 | |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 2 | |
| RALDESY ORAL SOLUTION 10 MG/ML | 4 | PA NSO; QL (1200 per 30 days) |
| <i>sertraline oral concentrate 20 mg/ml</i> (Zoloft) | 2 | |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i> (Zoloft) | 1 | |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 28 MG, 56 MG (28 MG X 2), 84 MG (28 MG X 3) | 5 | PA NSO; NM; NDS |
| <i>tranylcypromine oral tablet 10 mg</i> (Parnate) | 2 | |
| <i>trazodone oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | |
| <i>trimipramine oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>venlafaxine besylate oral tablet extended release 24hr 112.5 mg</i> | 4 | QL (60 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg</i> | 2 | QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 37.5 mg, 75 mg</i> | 2 | QL (90 per 30 days) |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | |
| <i>venlafaxine oral tablet extended release 24hr 150 mg, 225 mg, 37.5 mg</i> | 2 | QL (30 per 30 days) |
| <i>venlafaxine oral tablet extended release 24hr 75 mg</i> | 2 | QL (90 per 30 days) |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i> (Viibryd) | 2 | QL (30 per 30 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | 5 | PA NSO; NM; NDS; QL (28 per 14 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------------|
| ZURZUVAE ORAL CAPSULE 30 MG | 5 | PA NSO; NM; NDS; QL (14 per 14 days) |
| Antidiabetic Agents | | |
| Antidiabetic Agents, Miscellaneous | | |
| acarbose oral tablet 100 mg, 25 mg, 50 mg (Precose) | 2 | |
| FARXIGA ORAL TABLET 10 MG, 5 MG (dapagliflozin propanediol) | 3 | QL (30 per 30 days) |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 3 | QL (30 per 30 days) |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG | 3 | QL (30 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG, 50 MG | 3 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 3 | QL (30 per 30 days) |
| metformin oral solution 500 mg/5 ml (Riomet) | 2 | QL (765 per 30 days) |
| metformin oral tablet 1,000 mg | 1 | QL (75 per 30 days) |
| metformin oral tablet 500 mg | 1 | QL (150 per 30 days) |
| metformin oral tablet 750 mg | 1 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------------|
| <i>metformin oral tablet 850 mg</i> | 1 | QL (90 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | 1 | QL (120 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | 1 | QL (60 per 30 days) |
| <i>mifepristone oral tablet 300 mg</i> (Korlym) | 5 | PA; NM; NDS; QL (112 per 28 days) |
| <i>miglitol oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | QL (90 per 30 days) |
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 2 | QL (90 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 0.25 MG OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (2 MG/1.5 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 3 | PA; QL (3 per 28 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> (Actos) | 1 | QL (30 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-500 mg</i> | 2 | QL (90 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-850 mg</i> (Actoplus MET) | 2 | QL (90 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 2 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> | 2 | QL (240 per 30 days) |
| RYBELSUS ORAL TABLET 1.5 MG, 14 MG, 3 MG, 4 MG, 7 MG, 9 MG | 3 | PA; QL (30 per 30 days) |
| SYMLINPEN 120 SUBCUTANEOUS PEN INJECTOR 2,700 MCG/2.7 ML | 5 | PA; NM; NDS; QL (10.8 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|--|------------------------------------|
| SYMLINPEN 60 SUBCUTANEOUS PEN INJECTOR 1,500 MCG/1.5 ML | 5 | PA; NM; NDS; QL (10.8 per 28 days) |
| SYNJARDY ORAL TABLET 12.5- 1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 3 | QL (30 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5- 1,000 MG, 5-1,000 MG | 3 | QL (60 per 30 days) |
| TRADJENTA ORAL TABLET 5 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5- 1,000 MG, 5-2.5-1,000 MG | 3 | QL (60 per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG | (dapaglifloz propaned- metformin) 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-500 MG | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | (dapaglifloz propaned- metformin) 3 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits | |
|--|-------------------------------------|--|--|
| Insulins | | | |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 6 | max \$35 copay per month supply; QL (30 per 28 days) | |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 6 | max \$35 copay per month supply; QL (30 per 28 days) | |
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 6 | max \$35 copay per month supply; QL (40 per 28 days) | |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 6 | max \$35 copay per month supply; QL (40 per 28 days) | |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 6 | max \$35 copay per month supply; QL (24 per 28 days) | |
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | (Novolog Mix 70-30FlexPen U-100) | 6 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | (Novolog Mix 70-30 U-100 Insulin) | 6 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin aspart u-100 subcutaneous cartridge 100 unit/ml</i> | (Novolog PenFill U-100 Insulin) | 6 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous insulin pen 100 unit/ml (3 ml)</i> | (Novolog FlexPen U-100 Insulin) | 6 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous solution 100 unit/ml</i> | (Novolog U-100 Insulin aspart) | 6 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin glargine-yfgn subcutaneous insulin pen 100 unit/ml (3 ml)</i> | (Semglee(insulin glargine-yfgn)Pen) | 6 | max \$35 copay per month supply |
| <i>insulin glargine-yfgn subcutaneous solution 100 unit/ml</i> | (Semglee(insulin glargine-yfgn)) | 6 | max \$35 copay per month supply |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-------------------------|------------------|--|
| LANTUS SOLOSTAR U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | (insulin glargine) | 6 | max \$35 copay per month supply |
| LANTUS U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | (insulin glargine) | 6 | max \$35 copay per month supply |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) | | 6 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | | 6 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | | 6 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | | 6 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | | 6 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML | | 6 | max \$35 copay per month supply; QL (40 per 28 days) |
| SEMGLEE(INSULIN GLARGINE- YFGN) SUBCUTANEOUS SOLUTION 100 UNIT/ML | (insulin glargine-yfgn) | 6 | max \$35 copay per month supply |
| SEMGLEE(INSULIN GLARG- YFGN)PEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | (insulin glargine-yfgn) | 6 | max \$35 copay per month supply |
| SOLIQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | | 6 | max \$35 copay per month supply; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-------------------------------|------------------|--|
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) | (insulin glargine u-300 conc) | 6 | max \$35 copay per month supply |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) | (insulin glargine u-300 conc) | 6 | max \$35 copay per month supply |
| TRESIBA FLEXTOUCH U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | (insulin degludec) | 6 | max \$35 copay per month supply |
| TRESIBA FLEXTOUCH U-200 SUBCUTANEOUS INSULIN PEN 200 UNIT/ML (3 ML) | (insulin degludec) | 6 | max \$35 copay per month supply |
| TRESIBA U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | (insulin degludec) | 6 | max \$35 copay per month supply |
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | | 6 | max \$35 copay per month supply; QL (15 per 28 days) |
| Sulfonylureas | | | |
| glimepiride oral tablet 1 mg, 2 mg | | 1 | QL (30 per 30 days) |
| glimepiride oral tablet 4 mg | | 1 | QL (60 per 30 days) |
| glipizide oral tablet 10 mg | | 1 | QL (120 per 30 days) |
| glipizide oral tablet 2.5 mg | | 1 | QL (90 per 30 days) |
| glipizide oral tablet 5 mg | | 1 | QL (240 per 30 days) |
| glipizide oral tablet extended release 24hr 10 mg | | 1 | QL (60 per 30 days) |
| glipizide oral tablet extended release 24hr 2.5 mg, 5 mg | | 1 | QL (30 per 30 days) |
| glipizide-metformin oral tablet 2.5- 250 mg | | 2 | QL (240 per 30 days) |
| glipizide-metformin oral tablet 2.5- 500 mg, 5-500 mg | | 2 | QL (120 per 30 days) |
| glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg | | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 1 | |
| <i>glyburide-metformin oral tablet 1.25-250 mg, 2.5-500 mg, 5-500 mg</i> | 1 | |
| Antifungals | | |
| Antifungals | | |
| <i>ABELCET INTRAVENOUS SUSPENSION 5 MG/ML</i> | 4 | PA BvD |
| <i>amphotericin b injection recon soln 50 mg</i> | 2 | PA BvD |
| <i>amphotericin b liposome intravenous suspension for reconstitution 50 mg</i> (AmBisome) | 5 | PA BvD; NM; NDS |
| <i>ciclopirox topical cream 0.77 %</i> (Ciclodan) | 2 | QL (180 per 30 days) |
| <i>ciclopirox topical gel 0.77 %</i> | 2 | |
| <i>ciclopirox topical shampoo 1 %</i> | 2 | |
| <i>ciclopirox topical solution 8 %</i> (Ciclodan) | 2 | QL (19.8 per 30 days) |
| <i>ciclopirox topical suspension 0.77 %</i> (Loprox (as olamine)) | 2 | QL (180 per 30 days) |
| <i>clotrimazole mucous membrane troche 10 mg</i> | 2 | |
| <i>clotrimazole topical cream 1 %</i> (Antifungal (clotrimazole)) | 2 | |
| <i>clotrimazole topical solution 1 %</i> (Athlete's Foot (clotrimazole)) | 2 | |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | 2 | QL (90 per 30 days) |
| <i>clotrimazole-betamethasone topical lotion 1-0.05 %</i> | 2 | |
| <i>CRESEMDA ORAL CAPSULE 186 MG, 74.5 MG</i> | 5 | PA; NM; NDS |
| <i>econazole nitrate topical cream 1 %</i> | 2 | QL (170 per 30 days) |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|------------|------------------|----------------------------|
| <i>fluconazole oral suspension for reconstitution 40 mg/ml</i> | (Diflucan) | 2 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | | 2 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> | (Ancobon) | 5 | NM; NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | | 2 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | | 2 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 165 mg, 250 mg</i> | | 2 | |
| <i>itraconazole oral capsule 100 mg</i> | (Sporanox) | 2 | |
| <i>itraconazole oral solution 10 mg/ml</i> | | 5 | PA; NM; NDS |
| <i>ketoconazole oral tablet 200 mg</i> | | 2 | |
| <i>ketoconazole topical cream 2 %</i> | | 2 | QL (180 per 30 days) |
| <i>ketoconazole topical foam 2 %</i> | (Extina) | 2 | ST; QL (100 per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> | | 2 | QL (360 per 30 days) |
| <i>micafungin intravenous recon soln 100 mg, 50 mg</i> | (Mycamine) | 2 | |
| <i>miconazole-3 vaginal suppository 200 mg</i> | | 2 | |
| NOXAFL ORAL SUSP,DELAYED RELEASE FOR RECON 300 MG | | 5 | PA; NM; NDS |
| <i>nyamyc topical powder 100,000 unit/gram</i> | (nystatin) | 2 | QL (60 per 30 days) |
| <i>nystatin oral suspension 100,000 unit/ml</i> | | 2 | |
| <i>nystatin oral tablet 500,000 unit</i> | | 2 | |
| <i>nystatin topical cream 100,000 unit/gram</i> | | 2 | QL (60 per 30 days) |
| <i>nystatin topical ointment 100,000 unit/gram</i> | | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|------------|------------------|----------------------------|
| <i>nystatin topical powder 100,000 unit/gram</i> | (Nyamyc) | 2 | QL (60 per 30 days) |
| <i>nystatin-triamcinolone topical cream 100,000-0.1 unit/g-%</i> | | 2 | |
| <i>nystatin-triamcinolone topical ointment 100,000-0.1 unit/gram-%</i> | | 2 | |
| <i>nystop topical powder 100,000 unit/gram</i> | (nystatin) | 2 | QL (60 per 30 days) |
| <i>posaconazole oral suspension 200 mg/5 ml (40 mg/ml)</i> | (Noxafil) | 5 | PA; NM; NDS |
| <i>posaconazole oral tablet, delayed release (dr/ec) 100 mg</i> | (Noxafil) | 5 | PA; NM; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | | 1 | |
| <i>voriconazole intravenous recon soln 200 mg</i> | (Vfend IV) | 5 | PA BvD; NM; NDS |
| <i>voriconazole oral suspension for reconstitution 200 mg/5 ml (40 mg/ml)</i> | (Vfend) | 5 | PA; NM; NDS |
| <i>voriconazole oral tablet 200 mg, 50 mg</i> | | 2 | |
| Antigout Agents | | | |
| Antigout Agents, Other | | | |
| <i>allopurinol oral tablet 100 mg</i> | (Zyloprim) | 1 | |
| <i>allopurinol oral tablet 300 mg</i> | | 1 | |
| <i>colchicine oral capsule 0.6 mg</i> | (Mitigare) | 2 | QL (60 per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> | (Colcris) | 2 | QL (120 per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> | (Uloric) | 2 | ST; QL (30 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | | 2 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | | 2 | |
| Antihistamines | | | |
| Antihistamines | | | |
| <i>carbinoxamine maleate oral liquid 4 mg/5 ml</i> | (Carbzah) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------|------------------|----------------------------|
| <i>clemastine oral tablet 2.68 mg</i> | (Clemsza) | 2 | |
| <i>clemasz oral tablet 2.68 mg</i> | (clemastine) | 2 | |
| <i>clemsza oral tablet 2.68 mg</i> | (clemastine) | 2 | |
| <i>cyproheptadine oral syrup 2 mg/5 ml</i> | | 2 | |
| <i>cyproheptadine oral tablet 4 mg</i> | | 2 | |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | | 2 | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | | 2 | |
| <i>levocetirizine oral solution 2.5 mg/5 ml</i> | (Xyzal) | 2 | |
| <i>levocetirizine oral tablet 5 mg</i> | (24HR Allergy Relief) | 1 | |
| <i>promethazine oral syrup 6.25 mg/5 ml</i> | | 2 | |
| Anti-Infectives (Skin And Mucous Membrane) | | | |
| Anti-Infectives (Skin And Mucous Membrane) | | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> | (Cleocin) | 2 | |
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> | (Vandazole) | 2 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | | 2 | |
| <i>terconazole vaginal suppository 80 mg</i> | | 2 | |
| Antimigraine Agents | | | |
| Antimigraine Agents | | | |
| <i>AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML</i> | | 3 | PA; QL (1 per 30 days) |
| <i>AJOVY AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 225 MG/1.5 ML</i> | | 3 | PA; QL (1.5 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|---------------------------|------------------|---------------------------------|
| AJOVY SYRINGE SUBCUTANEOUS SYRINGE 225 MG/1.5 ML | | 3 | PA; QL (1.5 per 30 days) |
| <i>dihydroergotamine nasal spray, non-aerosol 0.5 mg/pump act. (4 mg/ml)</i> | (Migranal) | 5 | ST; NM; NDS; QL (8 per 28 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | | 3 | PA; QL (3 per 30 days) |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | | 2 | QL (9 per 30 days) |
| NURTEC ODT ORAL TABLET,DISINTEGRATING 75 MG | | 3 | PA; QL (18 per 30 days) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG | | 3 | PA; QL (30 per 30 days) |
| <i>rizatriptan oral tablet 10 mg</i> | (Maxalt) | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet 5 mg</i> | | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet,disintegrating 10 mg</i> | (Maxalt-MLT) | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet,disintegrating 5 mg</i> | | 2 | QL (18 per 30 days) |
| <i>sumatriptan 4 mg/0.5 ml inject outer, suv</i> | (Imitrex STATdose Pen) | 2 | QL (4 per 28 days) |
| <i>sumatriptan nasal spray,non-aerosol 20 mg/actuation, 5 mg/actuation</i> | | 2 | QL (12 per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> | (Imitrex) | 2 | QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> | (Imitrex) | 2 | QL (18 per 30 days) |
| <i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i> | (Imitrex STATdose Refill) | 2 | QL (4 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i> (Imitrex STATdose Pen) | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i> (Imitrex STATdose Pen) | 2 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> | 2 | QL (5 per 28 days) |
| <i>sumatriptan-naproxen oral tablet 85- 500 mg</i> (TrexiMet) | 2 | QL (9 per 27 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 3 | PA; QL (16 per 30 days) |
| <i>zolmitriptan oral tablet 2.5 mg, 5 mg</i> (Zomig) | 2 | QL (12 per 30 days) |
| <i>zolmitriptan oral tablet,disintegrating 2.5 mg, 5 mg</i> | 2 | QL (12 per 30 days) |
| Antimycobacterials | | |
| Antimycobacterials | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | |
| <i>ethambutol oral tablet 100 mg, 400 mg</i> | 2 | |
| <i>isoniazid oral solution 50 mg/5 ml</i> | 2 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| <i>pyrazinamide oral tablet 500 mg</i> | 2 | |
| <i>rifabutin oral capsule 150 mg</i> | 2 | |
| <i>rifampin intravenous recon soln 600 mg</i> (Rifadin) | 2 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | PA; NM; NDS |
| TRECATOR ORAL TABLET 250 MG | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| Antinausea Agents | | |
| Antinausea Agents | | |
| <i>aprepitant oral capsule 125 mg</i> | 2 | PA BvD; QL (2 per 28 days) |
| <i>aprepitant oral capsule 40 mg</i> | 2 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 mg</i> (Emend) | 2 | PA BvD; QL (4 per 28 days) |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> (Emend) | 2 | PA BvD |
| <i>compro rectal suppository 25 mg</i> (prochlorperazine) | 2 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> (Marinol) | 2 | PA; QL (60 per 30 days) |
| EMEND ORAL SUSPENSION FOR RECONSTITUTION 125 MG (25 MG/ ML FINAL CONC.) | 4 | PA BvD; QL (6 per 28 days) |
| <i>granisetron hcl oral tablet 1 mg</i> | 2 | PA BvD |
| <i>meclizine oral tablet 12.5 mg</i> | 1 | |
| <i>meclizine oral tablet 25 mg</i> (Dramamine (meclizine)) | 1 | |
| <i>ondansetron hcl oral solution 4 mg/5 ml</i> | 2 | PA BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>prochlorperazine edisylate injection solution 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> (Compazine) | 2 | |
| <i>prochlorperazine rectal suppository 25 mg</i> (Compro) | 2 | |
| <i>promethazine injection solution 25 mg/ml</i> (Phenergan) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>promethazine rectal suppository 12.5 mg, 25 mg, 50 mg</i> | 2 | |
| <i>promethegan rectal suppository 12.5 mg, 25 mg, 50 mg</i> | 2 | |
| <i>scopolamine base transdermal patch (Transderm-Scop) 3 day 1 mg over 3 days</i> | 2 | QL (10 per 30 days) |

Antiparasite Agents

Antiparasite Agents

| | | |
|---|---|----------------------------------|
| <i>albendazole oral tablet 200 mg</i> | 5 | NM; NDS |
| <i>atovaquone oral suspension 750 mg/5 ml</i> | 2 | |
| <i>atovaquone-proguanil oral tablet 250-100 mg</i> | 2 | |
| <i>atovaquone-proguanil oral tablet 62.5-25 mg</i> | 2 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>COARTEM ORAL TABLET 20-120 MG</i> | 4 | |
| <i>hydroxychloroquine oral tablet 100 mg</i> | 2 | QL (180 per 30 days) |
| <i>hydroxychloroquine oral tablet 200 mg</i> | 2 | QL (90 per 30 days) |
| <i>hydroxychloroquine oral tablet 300 mg</i> | 2 | QL (60 per 30 days) |
| <i>hydroxychloroquine oral tablet 400 mg</i> | 2 | QL (60 per 30 days) |
| <i>IMPAVIDO ORAL CAPSULE 50 MG</i> | 5 | PA; NM; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg</i> | 2 | |
| <i>ivermectin oral tablet 6 mg</i> | 2 | |
| <i>mefloquine oral tablet 250 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|--------------|------------------|------------------------------|
| <i>nitazoxanide oral tablet 500 mg</i> | (Alinia) | 5 | NM; NDS; QL (60 per 30 days) |
| <i>paromomycin oral capsule 250 mg</i> | (Humatin) | 2 | |
| <i>pentamidine inhalation recon soln 300 mg</i> | (Nebupent) | 2 | PA BvD |
| <i>pentamidine injection recon soln 300 mg</i> | (Pentam) | 2 | |
| <i>praziquantel oral tablet 600 mg</i> | (Biltricide) | 2 | |
| PRIMAQUINE ORAL TABLET 26.3 MG (15 MG BASE) | | 4 | |
| <i>pyrimethamine oral tablet 25 mg</i> | (Daraprim) | 5 | PA; NM; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> | (Qualaquin) | 2 | PA |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | | 2 | |

Antiparkinsonian Agents

Antiparkinsonian Agents

| | | | |
|--|-----------|---|----------------------------------|
| <i>amantadine hcl oral capsule 100 mg</i> | | 2 | |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | | 2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | | 2 | |
| <i>apomorphine subcutaneous cartridge 10 mg/ml</i> | (APOKYN) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>benztropine oral tablet 0.5 mg, 1 mg, 2 mg</i> | | 2 | |
| <i>bromocriptine oral capsule 5 mg</i> | | 2 | |
| <i>bromocriptine oral tablet 2.5 mg</i> | | 2 | |
| <i>cabergoline oral tablet 0.5 mg</i> | | 2 | |
| <i>carbidopa oral tablet 25 mg</i> | (Lodosyn) | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg</i> | (Sinemet) | 2 | |
| <i>carbidopa-levodopa oral tablet 25-100 mg</i> | (Dhivy) | 2 | |
| <i>carbidopa-levodopa oral tablet 25-250 mg</i> | | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet,disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa-entacapone oral tablet 12.5-50-200 mg, 18.75-75-200 mg, 25-100-200 mg, 31.25-125-200 mg, 37.5-150-200 mg, 50-200-200 mg</i> | 2 | |
| <i>entacapone oral tablet 200 mg</i> | 2 | |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE 42 MG | 5 | PA; NM; NDS; QL (300 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NM; NDS; QL (150 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10-15-20-25-30 MG | 5 | PA; NM; NDS |
| NEUPRO TRANSDERMAL PATCH 24 HOUR 1 MG/24 HOUR, 2 MG/24 HOUR, 3 MG/24 HOUR, 4 MG/24 HOUR, 6 MG/24 HOUR, 8 MG/24 HOUR | 4 | ST; QL (30 per 30 days) |
| ONAPGO SUBCUTANEOUS CARTRIDGE 4.9 MG/ ML | 5 | PA; NM; NDS; QL (600 per 30 days) |
| ONGENTYS ORAL CAPSULE 25 MG, 50 MG | 4 | PA; QL (30 per 30 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG, 258 MG, 322 MG/DAY(129 MG X1-193MG X1) | 4 | ST |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 2 | |
| <i>rasagiline oral tablet 0.5 mg, 1 mg (Azilect)</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 2 | |
| <i>ropinirole oral tablet extended release 24 hr 12 mg, 2 mg, 4 mg, 6 mg, 8 mg</i> | 2 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | |
| <i>trihexyphenidyl oral elixir 0.4 mg/ml</i> | 2 | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 2 | |
| VYALEV CONTIN. SUBCUTANEOUS INFUSION SOLUTION 12-240 MG/ML | 5 | PA; NM; NDS; QL (560 per 28 days) |
| Antipsychotic Agents | | |
| Antipsychotic Agents | | |
| ABILITY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML | 5 | NM; NDS; QL (2.4 per 42 days) |
| ABILITY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML | 5 | NM; NDS; QL (3.2 per 42 days) |
| ABILITY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG | 5 | NM; NDS; QL (2 per 28 days) |
| ABILITY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 5 | NM; NDS; QL (2 per 28 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 2 | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> (Abilify) | 2 | |
| <i>aripiprazole oral tablet,disintegrating 10 mg</i> | 2 | ST; QL (90 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| <i>aripiprazole oral tablet,disintegrating 15 mg</i> | 2 | ST; QL (60 per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 675 MG/2.4 ML | 5 | NM; NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML | 5 | NM; NDS; QL (3.9 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML | 5 | NM; NDS; QL (1.6 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML | 5 | NM; NDS; QL (2.4 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML | 5 | NM; NDS; QL (3.2 per 14 days) |
| <i>asenapine maleate sublingual tablet (Saphris) 10 mg, 2.5 mg, 5 mg</i> | 2 | QL (60 per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>chlorpromazine injection solution 25 mg/ml</i> | 2 | |
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i> | 2 | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | |
| <i>clozapine oral tablet 100 mg, 200 mg, 25 mg, 50 mg (Clozaril)</i> | 2 | |
| <i>clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 25 mg</i> | 2 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet,disintegrating 150 mg</i> | 2 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet,disintegrating 200 mg</i> | 2 | ST; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| COBENFY ORAL CAPSULE 100-20 MG, 125-30 MG, 50-20 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| COBENFY STARTER PACK ORAL CAPSULE,DOSE PACK 50 MG-20 MG /100 MG-20 MG | 5 | ST; NM; NDS |
| ERZOFRI INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NM; NDS; QL (0.75 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NM; NDS; QL (1 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NM; NDS; QL (1.5 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 351 MG/2.25 ML | 5 | NM; NDS; QL (2.25 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 5 | NM; NDS; QL (0.25 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NM; NDS; QL (0.5 per 21 days) |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| FANAPT TITRATION PACK A ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)- 4MG(2)-6MG(2) | 4 | ST |
| FANAPT TITRATION PACK B ORAL TABLETS,DOSE PACK 1 MG(6)-2MG(2)- 6 MG(2)-8 MG(2) | 4 | ST |
| FANAPT TITRATION PACK C ORAL TABLETS,DOSE PACK 1 MG(4)-2 MG(2) -6 MG (2) | 4 | ST |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 2 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 2 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml (Haldol Decanoate)</i> | 2 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml (1 ml), 50 mg/ml, 50 mg/ml(1ml)</i> | 2 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate intramuscular syringe 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | |
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | 5 | NM; NDS; QL (3.5 per 166 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | 5 | NM; NDS; QL (5 per 166 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NM; NDS; QL (0.75 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NM; NDS; QL (1 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NM; NDS; QL (1.5 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 3 | QL (0.25 per 21 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NM; NDS; QL (0.5 per 21 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | 5 | NM; NDS; QL (0.88 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | 5 | NM; NDS; QL (1.32 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 5 | NM; NDS; QL (1.75 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | 5 | NM; NDS; QL (2.63 per 70 days) |
| <i>loxpipine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> | (Latuda) 2 | QL (30 per 30 days) |
| <i>lurasidone oral tablet 80 mg</i> | (Latuda) 2 | QL (60 per 30 days) |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>molindone oral tablet 10 mg</i> | 2 | QL (240 per 30 days) |
| <i>molindone oral tablet 25 mg</i> | 2 | QL (270 per 30 days) |
| <i>molindone oral tablet 5 mg</i> | 5 | NM; NDS; QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular recon soln 10 mg</i> | 2 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 7.5 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>olanzapine oral tablet 2.5 mg, 20 mg, 5 mg (Zyprexa)</i> | 2 | |
| <i>olanzapine oral tablet,disintegrating 10 mg, 15 mg, 20 mg, 5 mg</i> | 2 | |
| <i>OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG</i> | 5 | ST; NM; NDS |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg</i> | 2 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 3 mg, 9 mg (Invega)</i> | 2 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg (Invega)</i> | 2 | QL (60 per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 2 | |
| <i>PERSERIS SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 120 MG, 90 MG</i> | 5 | NM; NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>prochlorperazine 10 mg/2 ml vl outer 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg (Seroquel)</i> | 2 | |
| <i>quetiapine oral tablet 150 mg</i> | 2 | QL (30 per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg, 300 mg, 400 mg, 50 mg (Seroquel XR)</i> | 2 | |
| <i>REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG</i> | 5 | NM; NDS; QL (30 per 30 days) |
| <i>risperidone microspheres intramuscular suspension,extended rel recon 12.5 mg/2 ml (Risperdal Consta)</i> | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres intramuscular suspension,extended rel recon 25 mg/2 ml (Rykindo)</i> | 2 | QL (2 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------|------------------|----------------------------------|
| <i>risperidone microspheres intramuscular suspension,extended rel recon 37.5 mg/2 ml, 50 mg/2 ml</i> | (Rykindo) | 5 | NM; NDS; QL (2 per 28 days) |
| <i>risperidone oral solution 1 mg/ml</i> | (Risperdal) | 2 | |
| <i>risperidone oral tablet 0.25 mg</i> | | 2 | |
| <i>risperidone oral tablet 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | (Risperdal) | 2 | |
| <i>risperidone oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | | 2 | |
| RYKINDO INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML | (risperidone microspheres) | 5 | NM; NDS; QL (2 per 28 days) |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | | 2 | |
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | | 2 | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | | 2 | |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML | | 5 | NM; NDS; QL (0.28 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML | | 5 | NM; NDS; QL (0.35 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML | | 5 | NM; NDS; QL (0.42 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML | | 5 | NM; NDS; QL (0.56 per 56 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML | 5 | NM; NDS; QL (0.7 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML | 5 | NM; NDS; QL (0.14 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML | 5 | NM; NDS; QL (0.21 per 28 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | ST; NM; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5 | ST; NM; NDS; QL (30 per 30 days) |
| VRAYLAR ORAL CAPSULE,DOSE PACK 1.5 MG (1)- 3 MG (6) | 4 | ST |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> (Geodon) | 2 | |
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i> (Geodon) | 2 | QL (6 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | 4 | QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 300 MG | 5 | NM; NDS; QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 405 MG | 5 | NM; NDS; QL (1 per 28 days) |
| Antivirals (Systemic) | | |
| Antiretrovirals | | |
| <i>abacavir oral solution 20 mg/ml</i> (Ziagen) | 2 | |
| <i>abacavir oral tablet 300 mg</i> | 2 | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| APRETUDE INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE 600 MG/3 ML (200 MG/ML) (cabotegravir) | 5 | NM; NDS; QL (24 per 365 days) |
| APTIVUS ORAL CAPSULE 250 MG | 5 | NM; NDS |
| <i>atazanavir oral capsule 150 mg</i> | 2 | |
| <i>atazanavir oral capsule 200 mg, 300 mg</i> (Reyataz) | 2 | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 5 | NM; NDS; QL (30 per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION,EXTENDED RELEASE 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML | 5 | NM; NDS |
| <i>cabotegravir intramuscular suspension,extended release 400 mg/2 ml (200 mg/ml)</i> | 5 | NM; NDS; QL (24 per 365 days) |
| <i>cabotegravir intramuscular suspension,extended release 600 mg/3 ml (200 mg/ml)</i> (Apretude) | 5 | NM; NDS; QL (24 per 365 days) |
| CIMDUO ORAL TABLET 300-300 MG | 5 | NM; NDS |
| <i>darunavir oral tablet 600 mg, 800 mg</i> (Prezista) | 5 | NM; NDS |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | NM; NDS |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 5 | NM; NDS |
| <i>didanosine oral capsule,delayed release(dr/ec) 250 mg, 400 mg</i> | 2 | |
| DOVATO ORAL TABLET 50-300 MG | 5 | NM; NDS |
| EDURANT ORAL TABLET 25 MG | 5 | NM; NDS |
| EDURANT PED ORAL TABLET FOR SUSPENSION 2.5 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | 2 | |
| <i>efavirenz oral tablet 600 mg</i> | 2 | |
| <i>efavirenz-emtricitabin-tenofovir oral tablet 600-200-300 mg</i> | 5 | NM; NDS |
| <i>efavirenz-lamivu-tenofovir disop oral tablet 400-300-300 mg</i> | 5 | NM; NDS |
| <i>efavirenz-lamivu-tenofovir disop oral (Symfi) tablet 600-300-300 mg</i> | 5 | NM; NDS |
| <i>emtricitabine oral capsule 200 mg (Emtriva)</i> | 2 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 133-200 mg, 167-250 mg</i> | 5 | NM; NDS |
| <i>emtricitabine-tenofovir (tdf) oral tablet 200-300 mg (Truvada)</i> | 2 | |
| <i>emtricitabine-rilpivirine-tenofdf oral tablet 200-25-300 mg</i> | 5 | NM; NDS |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | |
| EPIVIR HBV ORAL SOLUTION 25 MG/5 ML (5 MG/ML) | 4 | |
| <i>etravirine oral tablet 100 mg, 200 mg (Intelence)</i> | 5 | NM; NDS |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | NM; NDS |
| <i>fosamprenavir oral tablet 700 mg</i> | 5 | NM; NDS |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 5 | NM; NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | NM; NDS |
| INTELLENCE ORAL TABLET 25 MG | 4 | |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | NM; NDS |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| ISENTRESS ORAL TABLET 400 MG | 5 | NM; NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 100 MG | 5 | NM; NDS |
| ISENTRESS ORAL TABLET,CHEWABLE 25 MG | 3 | |
| JULUCA ORAL TABLET 50-25 MG | 5 | NM; NDS |
| KALETRA ORAL SOLUTION 400- (lopinavir-ritonavir) 100 MG/5 ML | 4 | QL (480 per 30 days) |
| <i>lamivudine oral solution 10 mg/ml</i> (Epivir) | 2 | |
| <i>lamivudine oral tablet 100 mg</i> | 2 | |
| <i>lamivudine oral tablet 150 mg, 300 mg</i> (Epivir) | 2 | |
| <i>lamivudine-zidovudine oral tablet 150-300 mg</i> | 2 | |
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |
| <i>lopinavir-ritonavir oral solution 400- 100 mg/5 ml</i> (Kaletra) | 2 | QL (480 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> (Kaletra) | 2 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> (Kaletra) | 2 | QL (120 per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> (Selzentry) | 5 | NM; NDS |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | 2 | QL (1200 per 30 days) |
| <i>nevirapine oral tablet 200 mg</i> | 2 | QL (60 per 30 days) |
| <i>nevirapine oral tablet extended release 24 hr 100 mg</i> | 2 | QL (90 per 30 days) |
| <i>nevirapine oral tablet extended release 24 hr 400 mg</i> | 2 | QL (30 per 30 days) |
| NORVIR ORAL POWDER IN PACKET 100 MG | 4 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| NORVIR ORAL SOLUTION 80 MG/ML | 4 | |
| ODEFSEY ORAL TABLET 200-25-25 MG | 5 | NM; NDS |
| PIFELTRO ORAL TABLET 100 MG | 5 | NM; NDS |
| PREZCOBIX ORAL TABLET 675-150 MG, 800-150 MG-MG | 5 | NM; NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | NM; NDS |
| PREZISTA ORAL TABLET 150 MG, 75 MG | 5 | NM; NDS |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | 4 | |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 5 | NM; NDS |
| <i>rilpivirine intramuscular suspension, extended release 600 mg/2 ml (300 mg/ml), 900 mg/3 ml (300 mg/ml)</i> | 5 | NM; NDS |
| <i>ritonavir oral tablet 100 mg (Norvir)</i> | 2 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 5 | NM; NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 5 | NM; NDS |
| SELZENTRY ORAL TABLET 25 MG | 3 | |
| SELZENTRY ORAL TABLET 75 MG | 5 | NM; NDS |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | 2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| SUNLENCA ORAL TABLET 300 MG, 300 MG (4-TABLET PACK), 300 MG (5-TABLET PACK) | 5 | NM; NDS |
| SUNLENCA SUBCUTANEOUS SOLUTION 309 MG/ML | 5 | PA BvD; NM; NDS |
| SYMTUZA ORAL TABLET 800-150-200-10 MG | 5 | NM; NDS |
| TEMIXYS ORAL TABLET 300-300 MG | 5 | NM; NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> (Viread) | 2 | |
| TIVICAY ORAL TABLET 10 MG | 4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | NM; NDS |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 5 | NM; NDS |
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | NM; NDS; QL (30 per 30 days) |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG | 4 | |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 5 | NM; NDS |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) | 5 | NM; NDS |
| VEMLIDY ORAL TABLET 25 MG | 5 | NM; NDS; QL (30 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 5 | NM; NDS |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 5 | NM; NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 5 | NM; NDS |
| VOCABRIA ORAL TABLET 30 MG | 4 | |
| <i>zidovudine oral capsule 100 mg</i> (Retrovir) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>zidovudine oral syrup 10 mg/ml</i> (Retrovir) | 2 | |
| <i>zidovudine oral tablet 300 mg</i> | 2 | |
| Antivirals, Miscellaneous | | |
| LIVTENCITY ORAL TABLET 200 MG | 5 | PA; NM; NDS |
| <i>oseltamivir oral capsule 30 mg</i> (Tamiflu) | 2 | QL (84 per 180 days) |
| <i>oseltamivir oral capsule 45 mg</i> (Tamiflu) | 2 | QL (48 per 180 days) |
| <i>oseltamivir oral capsule 75 mg</i> (Tamiflu) | 2 | QL (42 per 180 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> (Tamiflu) | 2 | QL (540 per 180 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (10)- 100 MG (10) | 2 | QL (20 per 5 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (6)- 100 MG (5) | 2 | QL (11 per 28 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG | 2 | QL (30 per 5 days) |
| PREVYMIS ORAL PELLETS IN PACKET 120 MG, 20 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 4 | QL (60 per 180 days) |
| <i>rimantadine oral tablet 100 mg</i> (Flumadine) | 2 | |
| Hcv Antivirals | | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| EPCLUSUSA ORAL TABLET 400-100 (sofosbuvir-velpatasvir) MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| HARVONI ORAL TABLET 45-200 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL TABLET 90-400 (ledipasvir-sofosbuvir) MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| MAVYRET ORAL TABLET 100-40 MG | 5 | PA; NM; NDS; QL (84 per 28 days) |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| Interferons | | |
| INTRON A INJECTION RECON SOLN 10 MILLION UNIT (1 ML), 18 MILLION UNIT (1 ML), 50 MILLION UNIT (1 ML) | 5 | NM; NDS |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | PA; NM; NDS |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 5 | PA; NM; NDS |
| Nucleosides And Nucleotides | | |
| <i>acyclovir oral capsule 200 mg</i> | 1 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> (Zovirax) | 2 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 2 | |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 2 | PA BvD |
| <i>adefovir oral tablet 10 mg</i> (Hepsera) | 2 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> (Baraclude) | 2 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | |
| <i>lagevrio (eua) oral capsule 200 mg</i> | 4 | QL (40 per 5 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>ribavirin oral capsule 200 mg</i> | 2 | |
| <i>ribavirin oral tablet 200 mg</i> | 2 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> (Valtrex) | 2 | |
| <i>valganciclovir oral recon soln 50 mg/ml</i> (Valcyte) | 5 | NM; NDS |
| <i>valganciclovir oral tablet 450 mg</i> (Valcyte) | 2 | |
| Blood Products/Modifiers/Volume Expanders | | |
| Anticoagulants | | |
| <i>dabigatran etexilate oral capsule 110 mg, 150 mg, 75 mg</i> (Pradaxa) | 2 | QL (60 per 30 days) |
| <i>ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS)</i> | 3 | |
| <i>ELIQUIS ORAL TABLET 2.5 MG</i> | 3 | QL (60 per 30 days) |
| <i>ELIQUIS ORAL TABLET 5 MG</i> | 3 | QL (74 per 30 days) |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 150 mg/ml</i> (Lovenox) | 2 | QL (60 per 30 days) |
| <i>enoxaparin subcutaneous syringe 120 mg/0.8 ml, 80 mg/0.8 ml</i> (Lovenox) | 2 | QL (48 per 30 days) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> (Lovenox) | 2 | QL (18 per 30 days) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> (Lovenox) | 2 | QL (24 per 30 days) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> (Lovenox) | 2 | QL (36 per 30 days) |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml</i> (Arixtra) | 5 | NM; NDS; QL (24 per 30 days) |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> (Arixtra) | 2 | QL (15 per 30 days) |
| <i>fondaparinux subcutaneous syringe 5 mg/0.4 ml</i> (Arixtra) | 5 | NM; NDS; QL (12 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| fondaparinux subcutaneous syringe (Arixtra) 7.5 mg/0.6 ml | 5 | NM; NDS; QL (18 per 30 days) |
| heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml | 2 | |
| jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg (warfarin) | 1 | |
| rivaroxaban oral suspension for reconstitution 1 mg/ml (Xarelto) | 2 | QL (600 per 30 days) |
| rivaroxaban oral tablet 2.5 mg (Xarelto) | 2 | QL (60 per 30 days) |
| warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg (Jantoven) | 1 | |
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) | 3 | |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION 1 MG/ML (rivaroxaban) | 3 | QL (600 per 30 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG (rivaroxaban) | 3 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG, 2.5 MG (rivaroxaban) | 3 | QL (60 per 30 days) |
| Blood Formation Modifiers | | |
| ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| CINRYZE INTRAVENOUS RECON SOLN 500 UNIT (5 ML) | 5 | PA; NM; NDS |
| DOPTELET (10 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| DOPTELET (15 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| DOPTELET (30 TAB PACK) ORAL TABLET 20 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>eltrombopag olamine oral powder in packet 12.5 mg</i> (Promacta) | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>eltrombopag olamine oral powder in packet 25 mg</i> (Promacta) | 5 | PA; NM; NDS; QL (180 per 30 days) |
| <i>eltrombopag olamine oral tablet 12.5 mg</i> (Promacta) | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>eltrombopag olamine oral tablet 25 mg</i> (Promacta) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>eltrombopag olamine oral tablet 50 mg, 75 mg</i> (Promacta) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| FYLNETRA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 5 | PA; NM; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 5 | PA; NM; NDS; QL (20 per 30 days) |
| LEUKINE INJECTION RECON SOLN 250 MCG | 5 | PA; NM; NDS |
| NEULASTA ONPRO SUBCUTANEOUS SYRINGE, W/ WEARABLE INJECTOR 6 MG/0.6 ML | 5 | PA; NM; NDS |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NM; NDS |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NM; NDS |
| NYVEPRIA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 3 | PA; QL (12 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML | 3 | PA; QL (4 per 28 days) |
| ROLVEDON SUBCUTANEOUS SYRINGE 13.2 MG/0.6 ML | 5 | PA; NM; NDS |
| STIMUFEND SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| ZARXIO INJECTION SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NM; NDS |
| Hematologic Agents, Miscellaneous | | |
| <i>anagrelide oral capsule 0.5 mg</i> (Agrylin) | 2 | |
| <i>anagrelide oral capsule 1 mg</i> | 2 | |
| CABLIVI INJECTION KIT 11 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| DROXIA ORAL CAPSULE 200 MG, 300 MG, 400 MG | 4 | |
| TAVALISSE ORAL TABLET 100 MG, 150 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | |
| Platelet-Aggregation Inhibitors | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 2 | |
| BRILINTA ORAL TABLET 60 MG, (ticagrelor) 90 MG | 3 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | |
| <i>clopidogrel oral tablet 75 mg</i> (Plavix) | 1 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 2 | |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> (Effient) | 2 | QL (30 per 30 days) |
| <i>ticagrelor oral tablet 60 mg, 90 mg</i> (Brilinta) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| Caloric Agents | | |
| Caloric Agents | | |
| CLINIMIX 5%/D15W SULFITE FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX 4.25%/D10W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 4.25%/D5W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX 5%-D20W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX 6%-D5W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 6-5 % | 4 | PA BvD |
| CLINIMIX 8%-D10W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| CLINIMIX 8%-D14W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | PA BvD |
| CLINIMIX E 2.75%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 2.75 % | 4 | PA BvD |
| CLINIMIX E 4.25%/D10W SUL FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX E 4.25%/D5W SULF FREE INTRAVENOUS PARENTERAL SOLUTION 4.25 % | 4 | PA BvD |
| CLINIMIX E 5%/D15W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| CLINIMIX E 5%/D20W SULFIT FREE INTRAVENOUS PARENTERAL SOLUTION 5 % | 4 | PA BvD |
| CLINIMIX E 8%-D10W SULFITEFREE INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| CLINIMIX E 8%-D14W SULFITEFREE INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | PA BvD |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i> | 2 | |
| PROCALAMINE 3% INTRAVENOUS PARENTERAL SOLUTION 3 % | 4 | PA BvD |
| PROSOL 20 % INTRAVENOUS PARENTERAL SOLUTION | 4 | PA BvD |
| TRAVASOL 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| TROPHAMINE 10 % INTRAVENOUS PARENTERAL SOLUTION 10 % | 4 | PA BvD |
| Cardiovascular Agents | | |
| Alpha-Adrenergic Agents | | |
| clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg | 1 | |
| clonidine transdermal patch weekly (Catapres-TTS-1) 0.1 mg/24 hr | 2 | |
| clonidine transdermal patch weekly (Catapres-TTS-2) 0.2 mg/24 hr | 2 | |
| clonidine transdermal patch weekly (Catapres-TTS-3) 0.3 mg/24 hr | 2 | |
| doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg | 1 | |
| droxidopa oral capsule 100 mg, 200 mg, 300 mg | 5 | PA; NM; NDS; QL (180 per 30 days) |
| guanfacine oral tablet 1 mg, 2 mg | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | |
| Angiotensin II Receptor Antagonists | | |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> | 2 | |
| <i>candesartan-hydrochlorothiazide oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> | 2 | |
| <i>ENTRESTO SPRINKLE ORAL PELLET 15-16 MG, 6-6 MG</i> | 3 | QL (240 per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg</i> | 2 | |
| <i>irbesartan oral tablet 75 mg</i> | 2 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> | 2 | |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> | 1 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> | 2 | |
| <i>olmesartan-amlodipine-hydrochlorothiazide oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> | 2 | |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> | 2 | |
| <i>sacubitril-valsartan oral tablet 24-26 mg, 49-51 mg, 97-103 mg</i> | 2 | QL (60 per 30 days) |
| <i>telmisartan oral tablet 20 mg</i> | 2 | |
| <i>telmisartan oral tablet 40 mg, 80 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>telmisartan-amlodipine oral tablet 40-10 mg, 40-5 mg, 80-10 mg, 80-5 mg</i> | 2 | |
| <i>telmisartan-hydrochlorothiazide oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> | 2 | |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> | 2 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320- 12.5 mg, 320-25 mg, 80-12.5 mg</i> | 2 | |
| Angiotensin-Converting Enzyme Inhibitors | | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>benazepril oral tablet 5 mg</i> | 1 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 2 | |
| <i>benazepril-hydrochlorothiazide oral tablet 5-6.25 mg</i> | 2 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 2 | |
| <i>enalapril maleate oral solution 1 mg/ml</i> | 2 | ST; QL (1200 per 30 days) |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> | 1 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg</i> | 1 | |
| <i>enalapril-hydrochlorothiazide oral tablet 5-12.5 mg</i> | 1 | |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> (Zestril) | 1 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Zestoretic) | 1 | |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 2 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 2 | |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Accupril) | 1 | |
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Accuretic) | 2 | |
| <i>ramipril oral capsule 1.25 mg, 2.5 mg, 5 mg</i> (Altace) | 1 | |
| <i>ramipril oral capsule 10 mg</i> | 1 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 1 | |
| <i>trandolapril-verapamil oral tablet, ir - er, biphasic 24hr 1-240 mg, 2-180 mg, 2-240 mg, 4-240 mg</i> | 2 | |
| Antiarrhythmic Agents | | |
| <i>amiodarone oral tablet 100 mg, 200 mg</i> (Pacerone) | 2 | |
| <i>amiodarone oral tablet 400 mg</i> | 2 | |
| <i>disopyramide phosphate oral capsule 100 mg, 150 mg</i> (Norpace) | 2 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> (Tikosyn) | 2 | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | |
| <i>mexiletine oral capsule 150 mg, 200 mg, 250 mg</i> | 2 | |
| MULTAQ ORAL TABLET 400 MG | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| pacerone oral tablet 100 mg, 200 mg, (amiodarone) 400 mg | 2 | |
| propafenone oral capsule,extended release 12 hr 225 mg, 325 mg, 425 mg | 2 | |
| propafenone oral tablet 150 mg, 225 mg, 300 mg | 2 | |
| quinidine gluconate oral tablet extended release 324 mg | 2 | |
| quinidine sulfate oral tablet 200 mg, 300 mg | 2 | |
| Beta-Adrenergic Blocking Agents | | |
| acebutolol oral capsule 200 mg, 400 mg | 2 | |
| atenolol oral tablet 100 mg, 25 mg, (Tenormin) 50 mg | 1 | |
| atenolol-chlorthalidone oral tablet (Tenoretic 100) 100-25 mg | 2 | |
| atenolol-chlorthalidone oral tablet (Tenoretic 50) 50-25 mg | 2 | |
| betaxolol oral tablet 10 mg, 20 mg | 2 | |
| bisoprolol fumarate oral tablet 10 mg, 2.5 mg, 5 mg | 2 | |
| bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg | 2 | |
| carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg (Coreg) | 1 | |
| labetalol oral tablet 100 mg, 200 mg, 300 mg | 2 | |
| metoprolol succinate oral tablet (Toprol XL) extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg | 1 | |
| metoprolol ta-hydrochlorothiaz oral tablet 100-25 mg, 100-50 mg, 50-25 mg | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> (Lopressor) | 1 | |
| <i>metoprolol tartrate oral tablet 25 mg</i> | 1 | |
| <i>nadolol oral tablet 20 mg, 40 mg, 80 mg</i> | 2 | |
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Bystolic) | 2 | |
| <i>pindolol oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>propranolol oral capsule,extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> (Inderal LA) | 2 | |
| <i>propranolol oral solution 20 mg/5 ml (4 mg/ml), 40 mg/5 ml (8 mg/ml)</i> | 2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> (sotalol) | 2 | |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> (sotalol) | 2 | |
| <i>sotalol oral tablet 120 mg, 160 mg, 80 mg</i> (Sotalol AF) | 2 | |
| <i>sotalol oral tablet 240 mg</i> (Betapace) | 2 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| Calcium-Channel Blocking Agents | | |
| <i>cartia xt oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (diltiazem hcl) | 2 | |
| <i>diltiazem 24hr er 360 mg cap once-a-day dosage</i> (Tiadylt ER) | 2 | |
| <i>diltiazem 24hr er 420 mg cap</i> (Tiadylt ER) | 2 | |
| <i>diltiazem hcl oral capsule,extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 2 | |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg</i> (Tiadylt ER) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------|------------------|----------------------------------|
| diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg | (Cartia XT) | 2 | |
| diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg | (Cardizem) | 2 | |
| diltiazem hcl oral tablet 90 mg | | 2 | |
| diltiazem hcl oral tablet extended release 24 hr 120 mg | (Cardizem LA) | 2 | |
| diltiazem hcl oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | (Matzim LA) | 2 | |
| dilt-xr oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg | (diltiazem hcl) | 2 | |
| matzim la oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | (diltiazem hcl) | 2 | |
| taztia xt oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg | (diltiazem hcl) | 2 | |
| tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg | (diltiazem hcl) | 2 | |
| verapamil oral capsule, 24 hr er pellet ct 100 mg, 200 mg, 300 mg | | 2 | |
| verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg | | 2 | |
| verapamil oral capsule,ext rel. pellets 24 hr 360 mg | | 4 | |
| verapamil oral tablet 120 mg, 40 mg, 80 mg | | 1 | |
| verapamil oral tablet extended release 120 mg, 180 mg, 240 mg | | 2 | |
| Cardiovascular Agents, Miscellaneous | | | |
| CAMZYOS ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 5 MG | | 5 | PA; NM; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 3 | QL (600 per 30 days) |
| <i>digoxin injection syringe 250 mcg/ml (0.25 mg/ml)</i> | 2 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> | 2 | |
| <i>digoxin oral tablet 62.5 mcg (0.0625 mg)</i> | 2 | |
| <i>epinephrine injection auto-injector 0.15 mg/0.15 ml</i> | 3 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml</i> | 2 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.3 mg/0.3 ml</i> | 3 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.3 mg/0.3 ml</i> | 2 | QL (4 per 30 days) |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> | 5 | PA; NM; NDS; QL (18 per 30 days) |
| <i>ivabradine oral tablet 5 mg, 7.5 mg</i> | 3 | QL (60 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> | 5 | NM; NDS |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg</i> | 2 | QL (60 per 30 days) |
| <i>ranolazine oral tablet extended release 12 hr 500 mg</i> | 2 | QL (120 per 30 days) |
| <i>sajazir subcutaneous syringe 30 mg/3 ml</i> (icatibant) | 5 | PA; NM; NDS; QL (18 per 30 days) |
| SYMJEPI INJECTION SYRINGE 0.15 MG/0.3 ML | 4 | QL (4 per 30 days) |
| SYMJEPI INJECTION SYRINGE 0.3 MG/0.3 ML | 4 | QL (4 per 30 days) |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 4 | PA; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| Dihydropyridines | | |
| amlodipine oral tablet 10 mg, 2.5 mg, 5 mg (Norvasc) | 1 | |
| amlodipine-benazepril oral capsule (Lotrel) 10-20 mg, 10-40 mg, 5-10 mg, 5-20 mg | 1 | |
| amlodipine-benazepril oral capsule 2.5-10 mg, 5-40 mg | 1 | |
| amlodipine-olmesartan oral tablet (Azor) 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg | 2 | |
| amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg (Exforge) | 2 | |
| amlodipine-valsartan-hctiazid oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg (Exforge HCT) | 2 | |
| felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg | 2 | |
| isradipine oral capsule 2.5 mg, 5 mg | 2 | |
| KATERZIA ORAL SUSPENSION 1 MG/ML | 4 | ST; QL (300 per 30 days) |
| nicardipine oral capsule 20 mg, 30 mg | 2 | |
| nifedipine oral capsule 10 mg, 20 mg | 2 | |
| nifedipine oral tablet extended release 24hr 30 mg, 60 mg, 90 mg (Procardia XL) | 2 | |
| nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg | 2 | |
| Diuretics | | |
| amiloride oral tablet 5 mg | 1 | |
| amiloride-hydrochlorothiazide oral tablet 5-50 mg | 2 | |
| bumetanide oral tablet 0.5 mg, 1 mg, 2 mg | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>furosemide injection solution 10 mg/ml</i> | 1 | |
| <i>furosemide injection syringe 10 mg/ml</i> | 1 | |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 2 | |
| <i>furosemide oral tablet 20 mg, 40 mg, (Lasix) 80 mg</i> | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>spironolactone oral tablet 100 mg, (Aldactone) 25 mg, 50 mg</i> | 1 | |
| <i>spironolacton-hydrochlorothiaz oral tablet 25-25 mg</i> | 2 | |
| <i>tolvaptan (polycys kidney dis) oral tablet 15 mg, 30 mg</i> | 5 | PA; NM; NDS; QL (120 per 30 days) |
| <i>tolvaptan (polycys kidney dis) oral tablets, sequential 15 mg (am)/ 15 mg (pm), 30 mg (am)/ 15 mg (pm), 45 mg (am)/ 15 mg (pm), 60 mg (am)/ 30 mg (pm), 90 mg (am)/ 30 mg (pm)</i> | 5 | PA; NM; NDS; QL (56 per 28 days) |
| <i>torsemide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| Dyslipidemics | | |
| amlodipine-atorvastatin oral tablet 10-10 mg, 5-10 mg (Caduet) | 2 | |
| amlodipine-atorvastatin oral tablet 10-20 mg, 10-40 mg, 10-80 mg, 5-20 mg, 5-40 mg, 5-80 mg (Caduet) | 2 | QL (30 per 30 days) |
| amlodipine-atorvastatin oral tablet 2.5-10 mg, 2.5-20 mg, 2.5-40 mg | 2 | |
| atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg (Lipitor) | 1 | QL (30 per 30 days) |
| cholestyramine (with sugar) oral powder in packet 4 gram (Questran) | 2 | |
| cholestyramine light oral powder in packet 4 gram | 2 | |
| colesevelam oral powder in packet 3.75 gram (WelChol) | 2 | |
| colesevelam oral tablet 625 mg (WelChol) | 2 | |
| colestipol oral packet 5 gram | 2 | |
| colestipol oral tablet 1 gram (Colestid) | 2 | |
| EZALLOR SPRINKLE ORAL CAPSULE, SPRINKLE 10 MG, 20 MG, 40 MG, 5 MG | 4 | ST; QL (30 per 30 days) |
| ezetimibe oral tablet 10 mg (Zetia) | 2 | QL (30 per 30 days) |
| ezetimibe-simvastatin oral tablet 10- 10 mg (Vytorin 10-10) | 2 | QL (30 per 30 days) |
| ezetimibe-simvastatin oral tablet 10- 20 mg (Vytorin 10-20) | 2 | QL (30 per 30 days) |
| ezetimibe-simvastatin oral tablet 10- 40 mg (Vytorin 10-40) | 2 | QL (30 per 30 days) |
| ezetimibe-simvastatin oral tablet 10- 80 mg (Vytorin 10-80) | 2 | QL (30 per 30 days) |
| fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-------------|------------------|----------------------------------|
| <i>fenofibrate nanocrystallized oral tablet 145 mg, 48 mg</i> | (Tricor) | 2 | |
| <i>fenofibrate oral tablet 120 mg, 40 mg, 54 mg</i> | | 2 | |
| <i>fenofibrate oral tablet 160 mg</i> | | 1 | |
| <i>fenofibric acid (choline) oral capsule,delayed release(dr/ec) 135 mg, 45 mg</i> | | 2 | |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> | | 2 | QL (60 per 30 days) |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i> | (Lescol XL) | 2 | |
| <i>gemfibrozil oral tablet 600 mg</i> | (Lopid) | 1 | |
| <i>icosapent ethyl oral capsule 0.5 gram</i> | (Vascepa) | 2 | QL (240 per 30 days) |
| <i>icosapent ethyl oral capsule 1 gram</i> | (Vascepa) | 2 | QL (120 per 30 days) |
| JUXTAPID ORAL CAPSULE 10 MG, 5 MG | | 5 | PA; NM; NDS; QL (28 per 28 days) |
| JUXTAPID ORAL CAPSULE 20 MG, 30 MG | | 5 | PA; NM; NDS; QL (56 per 28 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | | 1 | |
| NEXLETOL ORAL TABLET 180 MG | | 3 | ST; QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | | 3 | ST; QL (30 per 30 days) |
| <i>niacin oral tablet 500 mg</i> | (Niacor) | 2 | |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg</i> | | 2 | |
| <i>niacor oral tablet 500 mg</i> | (niacin) | 2 | |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> | (Lovaza) | 2 | ST; QL (120 per 30 days) |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i> | (Livalo) | 2 | QL (30 per 30 days) |
| <i>pravastatin oral tablet 10 mg, 80 mg</i> | | 1 | |
| <i>pravastatin oral tablet 20 mg, 40 mg</i> | | 1 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>prevalite oral powder in packet 4 gram</i> | 2 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML | 3 | ST; QL (7 per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML | 3 | ST; QL (6 per 28 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML | 3 | ST; QL (6 per 28 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Crestor) | 1 | QL (30 per 30 days) |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg</i> (Zocor) | 1 | QL (30 per 30 days) |
| <i>simvastatin oral tablet 5 mg, 80 mg</i> | 1 | QL (30 per 30 days) |
| Renin-Angiotensin-Aldosterone System Inhibitors | | |
| <i>aliskiren oral tablet 150 mg, 300 mg</i> (Tekturna) | 2 | |
| <i>eplerenone oral tablet 25 mg, 50 mg</i> (Inspira) | 2 | |
| KERENDIA ORAL TABLET 10 MG, 20 MG, 40 MG | 3 | PA; QL (30 per 30 days) |
| <i>spironolactone oral suspension 25 mg/5 ml</i> (CaroSpir) | 2 | ST; QL (600 per 30 days) |
| Vasodilators | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg</i> | 2 | |
| <i>isosorbide dinitrate oral tablet 40 mg</i> (Isordil) | 2 | |
| <i>isosorbide dinitrate oral tablet 5 mg</i> (Isordil Titrabose) | 2 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------|------------------|----------------------------|
| <i>isosorbide-hydralazine oral tablet 20-37.5 mg</i> | (BiDil) | 2 | |
| <i>minitran transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | (nitroglycerin) | 2 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | | 2 | |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> | (Nitrostat) | 2 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> | (Nitro-Dur) | 2 | |

Central Nervous System

Agents

Central Nervous System Agents

| | | |
|--|---|--------------------------------------|
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> | 2 | QL (60 per 30 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | 2 | QL (30 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 18 MG, 24 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 30 MG, 36 MG, 42 MG, 48 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | 5 | PA; NM; NDS; QL (210 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------------|
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24- 30 MG, 6 MG (14)-12 MG (14)-24 MG (14) | 5 | PA; NM; NDS |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NM; NDS; QL (15 per 30 days) |
| <i>clonidine hcl oral tablet extended release 12 hr 0.1 mg</i> | 2 | |
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> | 2 | PA; QL (60 per 30 days) |
| <i>dexmethylphenidate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 10 mg, 15 mg</i> | 2 | QL (120 per 30 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 5 mg</i> | 2 | QL (120 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> | 2 | QL (180 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 15 mg, 2.5 mg, 5 mg, 7.5 mg</i> | 2 | QL (120 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 20 mg</i> | 2 | QL (90 per 30 days) |
| <i>dextroamphetamine sulfate oral tablet 30 mg</i> | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 10 mg, 15 mg, 5 mg</i> | 2 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|---------------|------------------|----------------------------------|
| <i>dextroamphetamine-amphetamine oral capsule,extended release 24hr 20 mg, 25 mg, 30 mg</i> | (Adderall XR) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> | (Adderall) | 2 | QL (60 per 30 days) |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg</i> | (Tecfidera) | 5 | PA; NM; NDS; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> | (Tecfidera) | 5 | PA; NM; NDS |
| <i>dimethyl fumarate oral capsule,delayed release(dr/ec) 240 mg</i> | (Tecfidera) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| ENSPRYNG SUBCUTANEOUS SYRINGE 120 MG/ML | | 5 | PA; NM; NDS |
| <i>fingolimod oral capsule 0.5 mg</i> | (Gilenya) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> | (Glatopa) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> | (Glatopa) | 5 | PA; NM; NDS; QL (12 per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> | (glatiramer) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> | (glatiramer) | 5 | PA; NM; NDS; QL (12 per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> | (Intuniv ER) | 2 | |
| INGREZZA INITIATION PK(TARDIV) ORAL CAPSULE,DOSE PACK 40 MG (7)- 80 MG (21) | | 5 | PA; NM; NDS |
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG | | 5 | PA; NM; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| INGREZZA SPRINKLE ORAL CAPSULE, SPRINKLE 40 MG, 60 MG, 80 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML | 5 | PA; NM; NDS; QL (1.2 per 28 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | |
| <i>lithium carbonate oral tablet (Lithobid) extended release 300 mg</i> | 2 | |
| <i>lithium carbonate oral tablet extended release 450 mg</i> | 2 | |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | 2 | |
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG | 5 | PA; NM; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| MAYZENT ORAL TABLET 1 MG, 2 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| MAYZENT STARTER(FOR 1MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (7 TABS) | 3 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--|------------------|----------------------------|
| MAYZENT STARTER(FOR 2MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) | | 5 | PA; NM; NDS |
| <i>metadate er oral tablet extended release 20 mg</i> (methylphenidate hcl) | | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 10 mg, 20 mg, 40 mg, 50 mg, 60 mg</i> (Metadate CD) | | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70 30 mg</i> (Metadate CD) | | 2 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg, 20 mg, 40 mg</i> (Ritalin LA) | | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 30 mg</i> (Ritalin LA) | | 2 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 60 mg</i> | | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml</i> (Methylin) | | 2 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> (Ritalin) | | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 10 mg</i> | | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 20 mg</i> (Metadate ER) | | 2 | QL (90 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg (bx rating), 27 mg (bx rating), 54 mg (bx rating)</i> | | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 27 mg, 54 mg</i> (Concerta) | | 2 | QL (30 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg</i> (Concerta) | | 2 | QL (60 per 30 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 36 mg (bx rating)</i> | | 2 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|---------------------------------|------------------|-----------------------------------|
| <i>methylphenidate hcl oral tablet extended release 24hr 72 mg</i> | (Relexxii) | 2 | QL (30 per 30 days) |
| OCREVUS INTRAVENOUS SOLUTION 30 MG/ML | | 5 | PA; NM; NDS; QL (20 per 180 days) |
| OCREVUS ZUNOVO SUBCUTANEOUS SOLUTION 920 MG-23,000 UNIT/23 ML | | 5 | PA; NM; NDS; QL (23 per 180 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | | 5 | PA; NM; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 63 MCG/0.5 ML- 94 MCG/0.5 ML | | 5 | PA; NM; NDS |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | | 5 | PA; NM; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 63 MCG/0.5 ML- 94 MCG/0.5 ML | | 5 | PA; NM; NDS |
| <i>riluzole oral tablet 50 mg</i> | (Rilutek) | 2 | |
| SAVELLA ORAL TABLET 100 MG, 12.5 MG, 25 MG, 50 MG | | 3 | QL (60 per 30 days) |
| SAVELLA ORAL TABLETS,DOSE PACK 12.5 MG (5)-25 MG(8)-50 MG(42) | | 3 | |
| <i>teriflunomide oral tablet 14 mg, 7 mg</i> (Aubagio) | | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> (Xenazine) | | 5 | PA; NM; NDS; QL (112 per 28 days) |
| VUMERTY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | | 5 | PA; NM; NDS; QL (120 per 30 days) |
| Contraceptives | | | |
| Contraceptives | | | |
| <i>afirmelle oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>amethia oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (l norgest/e.estriadiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>amethyst (28) oral tablet 90-20 mcg (28)</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>apri oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>aranelle (28) oral tablet 0.5/1/0.5-35 mg-mcg</i> | | 2 | |
| <i>ashlyna oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (l norgest/e.estriadiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>aurovela 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>ayuna oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estriadiol/e.estriadiol) | 2 | |
| <i>balziva (28) oral tablet 0.4-35 mg-mcg</i> | | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>briellyn oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>camila oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>chateal eq (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>cryselle (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>cyclafem 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>cyclafem 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>dasetta 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>daysee oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (1 norgest/e.estriadiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>deblitane oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>desog-e.estriadiol/e.estriadiol oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (Azurette (28)) | 2 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> | (Aprि) | 2 | |
| <i>dolishale oral tablet 90-20 mcg (28)</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.02 mg</i> | (Jasmiel (28)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|------------------|----------------------------|
| <i>drospirenone-ethinyl estradiol oral tablet 3-0.03 mg</i> | (Syeda) | 2 | |
| <i>elinese oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>emoquette oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>emzahh oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>enilloring vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>errin oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>estarrylla oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg</i> | (Kelnor 1/35 (28)) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg</i> | (Valtya) | 2 | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> | (EluRyng) | 2 | QL (1 per 28 days) |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>feirza oral tablet 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>femynor oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 1 | |
| <i>gemmily oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>hailey fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>haloette vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>heather oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>iclevia oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>incassia oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>introvale oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>isibloom oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>jaimiess oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (l norgest/e.estriadiol-e.estrad) | 2 | QL (91 per 84 days) |
| <i>jasmiel (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>jencycla oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>jolessa oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>juleber oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estriadiol/e.estriadiol) | 2 | |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kelnor 1/50 (28) oral tablet 1-50 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 17.5 MCG/24 HR (5 YRS) 19.5 MG | | 4 | |
| <i>l norgest/e.estriadiol-e.estrad oral tablets,dose pack,3 month 0.1 mg-20 mcg (84)/10 mcg (7)</i> | (Camrese Lo) | 2 | QL (91 per 84 days) |
| <i>l norgest/e.estriadiol-e.estrad oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg</i> | (Rosyrah) | 2 | QL (91 per 84 days) |
| <i>l norgest/e.estriadiol-e.estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (Amethia) | 2 | QL (91 per 84 days) |
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>larissia oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|----------------------------------|------------------|----------------------------|
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>levonorgest-eth.estradiol-iron oral tablet 0.1 mg-0.02 mg (21)/iron (7)</i> | (Balcoltra) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg</i> | (Afirmelle) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.15-0.03 mg</i> | (Altavera (28)) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 90-20 mcg (28)</i> | (Amethyst (28)) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (Iclevia) | 2 | QL (91 per 84 days) |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (Enpresse) | 2 | |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| LILETTA INTRAUTERINE INTRAUTERINE DEVICE 20.4 MCG/24 HR (8 YRS) 52 MG | | 3 | |
| <i>lillow (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>loryna (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>lo-zumandimine (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>lutera (28) oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>lyeq oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>lyza oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| marlissa (28) oral tablet 0.15-0.03 mg | (levonorgestrel-ethinyl estrad) | 2 | |
| meleya oral tablet 0.35 mg | (norethindrone (contraceptive)) | 2 | |
| merzee oral capsule 1 mg-20 mcg (24)/75 mg (4) | (norethindrone-e.estriadiol-iron) | 2 | |
| microgestin 1.5/30 (21) oral tablet 1.5-30 mg-mcg | (norethindrone ac-eth estradiol) | 2 | |
| microgestin 1/20 (21) oral tablet 1-20 mg-mcg | (norethindrone ac-eth estradiol) | 2 | |
| microgestin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4) | (norethindrone-e.estriadiol-iron) | 2 | |
| microgestin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) | (norethindrone-e.estriadiol-iron) | 2 | |
| microgestin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) | (norethindrone-e.estriadiol-iron) | 2 | |
| mili oral tablet 0.25-0.035 mg | (norgestimate-ethinyl estradiol) | 2 | |
| MIRENA INTRAUTERINE INTRAUTERINE DEVICE 21 MCG/24HR (UP TO 8 YRS) 52 MG | | 4 | |
| mono-linyah oral tablet 0.25-0.035 mg | (norgestimate-ethinyl estradiol) | 2 | |
| NEXPLANON SUBDERMAL IMPLANT 68 MG | | 3 | |
| nikki (28) oral tablet 3-0.02 mg | (drospirenone-ethinyl estradiol) | 2 | |
| norelgestromin-ethin.estriadiol transdermal patch weekly 150-35 mcg/24 hr | (Xulane) | 2 | QL (3 per 28 days) |
| norethindrone (contraceptive) oral tablet 0.35 mg | (Camila) | 2 | |
| norethindrone ac-eth estradiol oral tablet 1.5-30 mg-mcg | (Aurovela 1.5/30 (21)) | 2 | |
| norethindrone ac-eth estradiol oral tablet 1-20 mg-mcg | (Aurovela 1/20 (21)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| <i>norethindrone-e.estriadiol-iron oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (Gemmily) | 2 | |
| <i>norethindrone-e.estriadiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (Aurovela Fe 1-20 (28)) | 2 | |
| <i>norethindrone-e.estriadiol-iron oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (Aurovela Fe 1.5/30 (28)) | 2 | |
| <i>norethindrone-e.estriadiol-iron oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (Tilia Fe) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (Tri-Lo-Estarrylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (Tri-Estarrylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.25-0.035 mg</i> | (Estarrylla) | 2 | |
| <i>norlyda oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i> | | 2 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>nylia 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>nymyo oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>orquidea oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>philith oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>pimtrea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estriadiol/e.estriadiol) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| <i>pirmella oral tablet 0.5/0.75/1 mg-35 mcg</i> | | 2 | |
| <i>pirmella oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>previfem oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 1 | |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>rosyrah oral tablets,dose pack,3 month 0.15 mg-20 mcg/ 0.15 mg-25 mcg</i> | (l norgest/e.estriadiol-e.estrad) | 2 | |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>simliya (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estriadiol/e.estriadiol) | 2 | |
| <i>simpesse oral tablets,dose pack,3 month 0.15 mg-30 mcg (84)/10 mcg (7)</i> | (l norgest/e.estriadiol-e.estrad) | 2 | QL (91 per 84 days) |
| SKYLA INTRAUTERINE INTRAUTERINE DEVICE 14 MCG/24 HR (3 YRS) 13.5 MG | | 4 | |
| SLYND ORAL TABLET 4 MG (28) | | 4 | |
| <i>sprintec (28) oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>syeda oral tablet 3-0.03 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estriadiol-iron) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|------------------|----------------------------|
| <i>taysofy oral capsule 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estriol-iron) | 2 | |
| <i>tilia fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone-e.estriol-iron) | 2 | |
| <i>tri-femynor oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-estarrylla oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone-e.estriol-iron) | 2 | |
| <i>tri-linyah oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-estarrylla oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-nymyo oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-previfem (28) oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> | (norgestimate-ethinyl estradiol) | 1 | |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>turqoz (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| <i>valtya oral tablet 1-50 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>velivet triphasic regimen (28) oral tablet 0.1/.125/.15-25 mg-mcg</i> | | 2 | |
| <i>vestura (28) oral tablet 3-0.02 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |
| <i>vienna oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estriadiol/e.estriadiol) | 2 | |
| <i>volnea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estriadiol/e.estriadiol) | 2 | |
| <i>vyfemla (28) oral tablet 0.4-35 mg-mcg</i> | | 2 | |
| <i>vylibra oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>xarah fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone-e.estriadiol-iron) | 2 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estriadiol) | 2 | QL (3 per 28 days) |
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estriadiol) | 2 | QL (3 per 28 days) |
| <i>zovia 1/35e (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>zumandimine (28) oral tablet 3-0.03 mg</i> | (drospirenone-ethinyl estradiol) | 2 | |

Dental And Oral Agents

Dental And Oral Agents

| | | | |
|---|---------------------|---|--|
| <i>cevimeline oral capsule 30 mg</i> | (Evoxac) | 2 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> | (Periogard) | 1 | |
| <i>denta 5000 plus dental cream 1.1 %</i> | (fluoride (sodium)) | 1 | |
| <i>dentagel dental gel 1.1 %</i> | (fluoride (sodium)) | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------|------------------|----------------------------|
| <i>fluoride (sodium) dental gel 1.1 %</i> | (DentaGel) | 1 | |
| <i>fluoride (sodium) dental solution 0.2 %</i> | (PreviDent) | 1 | |
| <i>periogard mucous membrane mouthwash 0.12 %</i> | (chlorhexidine gluconate) | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> | (Salagen (pilocarpine)) | 2 | |
| <i>sf 5000 plus dental cream 1.1 %</i> | (fluoride (sodium)) | 1 | |
| <i>sodium fluoride-pot nitrate dental paste 1.1-5 %</i> | (Denta 5000 Plus Sensitive) | 1 | |
| <i>triamcinolone acetonide dental paste 0.1 %</i> | (Kourzeq) | 2 | |

Dermatological Agents

Dermatological Agents, Other

| | | | |
|---|----------------|---|----------------------|
| <i>accutane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> | (isotretinoin) | 2 | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | | 2 | |
| <i>acyclovir topical cream 5 %</i> | (Zovirax) | 2 | QL (5 per 4 days) |
| <i>acyclovir topical ointment 5 %</i> | (Zovirax) | 2 | QL (30 per 30 days) |
| <i>ammonium lactate topical cream 12 %</i> | | 2 | |
| <i>ammonium lactate topical lotion 12 %</i> | (AmLactin) | 2 | |
| <i>calcipotriene scalp solution 0.005 %</i> | | 2 | QL (120 per 30 days) |
| <i>calcipotriene topical cream 0.005 %</i> | | 2 | QL (120 per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | | 2 | QL (120 per 30 days) |
| <i>fluorouracil topical cream 0.5 %</i> | (Carac) | 5 | NM; NDS |
| <i>fluorouracil topical cream 5 %</i> | (Efudex) | 2 | |
| <i>fluorouracil topical solution 2 %, 5 %</i> | | 2 | |
| <i>imiquimod topical cream in packet 5 %</i> | | 2 | QL (24 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| ISOPROPYL ALCOHOL TOPICAL SWAB 70 % | 1 | |
| KLISYRI (250 MG) TOPICAL OINTMENT IN PACKET 1 % | 3 | QL (5 per 5 days) |
| <i>methoxsalen oral capsule, liqd-filled, rapid rel 10 mg</i> | 5 | NM; NDS |
| PANRETIN TOPICAL GEL 0.1 % | 5 | NM; NDS; QL (60 per 28 days) |
| <i>penciclovir topical cream 1 %</i> (Denavir) | 2 | |
| <i>podofilox topical solution 0.5 %</i> | 2 | |
| REGRANEX TOPICAL GEL 0.01 % | 5 | PA; NM; NDS; QL (30 per 30 days) |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 4 | QL (180 per 30 days) |
| VALCHLOR TOPICAL GEL 0.016 % | 5 | PA NSO; NM; NDS |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> (isotretinoin) | 2 | |
| Dermatological Antibacterials | | |
| <i>clindamycin phosphate topical foam</i> (Clindacin) 1 % | 2 | QL (100 per 30 days) |
| <i>clindamycin phosphate topical solution</i> 1 % | 2 | QL (180 per 30 days) |
| <i>clindamycin phosphate topical swab</i> (Clindacin ETZ) 1 % | 2 | |
| <i>clindamycin-benzoyl peroxide topical gel</i> 1.2 %(1 % base) -5 % | 2 | |
| <i>clindamycin-benzoyl peroxide topical gel</i> 1-5 % | 2 | |
| <i>ery pads topical swab</i> 2 % (erythromycin with ethanol) | 2 | |
| <i>erythromycin with ethanol topical gel</i> (Erygel) 2 % | 2 | |
| <i>erythromycin with ethanol topical solution</i> 2 % | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| <i>erythromycin-benzoyl peroxide topical gel 3-5 %</i> | (Benzamycin) | 2 | |
| <i>gentamicin topical cream 0.1 %</i> | | 2 | QL (90 per 30 days) |
| <i>gentamicin topical ointment 0.1 %</i> | | 2 | QL (120 per 30 days) |
| <i>metronidazole topical cream 0.75 %</i> | (Rosadan) | 2 | |
| <i>metronidazole topical gel 0.75 %</i> | (Rosadan) | 2 | |
| <i>metronidazole topical gel 1 %</i> | (Metrogel) | 2 | |
| <i>metronidazole topical lotion 0.75 %</i> | (MetroLotion) | 2 | |
| <i>mupirocin topical ointment 2 %</i> | (Centany) | 1 | QL (220 per 30 days) |
| <i>neuac topical gel 1.2 %(1 % base) -5 %</i> | (clindamycin-benzoyl peroxide) | 1 | |
| <i>rosadan topical cream 0.75 %</i> | (metronidazole) | 2 | |
| <i>selenium sulfide topical lotion 2.5 %</i> | | 2 | |
| <i>silver sulfadiazine topical cream 1 %</i> | (SSD) | 2 | |
| <i>ssd topical cream 1 %</i> | (silver sulfadiazine) | 4 | |
| <i>sulfacetamide sodium (acne) topical suspension 10 %</i> | (Klaron) | 2 | |
| Dermatological Anti-Inflammatory Agents | | | |
| <i>ala-cort topical cream 1 %</i> | (hydrocortisone) | 2 | |
| <i>ala-scalp topical lotion 2 %</i> | (hydrocortisone) | 2 | |
| <i>alclometasone topical cream 0.05 %</i> | | 2 | |
| <i>alclometasone topical ointment 0.05 %</i> | | 2 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | | 2 | |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | | 2 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | | 2 | |
| <i>betamethasone valerate topical cream 0.1 %</i> | | 2 | |
| <i>betamethasone valerate topical foam 0.12 %</i> | (Luxiq) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>betamethasone valerate topical lotion 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 2 | |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical ointment 0.05 % (Diprolene (augmented))</i> | 2 | |
| <i>clobetasol scalp solution 0.05 %</i> | 2 | |
| <i>clobetasol topical cream 0.05 %</i> | 2 | |
| <i>clobetasol topical foam 0.05 % (Olux)</i> | 2 | |
| <i>clobetasol topical gel 0.05 %</i> | 2 | |
| <i>clobetasol topical lotion 0.05 % (Clobex)</i> | 2 | |
| <i>clobetasol topical ointment 0.05 %</i> | 2 | |
| <i>clobetasol topical shampoo 0.05 % (Clobex)</i> | 2 | |
| <i>clobetasol-emollient topical cream 0.05 %</i> | 2 | |
| <i>clobetasol-emollient topical foam 0.05 % (Olux-E)</i> | 2 | |
| <i>desonide topical cream 0.05 % (DesOwen)</i> | 2 | |
| <i>desonide topical lotion 0.05 %</i> | 2 | |
| <i>desonide topical ointment 0.05 %</i> | 2 | |
| <i>desoximetasone topical cream 0.05 %, 0.25 % (Topicort)</i> | 2 | QL (120 per 30 days) |
| <i>desoximetasone topical gel 0.05 % (Topicort)</i> | 2 | QL (120 per 30 days) |
| <i>desoximetasone topical ointment 0.05 %, 0.25 % (Topicort)</i> | 2 | |
| <i>diflorasone topical ointment 0.05 %</i> | 2 | QL (180 per 30 days) |
| <i>EUCRISA TOPICAL OINTMENT 2 %</i> | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>fluocinolone topical cream 0.01 %</i> | 2 | |
| <i>fluocinolone topical cream 0.025 % (Synalar)</i> | 2 | |
| <i>fluocinolone topical ointment 0.025 % (Synalar)</i> | 2 | |
| <i>fluocinonide topical cream 0.05 %</i> | 2 | |
| <i>fluocinonide topical cream 0.1 % (Vanos)</i> | 2 | |
| <i>fluocinonide topical gel 0.05 %</i> | 2 | |
| <i>fluocinonide topical ointment 0.05 %</i> | 2 | |
| <i>fluocinonide topical solution 0.05 %</i> | 2 | |
| <i>fluocinonide-emollient topical cream (Fluocinonide-E) 0.05 %</i> | 2 | |
| <i>fluticasone propionate topical cream 0.05 %</i> | 2 | |
| <i>fluticasone propionate topical ointment 0.005 %</i> | 2 | |
| <i>halobetasol propionate topical cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 2 | |
| <i>hydrocortisone 2.5% cream</i> | 2 | |
| <i>hydrocortisone butyrate topical cream 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>hydrocortisone butyrate topical lotion 0.1 %</i> | 2 | QL (236 per 30 days) |
| <i>hydrocortisone butyrate topical ointment 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>hydrocortisone butyrate topical solution 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>hydrocortisone topical cream 1 % (Ala-Cort)</i> | 2 | |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> | 2 | |
| <i>hydrocortisone topical lotion 2.5 %</i> | 2 | |
| <i>hydrocortisone topical ointment 1 % (Anti-Itch (HC))</i> | 1 | |
| <i>hydrocortisone topical ointment 2.5 %</i> | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|------------------|------------------|----------------------------|
| <i>hydrocortisone valerate topical cream 0.2 %</i> | | 2 | |
| <i>hydrocortisone valerate topical ointment 0.2 %</i> | | 2 | |
| <i>mometasone topical cream 0.1 %</i> | | 2 | |
| <i>mometasone topical ointment 0.1 %</i> | | 2 | |
| <i>mometasone topical solution 0.1 %</i> | | 2 | |
| <i>pimecrolimus topical cream 1 %</i> (Elidel) | | 2 | QL (100 per 30 days) |
| <i>procto-med hc topical cream with perineal applicator 2.5 %</i> | (hydrocortisone) | 2 | |
| <i>procosol hc topical cream with perineal applicator 2.5 %</i> | (hydrocortisone) | 2 | |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> | (hydrocortisone) | 2 | |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> | | 2 | QL (100 per 30 days) |
| <i>triamcinolone acetonide topical cream 0.025 %, 0.1 %</i> | | 1 | |
| <i>triamcinolone acetonide topical cream 0.5 %</i> | (Triderm) | 1 | |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | | 2 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | | 2 | |
| <i>triamcinolone acetonide topical ointment 0.05 %</i> | (Trianex) | 2 | |
| Dermatological Retinoids | | | |
| <i>adapalene topical cream 0.1 %</i> (Differin) | | 2 | |
| <i>ALTRENO TOPICAL LOTION 0.05 %</i> | | 4 | PA |
| <i>tazarotene topical cream 0.05 %, 0.1 %</i> (Tazorac) | | 2 | |
| <i>tretinoin topical cream 0.025 %</i> (Avita) | | 2 | PA |
| <i>tretinoin topical cream 0.05 %, 0.1 %</i> (Retin-A) | | 2 | PA |
| <i>tretinoin topical gel 0.01 %</i> (Retin-A) | | 2 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| <i>tretinoi</i> n topical gel 0.025 % | (Avita) | 2 | PA |
| <i>tretinoi</i> n topical gel 0.05 % | (Atralin) | 2 | PA |
| Scabicides And Pediculicides | | | |
| <i>malathion</i> topical lotion 0.5 % | (Ovide) | 2 | |
| <i>permethrin</i> topical cream 5 % | (Elimite) | 2 | QL (60 per 30 days) |
| Devices | | | |
| Devices | | | |
| 1ST TIER UNIFINE PENTP 5MM 31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTP 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTP 31GX3/16 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTP 32GX5/32 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ABOUTTIME PEN NEEDLE NEEDLE 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| ADVOCATE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 0.3 ML 29GX1/2 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 0.5 ML 29GX1/2 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE INS SYR 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ADVOCATE PEN NDL 12.7MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLES 5MM 31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ADVOCATE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ALCOHOL 70% SWABS | (Alcohol Pads) | 1 | PA; ST |
| ALCOHOL PADS TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | PA; ST |
| ALCOHOL PREP SWABS TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | PA; ST |
| ALCOHOL WIPES TOPICAL PADS, MEDICATED | (alcohol swabs) | 1 | PA; ST |
| AQINJECT PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| AQINJECT PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ASSURE ID DUO PRO NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| ASSURE ID DUO-SHIELD 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID DUO-SHIELD 30GX5/16" 30 GAUGE X 5/16" | 2 | PA; ST |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| ASSURE ID PRO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID SYR 0.5 ML 29GX1/2" (RX) 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| ASSURE ID SYR 0.5 ML 31GX15/64" 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| ASSURE ID SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| AUTOSHIELD DUO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| BD AUTOSHIELD DUO NDL 5MMX30G 30 GAUGE X 3/16" | 2 | PA; ST |
| BD ECLIPSE 30GX1/2" SYRINGE 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| BD ECLIPSE NEEDLE 30GX1/2" (OTC) 30 X 1/2 " | 2 | PA; ST |
| BD INS SYR 0.3 ML 8MMX31G(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| BD INS SYR UF 0.3 ML 12.7MMX30G 0.3 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| BD INS SYR UF 0.5 ML 12.7MMX30G NOT FOR RETAIL SALE 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INSULIN SYR 1 ML 25GX1" 1 ML 25 X 1" | | 2 | PA; ST |
| BD INSULIN SYR 1 ML 25GX5/8" 1 ML 25 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INSULIN SYR 1 ML 26GX1/2" 1 ML 26 X 1/2" | | 2 | PA; ST |
| BD INSULIN SYR 1 ML 27GX12.7MM 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INSULIN SYRINGE SLIP TIP SYRINGE 1 ML | (insulin syringe needleless) | 2 | PA; ST |
| BD NANO 2 GEN PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| BD SAFETGLD INS 0.3 ML 29G 13MM 0.3 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| BD SAFETGLD INS 0.5 ML 13MMX29G 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD SAFETYGLD INS 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| BD SAFETYGLD INS 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| BD SAFETYGLD INS 1 ML 29G 13MM 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| BD SAFETYGLID INS 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SAFETYGLIDE SYRINGE 27GX5/8 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| BD SAFTYGLD INS 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 29G 13MM 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 6MMX31G 0.5 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SINGLE USE SWAB | (alcohol swabs) | 1 | PA; ST |
| BD UF MICRO PEN NEEDLE 6MMX32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF MINI PEN NEEDLE 5MMX31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF NANO PEN NEEDLE 4MMX32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF ORIG PEN NDL 12.7MMX29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF SHORT PEN NEEDLE 8MMX31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| BD VEO INS 0.3 ML 6MMX31G (1/2) 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD VEO INS SYRING 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD VEO INS SYRN 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD VEO INS SYRN 0.5 ML 6MMX31G 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BORDERED GAUZE 2"X2" 2 X 2 " | (gauze bandage) | 1 | PA; ST |
| CAREFINE PEN NEEDLE 12.7MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| CAREFINE PEN NEEDLE 5MM 32G 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 8MM 30G 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH ALCOHOL 70% PREP PAD | (alcohol swabs) | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 1 ML 28GX5/16" 1 ML 28 X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| CARETOUCH SYR 1 ML 29GX5/16" 1 ML 29 GAUGE X 5/16 | | 2 | PA; ST |
| CARETOUCH SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| CLICKFINE PEN NEEDLE 32GX5/32" 32GX4MM, STERILE 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ 0.3 ML 31G 15/64" 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ 0.5 ML 31G 15/64" 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INS 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INS 1 ML 31G 15/64" 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INSULIN SYR 0.3 ML 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 4MM 32G SINGLE USE, MICRO 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 4MM 33G 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| COMFORT EZ PEN NEEDLES 5MM 31G MINI 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 5MM 33G 33 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 33G 33 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 31G SHORT 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 32G 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 33G 33 GAUGE X 5/16" | | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 30G 8MM 30 GAUGE X 5/16" | | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 31G 4MM 31 GAUGE X 5/32" | (pen needle, diabetic, safety) | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| COMFORT EZ SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| COMFORT EZ SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/3" 31 GAUGE X 1/3" | | 2 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/6" 31 GAUGE X 1/6" | | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 4MM 31 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 5MM 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 8MM 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 33G 4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 33G 6MM 33 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| COMFORT TOUCH PEN NDL 33GX5MM 33 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| CURAD GAUZE PADS 2" X 2" 2 X 2 " | (gauze bandage) | 1 | PA; ST |
| CURITY ALCOHOL PREPS 2 PLY,MEDIUM | (alcohol swabs) | 1 | PA; ST |
| CURITY GAUZE SPONGES (12 PLY)-200/BAG 2 X 2 " | | 1 | PA; ST |
| CURITY GUAZE PADS 1'S(12 PLY) 2 X 2 " | (gauze bandage) | 1 | PA; ST |
| DERMACEA 2"X2" GAUZE 12 PLY, USP TYPE VII 2 X 2 " | (gauze bandage) | 1 | PA; ST |
| DERMACEA GAUZE 2"X2" SPONGE 8 PLY 2 X 2 " | | 1 | PA; ST |
| DERMACEA NON-WOVEN 2"X2" SPNGE 2 X 2 " | | 1 | PA; ST |
| DROPLET 0.3 ML 29G 12.7MM(1/2) 0.3 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| DROPLET 0.3 ML 30G 12.7MM(1/2) 0.3 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| DROPLET 0.5 ML 29GX12.5MM(1/2) 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| DROPLET 0.5 ML 30GX12.5MM(1/2) 0.5 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| DROPLET INS 0.3 ML 29GX12.5MM 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.3 ML 30G 8MM(1/2) 0.3 ML 30 GAUGE X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-------------------------------------|------------------|----------------------------|
| DROPLET INS 0.3 ML 30GX12.5MM 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.3 ML 31G 6MM(1/2) 0.3 ML 31 GAUGE X 1/4" | (insulin syr/ndl u100 half mark) | 2 | PA; ST |
| DROPLET INS 0.3 ML 31G 8MM(1/2) 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| DROPLET INS 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.5 ML 30G 12.7MM 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.5 ML 30GX6MM(1/2) 0.5ML 30 GAUGE X 15/64" | | 2 | PA; ST |
| DROPLET INS 0.5 ML 30GX8MM(1/2) 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| DROPLET INS 0.5 ML 31GX6MM(1/2) 0.5 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| DROPLET INS 0.5 ML 31GX8MM(1/2) 0.5 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX6MM 0.3 ML 30 GAUGE X 15/64" | | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX8MM 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 31GX8MM 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| DROPLET INS SYR 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30G 8MM 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30GX12.5MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30GX6MM 1 ML 30 GAUGE X 15/64" | | 2 | PA; ST |
| DROPLET INS SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET MICRON 34G X 9/64" 34 GAUGE X 9/64" | | 2 | PA; ST |
| DROPLET PEN NEEDLE 29G 10MM 29 GAUGE X 3/8" | | 2 | PA; ST |
| DROPLET PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| DROPLET PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPSAFE ALCOHOL 70% PREP PADS | (alcohol swabs) | 1 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 6MM 0.5 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| DROPSAFE INSULN 1 ML 29G 12.5MM 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|--------------------------------|------------------|----------------------------|
| DRUG MART ULTRA COMFORT SYR 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | | 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | | 2 | PA; ST |
| EASY COMFORT 0.3 ML 31G 1/2" 0.3 ML 31 X 1/2" | | 2 | PA; ST |
| EASY COMFORT 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 0.5 ML 32GX5/16" 1/2 ML 32 GAUGE X 5/16" | | 2 | PA; ST |
| EASY COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT 1 ML 32GX5/16" 1 ML 32 GAUGE X 5/16" | | 2 | PA; ST |
| EASY COMFORT ALCOHOL 70% PAD | (alcohol swabs) | 1 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| EASY COMFORT INSULIN 1 ML SYR 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT PEN NDL 29G 4MM 29 GAUGE X 5/32" | | 2 | PA; ST |
| EASY COMFORT PEN NDL 29G 5MM 29 GAUGE X 3/16" | | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT SYR 0.5 ML 29G 8MM 1/2 ML 29 X5/16 " | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT SYR 1 ML 29G 8MM 1 ML 29 GAUGE X 5/16 | | 2 | PA; ST |
| EASY COMFORT SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| EASY GLIDE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH 0.3 ML SYR 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 30GX5/16 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 27GX1/2" 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 29GX1/2" 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 30GX1/2" 1 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH ALCOHOL 70% PADS GAMMA-STERILIZED | (alcohol swabs) | 1 | PA; ST |
| EASY TOUCH FLIPLOK 1 ML 27GX0.5 1 ML 27 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 29GX1/2 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 30GX1/2 1 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| EASY TOUCH INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 1 ML 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 1 ML RETRACTABLE 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| EASY TOUCH LUER LOK INSUL 1 ML | (insulin syringe needleless) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 30GX5/16 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX3/16 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX5/16 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| EASY TOUCH PEN NEEDLE 32GX3/16 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX5/32 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 29G 5MM 29 GAUGE X 3/16" | | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 29G 8MM 29 GAUGE X 5/16" | | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 30G 5MM 30 GAUGE X 3/16" | | 2 | PA; ST |
| EASY TOUCH SAF PEN NDL 30G 8MM 30 GAUGE X 5/16" | | 2 | PA; ST |
| EASY TOUCH SYR 0.5 ML 28G 12.7MM 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 28G 12.7MM 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH UNI-SLIP SYR 1 ML | (insulin syringe needleless) | 2 | PA; ST |
| EASYTOUCH SAF PEN NDL 30G 6MM 30 GAUGE X 1/4" | | 2 | PA; ST |
| EMBRACE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|------------------------------------|------------------|----------------------------|
| EMBRACE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| EQL INSULIN 0.5 ML SYRINGE 1/2 ML 29 | (Ultilet Insulin Syringe) | 2 | PA; ST |
| EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE 1/2 ML 30 GAUGE | (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| FP INSULIN 1 ML SYRINGE 1 ML 28 GAUGE | | 2 | PA; ST |
| FREESTYLE PREC 0.5 ML 30GX5/16 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| FREESTYLE PREC 0.5 ML 31GX5/16 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| FREESTYLE PREC 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| FREESTYLE PREC 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " | (gauze bandage) | 1 | PA; ST |
| GNP CLICKFINE 31G X 1/4" NDL 6MM, UNIVERSAL 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| GNP CLICKFINE 31G X 5/16" NDL 8MM, UNIVERSAL 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| GNP SIMPLI PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT 0.3 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| GNP ULT CMFRT 0.5 ML 29GX1/2" 1/2 ML 29 | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|--------------------------------|------------------|----------------------------|
| GNP ULTRA COMFORT 0.5 ML SYR 1/2 ML 30 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 29 GAUGE | | 2 | PA; ST |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 30 GAUGE X 7/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| GNP ULTRA COMFORT 3/10 ML SYR 0.3 ML 30 | (insulin syringe-needle u-100) | 2 | PA; ST |
| GS PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" | (1st Tier Unifine Pentips) | 2 | PA; ST |
| GS PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" | (1st Tier Unifine Pentips) | 2 | PA; ST |
| HEALTHWISE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-------------------------------------|------------------|----------------------------|
| HEALTHY ACCENTS PENTIP 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 5MM 31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| HEALTHY ACCENTS PENTP 12MM 29G 29 GAUGE X 1/2" | | 2 | PA; ST |
| HEB INCONTROL ALCOHOL 70% PADS | (alcohol swabs) | 1 | PA; ST |
| INCONTROL PEN NEEDLE 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| INCONTROL PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| INCONTROL PEN NEEDLE 5MM 31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| INCONTROL PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| INCONTROL PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| INPEN (FOR HUMALOG) BLUE SUBCUTANEOUS INSULIN PEN | | 3 | |
| INPEN (NOVOLOG OR FIASP) BLUE SUBCUTANEOUS INSULIN PEN | | 3 | |
| INSULIN 1 ML SYRINGE 1 ML 30 GAUGE X 7/16" | (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| INSULIN SYR 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | (Droplet Insulin Syr(half unit)) | 2 | PA; ST |
| INSULIN SYR 0.5 ML 28G 12.7MM (OTC) 1/2 ML 28 GAUGE X 1/2" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|--------------------------------|------------------|----------------------------|
| INSULIN SYRIN 0.5 ML 30GX1/2" (RX) 0.5 ML 30 GAUGE X 1/2" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRING 0.5 ML 27G 1/2" INNER 1/2 ML 27 GAUGE X 1/2" | (Easy Touch Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |
| INSULIN SYRINGE 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | (Sure Comfort Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 0.5 ML 1/2 ML 29 | (insulin syringe-needle u-100) | 2 | PA; ST |
| INSULIN SYRINGE 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | (Droplet Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 1 ML 29 GAUGE | | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 27G 1/2" INNER 1 ML 27 GAUGE X 1/2" | (Easy Touch Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" | (BD SafetyGlide Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 28G 12.7MM (OTC) 1 ML 28 GAUGE X 1/2" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 30GX1/2" SHORT NEEDLE (OTC) 1 ML 30 GAUGE X 1/2" | (BD Eclipse Luer-Lok) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | (Droplet Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE NEEDLELESS SYRINGE 1 ML | (Easy Touch Luer Lock Insulin) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 0.3 ML 29 GAUGE | (Ultilet Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 1 ML 29 GAUGE X 1/2" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 1/2 ML 28 GAUGE | (Monoject Syringe) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| INSULIN U-500 SYRINGE- NEEDLE SYRINGE 1/2 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| INSUPEN 30G ULTRAFIN NEEDLE 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN 31G ULTRAFIN NEEDLE 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN 32G 8MM PEN NEEDLE 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 29GX12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 32G 6MM (RX) 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| IV ANTISEPTIC WIPES | (alcohol swabs) | 1 | PA; ST |
| KENDALL ALCOHOL 70% PREP PAD | (alcohol swabs) | 1 | PA; ST |
| LISCO SPONGES 100/BAG 2 X 2 " | | 1 | PA; ST |
| LITE TOUCH 31GX1/4" PEN NEEDLE 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| LITE TOUCH INSULIN 0.5 ML SYR 1/2 ML 28 GAUGE, 1/2 ML 29 , 1/2 ML 30 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITE TOUCH INSULIN 1 ML SYR 1 ML 28 GAUGE, 1 ML 30 GAUGE X 7/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITE TOUCH INSULIN 1 ML SYR 1 ML 29 GAUGE | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| LITE TOUCH INSULIN SYR 1 ML 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITE TOUCH PEN NEEDLE 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| LITE TOUCH PEN NEEDLE 31G 31 GAUGE X 3/16", 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| LITETOUGH INS 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH SYRIN 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH SYRIN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| LITETOUGH SYRIN 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| MAGELLAN INSUL SYRINGE 0.3 ML 0.3 ML 30 X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| MAGELLAN INSUL SYRINGE 0.5 ML 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| MAGELLAN INSULIN SYR 0.3 ML 0.3 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| MAGELLAN INSULIN SYR 0.5 ML 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| MAGELLAN INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| MAXICOMFORT II PEN NDL 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| MAXICOMFORT INS 0.5 ML 27GX1/2" 1/2 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MAXI-COMFORT INS 0.5 ML 28G 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MAXICOMFORT INS 1 ML 27GX1/2" 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MAXI-COMFORT INS 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MAXICOMFORT PEN NDL 29G X 5MM 29 GAUGE X 3/16" | | 2 | PA; ST |
| MAXICOMFORT PEN NDL 29G X 8MM 29 GAUGE X 5/16" | | 2 | PA; ST |
| MICRODOT PEN NEEDLE 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| MICRODOT PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| MICRODOT PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| MICRODOT READYGARD NDL 31G 5MM OUTER 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| MINI PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (1st Tier Unifine Pentips) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|---------------------------------|------------------|----------------------------|
| MINI PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" | (CareFine Pen Needle) | 2 | PA; ST |
| MINI PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | (CareFine Pen Needle) | 2 | PA; ST |
| MINI PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | (Advocate Pen Needle) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 5MM 33 GAUGE X 3/16" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 6MM 33 GAUGE X 1/4" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI ULTRA-THIN II PEN NDL 31G STERILE 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| MONOJECT 0.5 ML SYRN 28GX1/2" 1/2 ML 28 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT 1 ML SYRN 27X1/2" 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT 1 ML SYRN 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 (OTC) 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC) 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 1 ML 25 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC) 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC) | (insulin syringes (disposable)) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|---------------------------------|------------------|----------------------------|
| MONOJECT INSULIN SYR 0.3 ML (OTC) 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML (OTC) 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 1 ML 3'S (OTC) 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR U-100 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR U-100 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| MONOJECT SYRINGE 0.3 ML 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT SYRINGE 0.5 ML 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| MS INSULIN SYR 1 ML 31GX5/16" (OTC) 1 ML 31 GAUGE X 5/16 | (Advocate Syringes) | 2 | PA; ST |
| MS INSULIN SYRINGE 0.3 ML 0.3 ML 30 | (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| NANO 2 GEN PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| NANO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| NOVOFINE 30 NEEDLE | | 2 | PA; ST |
| NOVOFINE 32G NEEDLES 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| NOVOFINE PLUS PEN NDL 32GX1/6" 32 GAUGE X 1/6" | | 2 | PA; ST |
| NOVOTWIST NEEDLE 32 GAUGE X 1/5" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| OMNIPOD 5 (G6/LIBRE 2 PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 G6-G7 INTRO KT(GEN5) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD 5 G6-G7 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 INTRO(G6/LIBRE2PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PDM KIT(GEN 3) | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PODS (GEN 3) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD DASH INTRO KIT (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PDM KIT (GEN 4) | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| PC UNIFINE PENTIPS 8MM NEEDLE SHORT 31 GAUGE X 5/16" | 2 | PA; ST |
| PEN NEEDLE 30G 5MM OUTER 30 GAUGE X 3/16" | 2 | PA; ST |
| PEN NEEDLE 30G 8MM INNER 30 GAUGE X 5/16" | 2 | PA; ST |
| PEN NEEDLE 30G X 5/16" 30 GAUGE X 5/16" | 2 | PA; ST |
| PEN NEEDLE 31G X 1/4" HRI 31 GAUGE X 1/4" | 2 | PA; ST |
| PEN NEEDLE 6MM 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2" | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| PEN NEEDLES 12MM 29G 29GX12MM,STRL 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 5MM 31G 31GX5MM,STRL,MINI (OTC) 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC) 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 29G 1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31G 1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 32G 1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 32GX5/32" 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| PIP PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| PIP PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| PREFPLS INS SYR 1 ML 30GX5/16" (OTC) 1 ML 30 GAUGE X 5/16 | (Advocate Syringes) | 2 | PA; ST |
| PREVENT PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | | 2 | PA; ST |
| PREVENT PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | | 2 | PA; ST |
| PRO COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| PRO COMFORT 0.5 ML 30GX5/16" (insulin syringe-needle 0.5 ML 30 GAUGE X 5/16" u-100) | 2 | PA; ST |
| PRO COMFORT 0.5 ML 31GX5/16" (insulin syringe-needle 0.5 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| PRO COMFORT 1 ML 30GX1/2" 1 (insulin syringe-needle ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| PRO COMFORT 1 ML 30GX5/16" 1 (insulin syringe-needle ML 30 GAUGE X 5/16 u-100) | 2 | PA; ST |
| PRO COMFORT 1 ML 31GX5/16" 1 (insulin syringe-needle ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| PRO COMFORT ALCOHOL 70% PADS (alcohol swabs) | 1 | PA; ST |
| PRO COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| PRO COMFORT PEN NDL 32G X 1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| PRO COMFORT PEN NDL 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PRO COMFORT PEN NDL 5MM 32G 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PRODIGY INS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| PRODIGY SYRNG 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| PRODIGY SYRNGE 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| PURE COMFORT ALCOHOL 70% PADS (alcohol swabs) | 1 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|---------------------------------|------------------|----------------------------|
| PURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 8MM 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 29G 12MM 29 GAUGE X 15/32" | | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" | (Comfort Touch Pen Needle) | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 5MM 31 GAUGE X 13/64" | | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 6MM 31 GAUGE X 15/64" | | 2 | PA; ST |
| RELION INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELION INS SYR 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELION INS SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELI-ON INSULIN 1 ML SYR 1 ML 29 GAUGE X 7/16" | | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10 0.3 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|------------------------------------|------------------|----------------------------|
| SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10 1 ML 28 GAUGE X 1/2" | | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| SAFETY PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" | (Comfort EZ PRO Safety Pen Ndl) | 2 | PA; ST |
| SAFETY PEN NEEDLE 5MM X 31G 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| SAFETY SYRINGE 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| SECURESAFE PEN NDL 30GX5/16" OUTER 30 GAUGE X 5/16" | | 2 | PA; ST |
| SECURESAFE SYR 0.5 ML 29G 1/2" OUTER 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| SECURESAFE SYRNG 1 ML 29G 1/2" OUTER 1 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | | 2 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | | 2 | PA; ST |
| SM ULT CFT 0.3 ML 31GX5/16(1/2) 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| STERILE PADS 2" X 2" 2 X 2 " | (gauze bandage) | 1 | PA; ST |
| SURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | | 2 | PA; ST |
| SURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | | 2 | PA; ST |
| NEEDLES, INSULIN DISP., SAFETY | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| SURE COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 3/10 ML SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 3/10 ML SYRINGE INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 30G PEN NEEDLE 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT ALCOHOL PREP PADS | (alcohol swabs) | 1 | PA; ST |
| SURE COMFORT INS 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT INS 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT PEN NDL 29GX1/2" 12.7MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| SURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-FINE PEN NEEDLES 12.7MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-FINE PEN NEEDLES 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-FINE PEN NEEDLES 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 1 ML 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSUL SYR U100 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSULIN SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-PREP ALCOHOL PREP PADS | (alcohol swabs) | 1 | PA; ST |
| TECHLITE 0.3 ML 29GX12MM (1/2) 0.3 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| TECHLITE 0.3 ML 30GX8MM (1/2) 0.3 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| TECHLITE 0.3 ML 31GX6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| TECHLITE 0.3 ML 31GX8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| TECHLITE 0.5 ML 30GX12MM (1/2) 0.5 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| TECHLITE 0.5 ML 30GX8MM (1/2) 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| TECHLITE 0.5 ML 31GX6MM (1/2) 0.5 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| TECHLITE 0.5 ML 31GX8MM (1/2) 0.5 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 29GX12MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 30GX12MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/16" 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| TERUMO INS SYRINGE U100-1 ML 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1 ML 1 ML 30 GAUGE X 3/8" | (Thinpro Insulin Syringe) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1/2 ML 1/2 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1/3 ML 0.3 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRNG U100-1/2 ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 31 X 3/8" | | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 31 X 3/8" | | 2 | PA; ST |
| THINPRO INS SYRIN U100-1 ML 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| THINPRO INS SYRIN U100-1 ML 1 ML 31 X 3/8" | | 2 | PA; ST |
| TOPCARE CLICKFINE 31G X 1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TOPCARE CLICKFINE 31G X 5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| TOPCARE ULTRA COMFORT SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 32G 5/16" 1/2 ML 32 GAUGE X 5/16" | | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | | 2 | PA; ST |
| TRUE COMFORT 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| TRUE COMFORT 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| TRUE COMFORT 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| TRUE COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT ALCOHOL 70% PADS | (alcohol swabs) | 1 | PA; ST |
| TRUE COMFORT PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| TRUE COMFORT PEN NDL 31GX5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 31GX6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 32GX4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | | 2 | PA; ST |
| TRUE COMFORT PRO ALCOHOL PADS | (alcohol swabs) | 1 | PA; ST |
| TRUE COMFORT SFTY 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| TRUE COMFR PRO 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFR SFTY 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| TRUE COMFR SFTY 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| TRUE COMFR SFTY 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| TRUEPLUS PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 31G X 1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUEPLUS SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-------------------------------------|------------------|----------------------------|
| ULTICAR INS 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | (insulin syr/ndl u100 half mark) | 2 | PA; ST |
| ULTICARE INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE INS SYR 0.3 ML 30G 8MM 0.3 ML 30 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 30G 8MM (OTC) 0.5 ML 30 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 31G 8MM (OTC) 0.5 ML 31 GAUGE X 5/16" | (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE SAFE PEN NDL 30G 8MM 30 GAUGE X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits | |
|---|-----------------------------------|----------------------------|--------|
| ULTICARE SAFE PEN NDL 5MM 30G 30 GAUGE X 3/16" | 2 | PA; ST | |
| ULTICARE SAFETY 0.5 ML 29GX1/2 (RX) 0.5 ML 29 GAUGE X 1/2" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 29G 12.7MM 0.3 ML 29 GAUGE X 1/2" | (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 31GX5/16" SHORT NDL 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE SYR 0.5 ML 31GX5/16" SHORT NDL 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTIGUARD SAFE 1 ML 30G 12.7MM 1 ML 30 X 1/2" | | 2 | PA; ST |
| ULTIGUARD SAFE0.3 ML 30G 12.7MM 0.3 ML 30 X 1/2" | | 2 | PA; ST |
| ULTIGUARD SAFE0.5 ML 30G 12.7MM 1/2 ML 30 X 1/2" | | 2 | PA; ST |
| ULTIGUARD SAFEPACK 1 ML 31G 8MM 1 ML 31 X 5/16" | | 2 | PA; ST |
| ULTIGUARD SAFEPACK 29G 12.7MM 29 GAUGE X 1/2" | | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 5MM 31 GAUGE X 3/16" | | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 6MM 31 GAUGE X 1/4" | | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 8MM 31 GAUGE X 5/16" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| ULTIGUARD SAFEPACK 32G 4MM 32 GAUGE X 5/32" | | 2 | PA; ST |
| ULTIGUARD SAFEPACK 32G 6MM 32 GAUGE X 1/4" | | 2 | PA; ST |
| ULTIGUARD SAFEPEK 0.3 ML 31G 8MM 0.3 ML 31 X 5/16" | | 2 | PA; ST |
| ULTIGUARD SAFEPEK 0.5 ML 31G 8MM 1/2 ML 31 X 5/16" | | 2 | PA; ST |
| ULTILET ALCOHOL STERL SWAB | (alcohol swabs) | 1 | PA; ST |
| ULTILET INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTILET INSULIN SYRINGE 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTILET INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTILET PEN NEEDLE 29 GAUGE | | 2 | PA; ST |
| ULTILET PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 0.5 ML 28GX1/2" CONVERTS TO 29G 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 0.5 ML SYRINGE 1/2 ML 28 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| ULTRA COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO 0.3 ML 30G 1/2" (1/2) 0.3 ML 30 GAUGE X 1/2" | | 2 | PA; ST |
| ULTRA FLO 0.3 ML 30G 5/16"(1/2) 0.3 ML 30 GAUGE X 5/16" | | 2 | PA; ST |
| ULTRA FLO 0.3 ML 31G 5/16"(1/2) 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 30G 5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA THIN PEN NDL 32G X 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| ULTRACARE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 30G X 5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 31G X 5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE 0.3 ML 30G 12.7MM 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE 0.3 ML 31G 6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ULTRA-FINE 0.3 ML 31G 8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTRA-FINE 0.5 ML 30G 12.7MM 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE INS SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE INS SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE PEN NDL 29G 12.7MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 1 ML 30G 12.7MM 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 30G 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 31G 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 29G 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 30G 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 31G 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| ULTRA-THIN II INS SYR 1 ML 29G 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS SYR 1 ML 30G 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II PEN NDL 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-THIN II PEN NDL 31GX5/16 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE OTC PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE OTC PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 12MM 29G 29GX12MM, STRL 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 31GX3/16" 31GX5MM,STRL,MINI 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS MAX 30GX3/16" 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS NEEDLES 29G 29 GAUGE | | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 29GX1/2" 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 30GX3/16" 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|----------------------------|
| UNIFINE PENTIPS PLUS 31GX1/4" ULTRA SHORT, 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 31GX3/16" MINI 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 31GX5/16" SHORT 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PENTIPS PLUS 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PROTECT 30G 5MM 30 GAUGE X 3/16" | | 2 | PA; ST |
| UNIFINE PROTECT 30G 8MM 30 GAUGE X 5/16" | | 2 | PA; ST |
| UNIFINE PROTECT 32G 4MM 32 GAUGE X 5/32" | | 2 | PA; ST |
| UNIFINE SAFECONTROL 30G 5MM 30 GAUGE X 3/16" | | 2 | PA; ST |
| UNIFINE SAFECONTROL 30G 8MM 30 GAUGE X 5/16" | | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 6MM 31 GAUGE X 1/4" | | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 8MM 31 GAUGE X 5/16" | | 2 | PA; ST |
| UNIFINE SAFECONTROL 32G 4MM 32 GAUGE X 5/32" | | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-----------------------------------|------------------|----------------------------|
| UNIFINE ULTRA PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| VANISHPOINT 0.5 ML 30GX1/2" SY OUTER 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| VANISHPOINT INS 1 ML 30GX3/16" 1 ML 30 GAUGE X 3/16" | | 2 | PA; ST |
| VANISHPOINT U-100 29X1/2 SYR 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE INS SYR 1 ML 29G 1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 5MM 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------------------------|------------------|-------------------------------------|
| VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER 32 GAUGE X 5/32" | | 2 | PA; ST |
| VERIFINE SYRING 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRING 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRNG 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRNG 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY 2 X 2 " | | 1 | PA; ST |
| V-GO 20 DEVICE | | 3 | QL (30 per 30 days) |
| V-GO 30 DEVICE | | 3 | QL (30 per 30 days) |
| V-GO 40 DEVICE | | 3 | QL (30 per 30 days) |
| WEBCOL ALCOHOL PREPS 20'S,LARGE | (alcohol swabs) | 1 | PA; ST |
| Enzyme Cofactors/Chaperones | | | |
| Enzyme Cofactors/Chaperones | | | |
| MIPLYFFA ORAL CAPSULE 124 MG, 47 MG, 62 MG, 93 MG | | 5 | PA; NM; NDS; QL (90 per 30 days) |
| Enzyme Replacement/Modifiers | | | |
| Enzyme Replacement/Modifiers | | | |
| CERDELGA ORAL CAPSULE 84 MG | | 5 | PA; NM; NDS |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 - 60,000 UNIT, 24,000-76,000 - 120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT | | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--|------------------|----------------------------------|
| GALAFOLD ORAL CAPSULE 123 MG | | 5 | PA; NM; NDS; QL (14 per 28 days) |
| <i>javygtor oral tablet,soluble 100 mg</i> (sapropterin) | | 5 | PA; NM; NDS |
| <i>miglustat oral capsule 100 mg</i> (Yargesa) | | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i> (Orfadin) | | 5 | PA; NM; NDS |
| ORFADIN ORAL SUSPENSION 4 MG/ML | | 5 | PA; NM; NDS |
| PALYNZIQ SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 2.5 MG/0.5 ML, 20 MG/ML | | 5 | PA; NM; NDS |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | | 5 | PA BvD; NM; NDS |
| REVCovi INTRAMUSCULAR SOLUTION 2.4 MG/1.5 ML (1.6 MG/ML) | | 5 | PA; NM; NDS |
| <i>sapropterin oral tablet,soluble 100 mg</i> (Javygtor) | | 5 | PA; NM; NDS |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML | | 5 | PA; NM; LA; NDS |
| <i>yargesa oral capsule 100 mg</i> (miglustat) | | 5 | PA; NM; NDS; QL (90 per 30 days) |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 - 42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000- 126,000- 168,000 UNIT, 5,000- 17,000- 24,000 UNIT, 60,000- 189,600- 252,600 UNIT | | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|-----------|-----------------------|
| Eye, Ear, Nose, Throat Agents | | |
| Eye, Ear, Nose, Throat Agents, Miscellaneous | | |
| <i>apraclonidine ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>atropine ophthalmic (eye) drops 1 % (Isopto Atropine)</i> | 2 | |
| <i>azelastine nasal spray,non-aerosol 137 mcg (0.1 %)</i> | 2 | QL (60 per 30 days) |
| <i>azelastine nasal spray,non-aerosol (Astepro Allergy) 205.5 mcg (0.15 %)</i> | 2 | QL (30 per 25 days) |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>bepotastine besilate ophthalmic (eye) (Bepreve) drops 1.5 %</i> | 2 | ST |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 2 | |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)</i> | 2 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i> | 2 | QL (15 per 10 days) |
| MIEBO (PF) OPHTHALMIC (EYE) DROPS 100 % | 3 | QL (12 per 28 days) |
| <i>olopatadine nasal spray,non-aerosol 0.6 %</i> | 2 | QL (30.5 per 30 days) |
| <i>olopatadine ophthalmic (eye) drops (Eye Allergy Itch- Redness Rlf) 0.1 %</i> | 2 | |
| <i>olopatadine ophthalmic (eye) drops (Advanced Eye Relief (olopatad)) 0.2 %</i> | 2 | |
| Eye, Ear, Nose, Throat Anti- Infectives Agents | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 2 | |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|------------------|------------------|----------------------------|
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i> | (Polycin) | 2 | |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | | 2 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops,suspension 0.3-0.1 %</i> | | 2 | QL (7.5 per 7 days) |
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | | 2 | QL (3.5 per 4 days) |
| <i>gatifloxacin ophthalmic (eye) drops 0.5 %</i> | | 2 | |
| <i>gentak ophthalmic (eye) ointment 0.3 % (3 mg/gram)</i> | | 2 | |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | | 2 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | | 2 | |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> | (Vigamox) | 2 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | | 4 | |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> | (Neo-Polycin HC) | 2 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | (Neo-Polycin) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> | (Maxitrol) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | (Maxitrol) | 2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits | |
|--|---------------------------------|----------------------------|--|
| <i>neomycin-polymyxin-hc ophthalmic (eye) drops,suspension 3.5-10,000-10 mg-unit-mg/ml</i> | 2 | | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | | |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | | |
| <i>neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g- 1%</i> | (neomycin-bacitracin-poly-hc) | 2 | |
| <i>neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> | (neomycin-bacitracin-polymyxin) | 2 | |
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> | (Ocuflax) | 2 | |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | | 2 | |
| <i>polycin ophthalmic (eye) ointment 500-10,000 unit/gram</i> | (bacitracin-polymyxin b) | 2 | |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | | 1 | |
| <i>sulfacetamide sodium ophthalmic (eye) drops 10 %</i> | | 2 | |
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | | 2 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | | 2 | |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i> | | 1 | |
| <i>tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 %</i> | | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| trifluridine ophthalmic (eye) drops 1 % | 2 | |
| XDEMVY OPHTHALMIC (EYE) DROPS 0.25 % | 5 | PA; NM; NDS; QL (10 per 42 days) |
| ZIRGAN OPHTHALMIC (EYE) GEL 0.15 % | 4 | |
| ZYLET OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % | 3 | |
| Eye, Ear, Nose, Throat Anti-Inflammatory Agents | | |
| ALREX OPHTHALMIC (EYE) DROPS,SUSPENSION 0.2 % (loteprednol etabonate) | 3 | ST |
| bromfenac ophthalmic (eye) drops 0.07 % (Prolensa) | 2 | |
| bromfenac ophthalmic (eye) drops 0.075 % (BromSite) | 2 | |
| bromfenac ophthalmic (eye) drops 0.09 % | 2 | |
| cyclosporine ophthalmic (eye) dropperette 0.05 % (Restasis) | 2 | QL (60 per 30 days) |
| dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 % | 2 | |
| diclofenac sodium ophthalmic (eye) drops 0.1 % | 2 | |
| disfluprednate ophthalmic (eye) drops 0.05 % (Durezol) | 2 | |
| EYSUVIS OPHTHALMIC (EYE) DROPS,SUSPENSION 0.25 % | 3 | QL (8.3 per 14 days) |
| flunisolide nasal spray,non-aerosol 25 mcg (0.025 %) | 2 | QL (50 per 25 days) |
| fluocinolone acetonide oil otic (ear) drops 0.01 % (DermOtic Oil) | 2 | |
| fluorometholone ophthalmic (eye) drops,suspension 0.1 % (FML Liquifilm) | 4 | |
| flurbiprofen sodium ophthalmic (eye) drops 0.03 % | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|------------------------------|------------------|----------------------------|
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> | (24 Hour Allergy Relief) | 1 | QL (16 per 30 days) |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | | 3 | |
| INVELTYS OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | | 3 | QL (5.6 per 14 days) |
| <i>ketorolac ophthalmic (eye) drops 0.5 %</i> | (Acular) | 2 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | | 3 | QL (3.5 per 14 days) |
| LOTEMAX SM OPHTHALMIC (EYE) DROPS,GEL 0.38 % | | 3 | QL (5 per 16 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,gel 0.5 %</i> | (Lotemax) | 2 | QL (10 per 14 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.2 %</i> | (Alrex) | 2 | ST |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.5 %</i> | | 2 | QL (15 per 19 days) |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> | (Allergy Nasal (mometasone)) | 2 | QL (34 per 30 days) |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i> | (Pred Forte) | 4 | |
| <i>prednisolone sodium phosphate ophthalmic (eye) drops 1 %</i> | | 2 | |
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % | | 3 | QL (60 per 30 days) |
| Gastrointestinal Agents | | | |
| Antilulcer Agents And Acid Suppressants | | | |
| <i>amoxicil-clarithromy-lansopraz oral combo pack 500-500-30 mg</i> | | 2 | |
| <i>cimetidine hcl oral solution 300 mg/5 ml</i> | | 2 | |
| <i>cimetidine oral tablet 200 mg</i> | (Acid Reducer (cimetidine)) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--|------------------|----------------------------------|
| <i>cimetidine oral tablet 300 mg, 400 mg, 800 mg</i> | | 2 | |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 20 mg</i> (Acid Reducer (esomeprazole)) | | 2 | QL (30 per 30 days) |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 40 mg</i> (Nexium) | | 2 | QL (60 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 10 mg, 20 mg</i> (Nexium Packet) | | 2 | ST; QL (30 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 40 mg</i> (Nexium Packet) | | 2 | ST; QL (60 per 30 days) |
| <i>famotidine oral suspension for reconstitution 40 mg/5 ml (8 mg/ml)</i> | | 2 | |
| <i>famotidine oral tablet 20 mg</i> (Acid Controller) | | 1 | |
| <i>famotidine oral tablet 40 mg</i> (Pepcid) | | 1 | |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i> (Acid Reducer (lansoprazole)) | | 2 | QL (30 per 30 days) |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i> (Prevacid) | | 2 | QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> (Cytotec) | | 2 | |
| <i>nizatidine oral capsule 150 mg, 300 mg</i> | | 2 | |
| <i>nizatidine oral solution 150 mg/10 ml</i> | | 2 | |
| <i>omeprazole oral capsule, delayed release(dr/ec) 10 mg, 20 mg, 40 mg</i> | | 1 | |
| <i>omeprazole-sodium bicarbonate oral capsule 20-1.1 mg-gram</i> (Zegerid OTC) | | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>omeprazole-sodium bicarbonate oral capsule 40-1.1 mg-gram</i> | | 2 | ST; QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 20 mg</i> (Protonix) | | 1 | QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 40 mg</i> (Protonix) | | 1 | QL (60 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|-----------------|------------------|----------------------------------|
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i> | (AcipHex) | 2 | QL (30 per 30 days) |
| <i>sucralfate oral tablet 1 gram</i> | (Carafate) | 2 | |
| Gastrointestinal Agents, Other | | | |
| <i>carglumic acid oral tablet, dispersible 200 mg</i> | (Carbaglu) | 5 | PA; NM; NDS |
| <i>constulose oral solution 10 gram/15 ml</i> | (lactulose) | 2 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> | (Gastrocrom) | 2 | |
| <i>dicyclomine oral capsule 10 mg</i> | | 2 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | | 2 | |
| <i>dicyclomine oral tablet 20 mg</i> | | 2 | |
| <i>diphenoxylate-atropine oral liquid 2.5-0.025 mg/5 ml</i> | | 2 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> | (Lomotil) | 2 | |
| <i>enulose oral solution 10 gram/15 ml</i> | (lactulose) | 2 | |
| GATTEX 30-VIAL SUBCUTANEOUS KIT 5 MG | | 5 | PA; NM; NDS |
| <i>generlac oral solution 10 gram/15 ml</i> | (lactulose) | 2 | |
| <i>glycopyrrolate oral tablet 1 mg</i> | (Robinul) | 2 | |
| <i>glycopyrrolate oral tablet 2 mg</i> | (Robinul Forte) | 2 | |
| IQIRVO ORAL TABLET 80 MG | | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>kionex (with sorbitol) oral suspension 15-20 gram/60 ml</i> | | 2 | |
| <i>lactulose oral solution 10 gram/15 ml</i> | (Constulose) | 2 | |
| LINZESSIONAL CAPSULE 145 MCG, 290 MCG, 72 MCG | | 3 | QL (30 per 30 days) |
| LIVDELZI ORAL CAPSULE 10 MG | | 5 | PA; NM; NDS; QL (30 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM | | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|----------------------------------|------------------|---------------------------------------|
| <i>loperamide oral capsule 2 mg</i> | (Anti-Diarrheal (loperamide)) | 2 | |
| <i>lubiprostone oral capsule 24 mcg</i> | (Amitiza) | 2 | QL (60 per 30 days) |
| <i>lubiprostone oral capsule 8 mcg</i> | (Amitiza) | 2 | QL (120 per 30 days) |
| <i>methscopolamine oral tablet 2.5 mg, 5 mg</i> | | 2 | |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | | 2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> | (Reglan) | 1 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | | 3 | QL (30 per 30 days) |
| OCALIVA ORAL TABLET 10 MG, 5 MG | | 5 | PA; NM; NDS; QL (30 per 30 days) |
| RAVICTI ORAL LIQUID 1.1 GRAM/ML | | 5 | PA; NM; NDS |
| RELISTOR ORAL TABLET 150 MG | | 5 | PA; NM; NDS; QL (90 per 30 days) |
| RELISTOR SUBCUTANEOUS SOLUTION 12 MG/0.6 ML | | 5 | PA; NM; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML | | 5 | PA; NM; NDS; QL (16.8 per 28 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML | | 5 | PA; NM; NDS; QL (11.2 per 28 days) |
| <i>sodium phenylbutyrate oral tablet 500 mg</i> | (Buphenyl) | 5 | PA; NM; NDS |
| <i>sodium polystyrene sulfonate oral powder 15 gram</i> | | 2 | |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | | 2 | |
| <i>ursodiol oral capsule 200 mg, 400 mg</i> | (Reltone) | 5 | NM; NDS |
| <i>ursodiol oral capsule 300 mg</i> | | 2 | |
| <i>ursodiol oral tablet 250 mg</i> | | 2 | |
| <i>ursodiol oral tablet 500 mg</i> | (URSO Forte) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| VELTASSA ORAL POWDER IN PACKET 1 GRAM, 16.8 GRAM, 25.2 GRAM, 8.4 GRAM | 3 | |
| XERMELO ORAL TABLET 250 MG | 5 | PA; NM; NDS; QL (84 per 28 days) |
| Laxatives | | |
| CLENPIQ ORAL SOLUTION 10 MG-3.5 GRAM- 12 GRAM/160 ML, 10 MG-3.5 GRAM- 12 GRAM/175 ML | 3 | |
| <i>gavilyte-c oral recon soln 240-22.72- (peg 3350-electrolytes) 6.72 -5.84 gram</i> | 2 | |
| <i>gavilyte-g oral recon soln 236-22.74- (peg 3350-electrolytes) 6.74 -5.86 gram</i> | 2 | |
| <i>gavilyte-n oral recon soln 420 gram (peg-electrolyte soln)</i> | 2 | |
| <i>peg 3350-electrolytes oral recon soln (GaviLyte-G) 236-22.74-6.74 -5.86 gram</i> | 2 | |
| <i>peg-electrolyte soln oral recon soln (GaviLyte-N) 420 gram</i> | 2 | |
| <i>sodium,potassium,mag sulfates oral (Suprep Bowel Prep Kit) recon soln 17.5-3.13-1.6 gram</i> | 3 | |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram 2 pack (480ml)</i> | 2 | |
| SUTAB ORAL TABLET 1.479- 0.188- 0.225 GRAM | 3 | |
| Phosphate Binders | | |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 2 | |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | 2 | |
| <i>lanthanum oral tablet,chewable (Fosrenol) 1,000 mg, 500 mg, 750 mg</i> | 5 | NM; NDS |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>sevelamer carbonate oral tablet 800 mg (Renvela)</i> | 2 | |
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | 2 | |
| Genitourinary Agents | | |
| Antispasmodics, Urinary | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>fesoterodine oral tablet extended release 24 hr 4 mg, 8 mg (Toviaz)</i> | 2 | |
| <i>flavoxate oral tablet 100 mg</i> | 2 | |
| <i>MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG (mirabegron)</i> | 2 | |
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | 2 | |
| <i>oxybutynin chloride oral tablet 2.5 mg, 5 mg</i> | 2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg, 5 mg</i> | 2 | |
| <i>solifenacin oral tablet 10 mg, 5 mg (Vesicare)</i> | 1 | |
| <i>tolterodine oral capsule,extended release 24hr 2 mg, 4 mg</i> | 2 | |
| <i>tolterodine oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>trospium oral capsule,extended release 24hr 60 mg</i> | 2 | |
| <i>trospium oral tablet 20 mg</i> | 2 | |
| Genitourinary Agents, Miscellaneous | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg (Uroxatral)</i> | 2 | QL (30 per 30 days) |
| <i>dutasteride oral capsule 0.5 mg (Avodart)</i> | 2 | |
| <i>dutasteride-tamsulosin oral capsule, er multiphase 24 hr 0.5-0.4 mg (Jalyn)</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|---------------------|------------------|-----------------------------------|
| <i>finasteride oral tablet 5 mg</i> | (Proscar) | 1 | |
| <i>tamsulosin oral capsule 0.4 mg</i> | (Flomax) | 1 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | | 1 | |
| <i>tiopronin oral tablet 100 mg</i> | (Thiola) | 5 | NM; NDS |
| Heavy Metal Antagonists | | | |
| Heavy Metal Antagonists | | | |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> | (Jadenu Sprinkle) | 5 | PA; NM; NDS |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> | (Jadenu) | 2 | PA |
| <i>deferasirox oral tablet, dispersible 125 mg, 250 mg, 500 mg</i> | (Exjade) | 2 | PA |
| <i>deferiprone oral tablet 1,000 mg, 500 mg</i> | (Ferriprox) | 5 | PA; NM; NDS |
| FERRIPROX ORAL SOLUTION 100 MG/ML | | 5 | PA; NM; NDS |
| <i>penicillamine oral tablet 250 mg</i> | (Depen Titratabs) | 5 | PA; NM; NDS |
| <i>trientine oral capsule 250 mg</i> | (Syprine) | 5 | PA; NM; NDS; QL (240 per 30 days) |
| Hormonal Agents, Stimulant/Replacement/Modifying | | | |
| Androgens | | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | | 2 | |
| <i>oxandrolone oral tablet 10 mg, 2.5 mg</i> | | 2 | PA |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml</i> | (Depo-Testosterone) | 2 | PA |
| <i>testosterone cypionate intramuscular oil 200 mg/ml (1 ml)</i> | | 2 | PA |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | | 2 | PA; QL (5 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|--------------------------------|------------------|----------------------------|
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> | (Vogelxo) | 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> | (AndroGel) | 2 | PA; QL (150 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram)</i> | | 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (50 mg/5 gram)</i> | (Vogelxo) | 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal solution in metered pump w/app 30 mg/actuation (1.5 ml)</i> | | 2 | PA; QL (180 per 30 days) |
| XYOSTED SUBCUTANEOUS AUTO-INJECTOR 100 MG/0.5 ML, 50 MG/0.5 ML, 75 MG/0.5 ML | | 3 | PA; QL (2 per 28 days) |
| Estrogens And Antiestrogens | | | |
| <i>abigale lo oral tablet 0.5-0.1 mg</i> | (estradiol-norethindrone acet) | 1 | |
| <i>abigale oral tablet 1-0.5 mg</i> | (estradiol-norethindrone acet) | 2 | |
| <i>amabelz oral tablet 0.5-0.1 mg, 1-0.5 mg</i> | (estradiol-norethindrone acet) | 2 | |
| <i>dotti transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | (estradiol) | 2 | QL (8 per 28 days) |
| DUAVEE ORAL TABLET 0.45-20 MG | | 3 | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | (Estrace) | 1 | |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | (Dotti) | 2 | QL (8 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|-------------------------------------|------------------|----------------------------|
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | (Climara) | 2 | QL (4 per 28 days) |
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> | (Estrace) | 2 | |
| <i>estradiol vaginal tablet 10 mcg</i> | (Yuvafem) | 2 | QL (18 per 28 days) |
| <i>estradiol valerate intramuscular oil 10 mg/ml, 20 mg/ml</i> | (Delestrogen) | 2 | |
| <i>estradiol valerate intramuscular oil 40 mg/ml</i> | | 2 | |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg</i> | (Abigale Lo) | 2 | |
| <i>estradiol-norethindrone acet oral tablet 1-0.5 mg</i> | (Abigale) | 2 | |
| FEMRING VAGINAL RING 0.05 MG/24 HR, 0.1 MG/24 HR | | 4 | QL (1 per 84 days) |
| <i>fyavolv oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>jinteli oral tablet 1-5 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>lyllana transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> | (estradiol) | 2 | QL (8 per 28 days) |
| <i>mimvey oral tablet 1-0.5 mg</i> | (estradiol-norethindrone acet) | 2 | |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-5 mg-mcg</i> | (Fyavolv) | 2 | |
| PREMARIN ORAL TABLET 0.3 MG, 0.45 MG, 0.9 MG | | 3 | |
| PREMARIN ORAL TABLET 0.625 MG, 1.25 MG | (conjugated estrogens) | 3 | |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG-5MG(14) | 3 | |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | |
| <i>raloxifene oral tablet 60 mg</i> (Evista) | 2 | |
| <i>yuvafem vaginal tablet 10 mcg</i> (estradiol) | 2 | QL (18 per 28 days) |
| Glucocorticoids/Mineralocorticoids | | |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i> | 2 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 2 | |
| <i>dexamethasone sodium phosphate injection solution 10 mg/ml, 4 mg/ml</i> | 1 | |
| <i>fludrocortisone oral tablet 0.1 mg</i> | 2 | |
| HEMADY ORAL TABLET 20 MG | 4 | |
| <i>hydrocortisone oral tablet 10 mg, 20</i> (Cortef) <i>mg, 5 mg</i> | 2 | |
| <i>methylprednisolone acetate injection</i> (Depo-Medrol) <i>suspension 40 mg/ml</i> | 2 | |
| <i>methylprednisolone oral tablet 16</i> (Medrol) <i>mg, 4 mg, 8 mg</i> | 2 | |
| <i>methylprednisolone oral tablet 32 mg</i> | 2 | |
| <i>methylprednisolone oral tablets,dose pack 4 mg</i> | 1 | |
| <i>prednisolone 15 mg/5 ml soln d/f 15 mg/5 ml (3 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone oral solution 15 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone sodium phosphate oral</i> (Pediapred) <i>solution 5 mg base/5 ml (6.7 mg/5 ml)</i> | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| <i>prednisone oral solution 5 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD |
| <i>prednisone oral tablets, dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i> | 2 | |
| <i>triamcinolone acetonide injection suspension 40 mg/ml</i> (Kenalog) | 2 | |
| Pituitary | | |
| ACTHAR INJECTION GEL 80 UNIT/ML | 5 | PA; NM; NDS; QL (35 per 28 days) |
| ACTHAR SELFJECT SUBCUTANEOUS PEN INJECTOR 40 UNIT/0.5 ML | 5 | PA; NM; NDS; QL (15 per 30 days) |
| ACTHAR SELFJECT SUBCUTANEOUS PEN INJECTOR 80 UNIT/ML | 5 | PA; NM; NDS; QL (30 per 30 days) |
| CORTROPHIN GEL INJECTION GEL 80 UNIT/ML | 5 | PA; NM; NDS; QL (35 per 28 days) |
| CORTROPHIN GEL SUBCUTANEOUS SYRINGE 40 UNIT/0.5 ML | 5 | PA; NM; NDS; QL (15 per 30 days) |
| CORTROPHIN GEL SUBCUTANEOUS SYRINGE 80 UNIT/ML | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>desmopressin 10 mcg/0.1 ml spr 10 mcg/spray (0.1 ml)</i> | 2 | |
| <i>desmopressin nasal spray, non-aerosol 10 mcg/spray (0.1 ml)</i> | 2 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg (DDAVP)</i> | 2 | |
| EGRIFTA SV SUBCUTANEOUS RECON SOLN 2 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| EGRIFTA WR SUBCUTANEOUS KIT 11.6 MG | 5 | PA; NM; NDS; QL (4 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 5 | PA; NM; NDS |
| <i>lanreotide subcutaneous syringe 120 mg/0.5 ml</i> (Somatuline Depot) | 5 | PA NSO; NM; NDS; QL (0.5 per 28 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG, 30 MG | 5 | PA; NM; NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR KIT 11.25 MG, 15 MG, 7.5 MG (PED) | 5 | PA; NM; NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | PA; NM; NDS |
| LUTRATE DEPOT (3 MONTH) (leuprolide (3 month)) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG | 4 | PA NSO |
| NORDITROPIN FLEXPEN SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 5 | PA; NM; NDS |
| <i>octreotide acetate injection solution 1,000 mcg/ml, 200 mcg/ml</i> | 2 | |
| <i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml, 500 mcg/ml</i> (Sandostatin) | 2 | |
| ORGOVYX ORAL TABLET 120 MG | 5 | PA NSO; NM; NDS |
| ORILISSA ORAL TABLET 150 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| ORILISSA ORAL TABLET 200 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | 5 | PA; NM; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 60 MG/0.2 ML | (lanreotide) 5 | PA NSO; NM; NDS; QL (0.2 per 28 days) |
| SOMATULINE DEPOT SUBCUTANEOUS SYRINGE 90 MG/0.3 ML | (lanreotide) 5 | PA NSO; NM; NDS; QL (0.3 per 28 days) |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NM; NDS |
| SYNAREL NASAL SPRAY, NON- AEROSOL 2 MG/ML | 5 | PA; NM; NDS |
| Progestins | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML | 3 | QL (0.65 per 84 days) |
| <i>gallifrey oral tablet 5 mg</i> (norethindrone acetate) | 2 | |
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i> (Depo-Provera) | 2 | |
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i> (Depo-Provera) | 2 | |
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i> (Provera) | 1 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> | 2 | |
| <i>norethindrone acetate oral tablet 5 mg</i> (Gallifrey) | 2 | |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> (Prometrium) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits | |
|--|------------------|----------------------------|-----------------|
| Thyroid And Antithyroid Agents | | | |
| <i>levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg</i> | (Euthyrox) | 1 | |
| <i>levothyroxine oral tablet 300 mcg</i> | (Levo-T) | 1 | |
| <i>liothyronine oral tablet 25 mcg, 50 mcg</i> | (Cytomel) | 2 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | | 1 | |
| <i>propylthiouracil oral tablet 50 mg</i> | | 2 | |
| Immunological Agents | | | |
| Immunological Agents | | | |
| ACTEMRA ACTPEN SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 5 | PA; NM; NDS | |
| ACTEMRA INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) | 5 | PA; NM; NDS | |
| ACTEMRA SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 5 | PA; NM; NDS | |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 5 | PA; NM; NDS | |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG | (tacrolimus) | 4 | PA BvD |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 5 MG | (tacrolimus) | 5 | PA BvD; NM; NDS |
| <i>auranofin oral capsule 3 mg</i> | (Ridaura) | 5 | NM; NDS |
| AVSOLA INTRAVENOUS RECON SOLN 100 MG | | 5 | PA; NM; NDS |
| <i>azathioprine oral tablet 50 mg</i> | (Imuran) | 2 | PA BvD |
| <i>azathioprine sodium injection recon soln 100 mg</i> | | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits | |
|--|------------------|-------------------------------------|--------|
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML | 5 | PA; NM; NDS; QL (8 per 28 days) | |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 5 | PA; NM; NDS; QL (8 per 28 days) | |
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML | 5 | PA NSO; NM; NDS; QL (2 per 28 days) | |
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) | 5 | PA; NM; NDS | |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 5 | PA; NM; NDS | |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NM; NDS | |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NM; NDS | |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 5 | PA; NM; NDS | |
| COSENTYX UNOREADY PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | 5 | PA; NM; NDS | |
| <i>cyclosporine intravenous solution 250 mg/5 ml</i> | (Sandimmune) | 2 | PA BvD |
| <i>cyclosporine modified oral capsule 100 mg, 25 mg</i> | (Gengraf) | 2 | PA BvD |
| <i>cyclosporine modified oral capsule 50 mg</i> | | 2 | PA BvD |
| <i>cyclosporine modified oral solution 100 mg/ml</i> | (Gengraf) | 2 | PA BvD |
| <i>cyclosporine oral capsule 100 mg, 25 mg</i> | (Sandimmune) | 2 | PA BvD |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| CYLTEZO(CF) PEN CROHN'S-UC- HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 5 | PA; NM; NDS |
| CYLTEZO(CF) PEN PSORIASIS- UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 5 | PA; NM; NDS |
| CYLTEZO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 5 | PA; NM; NDS |
| CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 5 | PA; NM; NDS |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NM; NDS |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NM; NDS |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| <i>everolimus (immunosuppressive) oral</i> (Zortress) tablet 0.25 mg, 0.5 mg, 0.75 mg, 1 mg | 5 | PA BvD; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--|
| GAMMAGARD S-D (IGA < 1 MCG/ML) INTRAVENOUS RECON SOLN 10 GRAM, 5 GRAM | 5 | PA BvD; NM; NDS |
| GAMMAPLEX INTRAVENOUS SOLUTION 10 %, 10 % (100 ML), 10 % (200 ML) | 5 | PA BvD; NM; NDS |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | 5 | PA BvD; NM; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg</i> (cyclosporine modified) | 2 | PA BvD |
| <i>gengraf oral solution 100 mg/ml</i> (cyclosporine modified) | 2 | PA BvD |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN PSOR-UVEITS-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN CROHNS-UC-HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN PEDIATRIC UC SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NM; NDS |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--|
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| ILARIS (PF) SUBCUTANEOUS SOLUTION 150 MG/ML | 5 | PA; NM; NDS |
| ILUMYA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; NM; NDS |
| INFLECTRA INTRAVENOUS RECON SOLN 100 MG | 5 | PA; NM; NDS |
| <i>infliximab intravenous recon soln 100 mg</i> (Remicade) | 5 | PA; NM; NDS |
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 5 | PA; NM; NDS |
| <i>leflunomide oral tablet 10 mg, 20 mg</i> (Arava) | 2 | |
| <i>mycophenolate mofetil (hcl) intravenous recon soln 500 mg</i> | 2 | PA BvD |
| <i>mycophenolate mofetil oral capsule 250 mg</i> | 2 | PA BvD |
| <i>mycophenolate mofetil oral suspension for reconstitution 200 mg/ml</i> | 5 | PA BvD; NM; NDS |
| <i>mycophenolate mofetil oral tablet 500 mg</i> | 2 | PA BvD |
| <i>mycophenolate sodium oral tablet, delayed release (dr/ec) 180 mg, 360 mg</i> (Myfortic) | 2 | PA BvD |
| NIKTIMVO INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS |
| NULOJIX INTRAVENOUS RECON SOLN 250 MG | 5 | PA BvD; NM; NDS |
| ORENCIA (WITH MALTOSE) INTRAVENOUS RECON SOLN 250 MG | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------------|
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO- INJECTOR 125 MG/ML | 5 | PA; NM; NDS |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML | 5 | PA; NM; NDS |
| OTEZLA ORAL TABLET 20 MG, 30 MG | 5 | PA; NM; NDS |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)- 20 MG (51), 10 MG (4)-20 MG (4)- 30 MG (47), 10 MG (4)-20 MG (4)- 30 MG(19) | 5 | PA; NM; NDS |
| PROGRAF INTRAVENOUS SOLUTION 5 MG/ML | 4 | PA BvD |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 4 | PA BvD |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML | 4 | ST |
| RENFLEXIS INTRAVENOUS RECON SOLN 100 MG | 5 | PA; NM; NDS |
| REZUROCK ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS |
| RIDAURA ORAL CAPSULE 3 MG (auranofin) | 5 | NM; NDS |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML | 5 | PA; NM; NDS; QL (360 per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 5 | PA; NM; NDS |
| SELARSDI INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NM; NDS |
| SELARSDI SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | 3 | PA |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|---|--------------------|------------------|-----------------------------------|
| SELARSDI SUBCUTANEOUS SYRINGE 90 MG/ML | (ustekinumab-aekn) | 5 | PA; NM; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> | | 5 | PA BvD; NM; NDS |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | | 2 | PA BvD |
| SKYRIZI INTRAVENOUS SOLUTION 60 MG/ML | | 5 | PA; NM; NDS |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML | | 5 | PA; NM; NDS |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML, 75 MG/0.83 ML | | 5 | PA; NM; NDS |
| SKYRIZI SUBCUTANEOUS SYRINGE KIT 150MG/1.66ML(75 MG/0.83 ML X2) | | 5 | PA; NM; NDS |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) | | 5 | PA; NM; NDS |
| STELARA INTRAVENOUS SOLUTION 130 MG/26 ML | (ustekinumab) | 5 | PA; NM; NDS |
| STELARA SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | (ustekinumab) | 5 | PA; NM; NDS |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML | (ustekinumab) | 5 | PA; NM; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> | (Prograf) | 2 | PA BvD |
| TAVNEOS ORAL CAPSULE 10 MG | | 5 | PA; NM; NDS; QL (180 per 30 days) |
| TREMFYA INTRAVENOUS SOLUTION 200 MG/20 ML (10 MG/ML) | | 5 | PA; NM; NDS |
| TREMFYA PEN INDUCTION PK-CROHN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| TREMFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | 5 | PA; NM; NDS |
| TREMFYA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NM; NDS |
| TREMFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML | 5 | PA; NM; NDS |
| TYENNE AUTOINJECTOR SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 5 | PA; NM; NDS |
| TYENNE INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) | 5 | PA; NM; NDS |
| TYENNE SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 5 | PA; NM; NDS |
| XELJANZ ORAL SOLUTION 1 MG/ML | 5 | PA; NM; NDS |
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5 | PA; NM; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 5 | PA; NM; NDS |
| YESINTEK INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NM; NDS |
| YESINTEK SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 3 | PA |
| YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | 3 | PA |
| YESINTEK SUBCUTANEOUS SYRINGE 90 MG/ML | 5 | PA; NM; NDS |
| YUFLYMA(CF) AI CROHN'S-UC- (adalimumab-aaty) HS SUBCUTANEOUS AUTO- INJECTOR, KIT 80 MG/0.8 ML | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| YUFLYMA(CF) AUTOINJECTOR (adalimumab-aaty) SUBCUTANEOUS AUTO-INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 5 | PA; NM; NDS |
| YUFLYMA(CF) SUBCUTANEOUS (adalimumab-aaty) SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NM; NDS |
| Vaccines | | |
| ABRYSVO (PF) INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML | 3 | \$0 copay |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 3 | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 3 | \$0 copay |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 3 | \$0 copay |
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 120 MCG/0.5 ML | 3 | \$0 copay |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 3 | \$0 copay |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 3 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML | 3 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5- 8-5 LF-MCG-LF/0.5ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG- LF/0.5ML | 3 | |
| DENGVAXIA (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP4.5-6 CCID50/0.5 ML | 3 | QL (3 per 365 days) |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 3 | PA BvD; \$0 copay |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 3 | PA BvD; \$0 copay |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 3 | \$0 copay |
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 3 | \$0 copay |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML | 3 | \$0 copay |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT/0.5 ML | 3 | |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 3 | |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 3 | PA BvD; \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25-58-10 LF-MCG-LF/0.5ML | 3 | |
| IPOP INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 3 | \$0 copay |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 3 | \$0 copay |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 | 3 | \$0 copay |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 3 | |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 3 | \$0 copay |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 3 | \$0 copay |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 3 | \$0 copay |
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 3 | \$0 copay |
| MRESVIA (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML | 3 | \$0 copay |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 3 | |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 3 | |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| PENBRAYA MENACWY COMPONENT(PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 5 MCG/0.5 ML | 3 | \$0 copay |
| PENBRAYA MENB COMPONENT (PF) INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 3 | \$0 copay |
| PENENVY MEN A-B-C-W-Y (PF) INTRAMUSCULAR KIT 0.5 ML | 3 | \$0 copay |
| PENENVY MENACWY COMPONENT(PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 10-5 MCG | 3 | \$0 copay |
| PENENVY MENB COMPONENT (PF) INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 3 | \$0 copay |
| PENTACEL (PF) INTRAMUSCULAR KIT 15 LF UNIT-20 MCG-5 LF/0.5 ML, 15LF- 20MCG-5LF- 62 DU/0.5 ML | 3 | |
| PREHEVBARIO (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML | 3 | PA BvD; \$0 copay |
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2- 3.3CCID50/0.5ML | 3 | \$0 copay |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3-4.3-3- 3.99 TCID50/0.5 | 3 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML | 3 | |
| QUADRACEL (PF) INTRAMUSCULAR SYRINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML | 3 | |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML | 3 | |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 3 | |
| ROTAQUE VACCINE ORAL SOLUTION 2 ML | 3 | |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 3 | \$0 copay; QL (2 per 365 days) |
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML | 3 | \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 3 | \$0 copay |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| TETANUS,DIPHTHERIA TOX PED(PF) INTRAMUSCULAR SUSPENSION 5-25 LF UNIT/0.5 ML | 3 | |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML | 3 | |
| TICOVAC INTRAMUSCULAR SYRINGE 2.4 MCG/0.5 ML | 3 | \$0 copay |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 3 | \$0 copay |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 3 | \$0 copay |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 3 | \$0 copay |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML | 3 | (typhoid vi polysacch vaccine) |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML | 3 | |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 50 UNIT/ML | 3 | \$0 copay |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML | 3 | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 50 UNIT/ML | 3 | \$0 copay |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 3 | \$0 copay |
| VAXCHORA VACCINE ORAL SUSPENSION FOR RECONSTITUTION 4X10EXP8 TO 2X 10EXP9 CF UNIT | 3 | \$0 copay |
| VIMKUNYA INTRAMUSCULAR SYRINGE 40 MCG/0.8 ML | 3 | \$0 copay |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| VIVOTIF ORAL CAPSULE,DELAYED RELEASE(DR/EC) 2 BILLION UNIT | 3 | \$0 copay |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML, 10 EXP4.74 UNIT/0.5 ML(2.5 ML IN 1 VIAL) | 3 | \$0 copay |
| Inflammatory Bowel Disease Agents | | |
| Inflammatory Bowel Disease Agents | | |
| <i>alosetron oral tablet 0.5 mg, 1 mg (Lotronex)</i> | 2 | |
| <i>balsalazide oral capsule 750 mg (Colazal)</i> | 2 | |
| <i>budesonide oral capsule,delayed,extend.release 3 mg</i> | 2 | |
| <i>budesonide rectal foam 2 mg/actuation (Uceris)</i> | 2 | |
| DIPENTUM ORAL CAPSULE 250 MG | 5 | ST; NM; NDS |
| <i>hydrocortisone rectal enema 100 mg/60 ml (Cortenema)</i> | 2 | |
| <i>mesalamine oral capsule (with del rel tablets) 400 mg</i> | 2 | |
| <i>mesalamine oral capsule, extended release 500 mg (Pentasa)</i> | 2 | |
| <i>mesalamine oral capsule,extended release 24hr 0.375 gram (Apriso)</i> | 2 | |
| <i>mesalamine oral tablet,delayed release (dr/ec) 1.2 gram (Lialda)</i> | 2 | QL (120 per 30 days) |
| <i>mesalamine oral tablet,delayed release (dr/ec) 800 mg</i> | 2 | |
| <i>mesalamine rectal enema 4 gram/60 ml (Rowasa)</i> | 2 | |
| <i>mesalamine rectal suppository 1,000 mg (Canasa)</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------|------------------|---------------------------------|
| <i>sulfasalazine oral tablet 500 mg</i> | (Azulfidine) | 2 | |
| <i>sulfasalazine oral tablet,delayed release (dr/ec) 500 mg</i> | (Azulfidine EN-tabs) | 4 | |
| Metabolic Bone Disease Agents | | | |
| Metabolic Bone Disease Agents | | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | | 2 | QL (300 per 28 days) |
| <i>alendronate oral tablet 10 mg</i> | | 1 | QL (30 per 30 days) |
| <i>alendronate oral tablet 35 mg</i> | | 1 | QL (4 per 28 days) |
| <i>alendronate oral tablet 70 mg</i> | (Fosamax) | 1 | QL (4 per 28 days) |
| <i>calcitonin (salmon) nasal spray,non-aerosol 200 unit/actuation</i> | | 2 | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | | 2 | |
| <i>calcitriol oral solution 1 mcg/ml</i> | (Rocaltrol) | 2 | |
| <i>cinacalcet oral tablet 30 mg, 60 mg</i> | (Sensipar) | 2 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> | (Sensipar) | 5 | NM; NDS; QL (120 per 30 days) |
| <i>doxercalciferol oral capsule 0.5 mcg, 1 mcg, 2.5 mcg</i> | | 2 | |
| <i>ibandronate oral tablet 150 mg</i> | | 2 | QL (1 per 28 days) |
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE | | 5 | PA; NM; NDS; QL (2 per 28 days) |
| OSENVELT SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | | 5 | PA; NM; NDS |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg</i> | (Zemplar) | 2 | |
| <i>paricalcitol oral capsule 4 mcg</i> | | 2 | |
| PROLIA SUBCUTANEOUS SYRINGE 60 MG/ML | | 3 | QL (1 per 180 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------------|
| RAYALDEE ORAL CAPSULE, EXTENDED RELEASE 24 HR 30 MCG | 3 | QL (60 per 30 days) |
| risedronate oral tablet 150 mg (Actonel) | 2 | QL (1 per 28 days) |
| risedronate oral tablet 30 mg, 5 mg | 2 | QL (30 per 30 days) |
| risedronate oral tablet 35 mg (Actonel) | 2 | QL (4 per 28 days) |
| risedronate oral tablet 35 mg (12 pack), 35 mg (4 pack) | 2 | QL (4 per 28 days) |
| risedronate oral tablet, delayed release (dr/ec) 35 mg | 2 | QL (4 per 28 days) |
| STOBOCLO SUBCUTANEOUS SYRINGE 60 MG/ML | 3 | QL (1 per 180 days) |
| teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml) | 5 | PA; NM; NDS; QL (2.48 per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 5 | PA; NM; NDS; QL (1.56 per 30 days) |
| XGEVA SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 5 | PA; NM; NDS |
| Miscellaneous Therapeutic Agents | | |
| Miscellaneous Therapeutic Agents | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 5 | PA; NM; NDS |
| ANDEMBRY AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 200 MG/1.2 ML | 5 | PA; NM; NDS |
| BAQSIMI NASAL SPRAY, NON-AEROSOL 3 MG/ACTUATION | 3 | |
| betaine oral powder 1 gram/scoop (Cystadane) | 5 | PA; NM; NDS |
| buspirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg | 1 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| COSENTYX INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA; NM; NDS |
| <i>diazoxide oral suspension 50 mg/ml</i> (Proglycem) | 2 | |
| ELMIRON ORAL CAPSULE 100 MG | 4 | |
| EVRYSDI ORAL RECON SOLN 0.75 MG/ML | 5 | PA; NM; NDS |
| EVRYSDI ORAL TABLET 5 MG | 5 | PA; NM; NDS |
| <i>glutamine (sickle cell) oral powder in packet 5 gram</i> (Endari) | 5 | PA; NM; NDS; QL (180 per 30 days) |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML | 3 | |
| <i>hydroxyzine pamoate oral capsule 100 mg</i> | 2 | |
| <i>hydroxyzine pamoate oral capsule 25 mg, 50 mg</i> | 1 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | |
| <i>levocarnitine (with sugar) oral solution 100 mg/ml</i> (Carnitor) | 2 | |
| <i>levocarnitine oral tablet 330 mg</i> (Carnitor) | 2 | |
| <i>mesna oral tablet 400 mg</i> (Mesnex) | 5 | NM; NDS |
| <i>nitroglycerin rectal ointment 0.4 % (w/w)</i> (Rectiv) | 2 | QL (30 per 30 days) |
| <i>pyridostigmine bromide oral syrup 60 mg/5 ml</i> (Mestinon) | 2 | |
| <i>pyridostigmine bromide oral tablet 30 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|---------------------|---|
| <i>pyridostigmine bromide oral tablet</i> <i>60 mg</i> | (Mestinon) | 2 |
| <i>pyridostigmine bromide oral tablet</i> <i>extended release 180 mg</i> | (Mestinon Timespan) | 2 |
| RIVFLOZA SUBCUTANEOUS SOLUTION 80 MG/0.5 ML (160 MG/ML) | 5 | PA; NM; NDS |
| RIVFLOZA SUBCUTANEOUS SYRINGE 128 MG/0.8 ML, 160 MG/ML | 5 | PA; NM; NDS |
| TAKHZYRO SUBCUTANEOUS SOLUTION 300 MG/2 ML (150 MG/ML) | 5 | PA; NM; NDS; QL (4 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NM; NDS; QL (2 per 28 days) |
| TAKHZYRO SUBCUTANEOUS SYRINGE 300 MG/2 ML (150 MG/ML) | 5 | PA; NM; NDS; QL (4 per 28 days) |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| TYBOST ORAL TABLET 150 MG | 3 | QL (30 per 30 days) |
| VEOZAH ORAL TABLET 45 MG | 4 | PA; QL (30 per 30 days) |
| VOWST ORAL CAPSULE | 5 | PA; NM; NDS; QL (12 per 30 days) |
| ZEGALOGUE AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 0.6 MG/0.6 ML | 3 | |
| ZEGALOGUE SYRINGE SUBCUTANEOUS SYRINGE 0.6 MG/0.6 ML | 3 | |
| ZYMFENTRA SUBCUTANEOUS PEN INJECTOR KIT 120 MG/ML | 5 | PA; NM; NDS |
| ZYMFENTRA SUBCUTANEOUS SYRINGE KIT 120 MG/ML | 5 | PA; NM; NDS |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|-----------|----------------------|
| Ophthalmic Agents | | |
| Antiglaucoma Agents | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | |
| <i>acetazolamide sodium injection recon soln 500 mg</i> | 2 | |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>bimatoprost ophthalmic (eye) drops 0.03 %</i> | 2 | QL (2.5 per 25 days) |
| <i>brimonidine ophthalmic (eye) drops (Alphagan P) 0.1 %, 0.15 %</i> | 2 | |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | 2 | |
| <i>brimonidine-timolol ophthalmic (eye) (Combigan) drops 0.2-0.5 %</i> | 2 | |
| <i>brinzolamide ophthalmic (eye) (Azopt) drops, suspension 1 %</i> | 2 | |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 2 | |
| <i>dorzolamide ophthalmic (eye) drops 2 %</i> | 2 | |
| <i>dorzolamide-timolol ophthalmic (eye) (Cosopt) drops 22.3-6.8 mg/ml</i> | 2 | |
| <i>latanoprost ophthalmic (eye) drops (Xalatan) 0.005 %</i> | 1 | QL (2.5 per 25 days) |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 %</i> | 3 | QL (2.5 per 25 days) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 3 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 3 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1-0.2 % | 3 | |
| <i>tafluprost (pf) ophthalmic (eye) dropperette 0.0015 %</i> | 2 | QL (30 per 30 days) |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i> | 1 | |
| <i>timolol maleate ophthalmic (eye) gel forming solution 0.25 %, 0.5 %</i> | 2 | |
| <i>timolol ophthalmic (eye) drops 0.5 % (Betimol)</i> | 1 | |
| <i>travoprost ophthalmic (eye) drops (Travatan Z) 0.004 %</i> | 2 | QL (2.5 per 25 days) |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 4 | QL (5 per 30 days) |

Replacement Preparations

Replacement Preparations

| | | | |
|---|----------------------------------|---|--|
| <i>d5 % (d-glucose)-0.9 % sodchl intravenous parenteral solution</i> | (d5 % and 0.9 % sodium chloride) | 2 | |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | (D5 % (d-glucose)-0.9 % sodchl) | 2 | |
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i> | | 2 | |
| ISOLYTE S IV SOLUTION-EXCEL SINGLE USE | | 4 | |
| ISOLYTE S PH 7.4 INTRAVENOUS PARENTERAL SOLUTION | | 4 | |
| ISOLYTE-P IN 5 % DEXTROSE INTRAVENOUS PARENTERAL SOLUTION 5 % | | 4 | |
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> | (potassium chloride) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------|------------------|----------------------------|
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> | (potassium chloride) | 2 | |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> | (potassium chloride) | 2 | |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i> | | 4 | |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i> | | 2 | |
| PLASMA-LYTE A INTRAVENOUS PARENTERAL SOLUTION | (electrolyte-a) | 4 | |
| <i>potassium chloride intravenous solution 2 meq/ml</i> | | 2 | PA BvD |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | | 2 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | | 2 | |
| <i>potassium chloride oral tablet extended release 10 meq</i> | (Klor-Con 10) | 2 | |
| <i>potassium chloride oral tablet extended release 15 meq, 20 meq</i> | | 2 | |
| <i>potassium chloride oral tablet extended release 8 meq</i> | (Klor-Con 8) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 10 meq</i> | (Klor-Con M10) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 15 meq</i> | (Klor-Con M15) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 20 meq</i> | (Klor-Con M20) | 2 | |
| <i>potassium chloride-0.45 % nacl intravenous parenteral solution 20 meq/l</i> | | 2 | |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg)</i> | (Urocit-K 10) | 2 | |
| <i>potassium citrate oral tablet extended release 15 meq</i> | (Urocit-K 15) | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>potassium citrate oral tablet extended release 5 meq (540 mg)</i> | 2 | |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i> | 2 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | 2 | |
| <i>sodium chloride 0.9% solution mini-bag, single use</i> | 2 | |

Respiratory Tract Agents

Anti-Inflammatories, Inhaled Corticosteroids

| | | | |
|---|----------------------------------|---|------------------------------|
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION | (fluticasone propion-salmeterol) | 3 | QL (12 per 30 days) |
| AIRSUPRA 90-80 MCG INHALER 90-80 MCG/ACTUATION | | 3 | QL (32.1 per 30 days) |
| ARNUITY ELLIPTA INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION | (fluticasone furoate) | 3 | QL (30 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 100-25 MCG/DOSE, 200-25 MCG/DOSE | (fluticasone furoate-vilanterol) | 3 | QL (60 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 50-25 MCG/DOSE | | 3 | QL (60 per 30 days) |
| <i>breyna inhalation hfa aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | (budesonide-formoterol) | 2 | QL (30.9 per 30 days) |
| <i>budesonide inhalation suspension for nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml</i> | (Pulmicort) | 2 | PA BvD; QL (120 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits | |
|---|----------------------------------|----------------------------|-----------------------|
| <i>budesonide-formoterol inhalation hfa (Breyna) aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | 2 | QL (30.6 per 30 days) | |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation</i> | 2 | QL (12 per 30 days) | |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 220 mcg/actuation</i> | 2 | QL (24 per 30 days) | |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation</i> | 2 | QL (21.2 per 30 days) | |
| <i>fluticasone propion-salmeterol (Wixela Inhub) inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 2 | QL (60 per 30 days) | |
| <i>wixela inhlu inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | (fluticasone propion-salmeterol) | 2 | QL (60 per 30 days) |
| Antileukotrienes | | | |
| <i>montelukast oral tablet 10 mg</i> | (Singulair) | 1 | |
| <i>montelukast oral tablet, chewable 4 mg, 5 mg</i> | (Singulair) | 2 | |
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> | (Accolate) | 2 | |
| Bronchodilators | | | |
| <i>AIRSUPRA INHALATION HFA AEROSOL INHALER 90-80 MCG/ACTUATION</i> | 3 | QL (32.1 per 30 days) | |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation</i> | (Ventolin HFA) | 2 | QL (17 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | | 2 | QL (13.4 per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i> | | 2 | QL (36 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|--------------------------------|------------------------------|
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5 mg/0.5 ml</i> | 2 | PA BvD |
| <i>albuterol sulfate oral syrup 2 mg/5 ml</i> | 2 | |
| <i>albuterol sulfate oral tablet 2 mg, 4 mg</i> | 2 | |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION | (umeclidinium-vilanterol) 3 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 4 | QL (25.8 per 28 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION | 3 | QL (10.7 per 30 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 3 | QL (8 per 30 days) |
| <i>ipratropium bromide inhalation solution 0.02 %</i> | 2 | PA BvD |
| <i>ipratropium-albuterol inhalation solution for nebulization 0.5 mg-3 mg(2.5 mg base)/3 ml</i> | 2 | PA BvD; QL (540 per 30 days) |
| PROAIR RESPICLICK INHALATION AEROSOL POWDR BREATH ACTIVATED 90 MCG/ACTUATION | 4 | QL (2 per 30 days) |
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 3 | QL (60 per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION, 2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------------|
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 3 | QL (4 per 28 days) |
| <i>terbutaline oral tablet 2.5 mg, 5 mg</i> | 2 | |
| <i>theophylline oral solution 80 mg/15 ml</i> | 2 | |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg</i> | 2 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 2 | |
| <i>tiotropium bromide inhalation capsule, w/inhalation device 18 mcg</i> (Spiriva with HandiHaler) | 2 | QL (30 per 30 days) |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200-62.5-25 MCG | 3 | QL (60 per 30 days) |
| Respiratory Tract Agents, Other | | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 2 | PA BvD |
| ALYFTREK ORAL TABLET 10-50-125 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| ALYFTREK ORAL TABLET 4-20-50 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| BRONCHITOL INHALATION CAPSULE, W/INHALATION DEVICE 40 MG | 5 | NM; NDS; QL (560 per 28 days) |
| CINQAIR INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA; NM; NDS |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 2 | PA BvD |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 5 | PA; NM; NDS; QL (1 per 28 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------------|
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 5 | PA; NM; LA; NDS; QL (0.4 per 28 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG, 75-94 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> (Esbriet) | 5 | PA; NM; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> (Esbriet) | 5 | PA; NM; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg</i> | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>pirfenidone oral tablet 801 mg</i> (Esbriet) | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>roflumilast oral tablet 250 mcg</i> (Daliresp) | 2 | QL (28 per 28 days) |
| <i>roflumilast oral tablet 500 mcg</i> (Daliresp) | 2 | QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------------|
| SYMDEKO ORAL TABLETS, SEQUENTIAL 100-150 MG (D)/ 150 MG (N), 50-75 MG (D)/ 75 MG (N) | 5 | PA; NM; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50- 75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) | 5 | PA; NM; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) | 5 | PA; NM; NDS; QL (84 per 28 days) |
| WINREVAIR SUBCUTANEOUS KIT 120 MG (60 MG X 2), 45 MG, 60 MG, 90 MG (45 MG X 2) | 5 | PA; NM; NDS; QL (1 per 21 days) |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NM; NDS |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 5 | PA; NM; NDS |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NM; NDS |
| Skeletal Muscle Relaxants | | |
| Skeletal Muscle Relaxants | | |
| <i>baclofen oral tablet 10 mg, 15 mg, 20 mg, 5 mg</i> | 2 | |
| <i>chlorzoxazone oral tablet 500 mg</i> | 2 | |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 2 | |
| <i>dantrolene oral capsule 100 mg, 50 mg</i> | 2 | |
| <i>dantrolene oral capsule 25 mg (Dantrium)</i> | 2 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>tizanidine oral tablet 2 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | | Drug Tier | Requirements/Limits |
|--|----------------------------------|------------------|---------------------------------------|
| <i>tizanidine oral tablet 4 mg</i> | (Zanaflex) | 2 | |
| Sleep Disorder Agents | | | |
| Sleep Disorder Agents | | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> | (Nuvigil) | 2 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | | 3 | QL (30 per 30 days) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> | (Lunesta) | 2 | QL (30 per 30 days) |
| HETLIOZ LQ ORAL SUSPENSION 4 MG/ML | | 5 | PA; NM; NDS; QL (150 per 30 days) |
| <i>modafinil oral tablet 100 mg</i> | (Provigil) | 2 | PA; QL (30 per 30 days) |
| <i>modafinil oral tablet 200 mg</i> | (Provigil) | 2 | PA; QL (60 per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> | (Xyrem) | 5 | PA; NM; LA; NDS; QL (540 per 30 days) |
| <i>tasimelteon oral capsule 20 mg</i> | (Hetlioz) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | | 2 | QL (30 per 30 days) |
| <i>zolpidem oral tablet 10 mg, 5 mg</i> | (Ambien) | 1 | QL (30 per 30 days) |
| <i>zolpidem oral tablet, ext release multiphase 12.5 mg, 6.25 mg</i> | (Ambien CR) | 2 | QL (30 per 30 days) |
| Vasodilating Agents | | | |
| Vasodilating Agents | | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> | (tadalafil (pulm. hypertension)) | 2 | PA; QL (60 per 30 days) |
| <i>ambrisentan oral tablet 10 mg, 5 mg</i> | (Letairis) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> | (Tracleer) | 5 | PA; NM; LA; NDS; QL (60 per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | | 5 | PA; NM; NDS; QL (30 per 30 days) |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------------|
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> (Revatio) | 2 | PA; QL (360 per 30 days) |
| <i>tadalafil oral tablet 2.5 mg</i> | 2 | PA |
| <i>tadalafil oral tablet 5 mg</i> (Cialis) | 2 | PA |
| <i>treprostinil sodium injection solution 1 mg/ml, 10 mg/ml, 2.5 mg/ml, 5 mg/ml</i> (Remodulin) | 5 | PA; NM; NDS |
| TYVASO INHALATION SOLUTION FOR NEBULIZATION 1.74 MG/2.9 ML (0.6 MG/ML) | 5 | PA; NM; NDS |
| UPTRAVI INTRAVENOUS RECON SOLN 1,800 MCG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 5 | PA; NM; NDS; QL (240 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) | 5 | PA; NM; NDS |
| Vitamins And Minerals | | |
| Vitamins And Minerals | | |
| <i>bal-care dha combo pack 27-1-430 mg</i> | 2 | |
| <i>bal-care dha essential pack 27 mg iron-1 mg -374 mg</i> | 2 | |
| <i>c-nate dha softgel 28 mg iron-1 mg - 200 mg</i> | 2 | |
| <i>completenate tablet chew 29 mg iron-1 mg</i> | 2 | |
| <i>folivane-ob capsule 85-1 mg</i> | 2 | |
| <i>kosher prenatal plus iron tab 30 mg iron- 1 mg</i> | 2 | |
| <i>marnatal-f capsule 60 mg iron-1 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|----------------------------------|----------------------------|
| <i>m-natal plus tablet 27 mg iron- 1 mg (pnv,calcium 72-iron-folic acid)</i> | 2 | |
| <i>mynatal advance oral tablet 90-1-50 mg</i> | 2 | |
| <i>mynatal capsule 65 mg iron- 1 mg</i> | 2 | |
| <i>mynatal oral tablet 90-1-50 mg</i> | 2 | |
| <i>mynatal plus captab 65 mg iron- 1 mg</i> | 2 | |
| <i>mynatal-z captab 65 mg iron- 1 mg</i> | 2 | |
| <i>mynate 90 plus oral tablet extended release 90 mg iron-1 mg</i> | 2 | |
| <i>newgen tablet 32-1,000 mg-mcg</i> | 2 | |
| <i>niva-plus tablet 27 mg iron- 1 mg</i> | 2 | |
| <i>obstetrix dha combo pack 29 mg iron- 1,700 mcg dfe</i> | 2 | |
| <i>obstetrix dha oral combo pack,tablet and cap,dr 29 mg iron-1 mg -50 mg</i> | 2 | |
| <i>o-cal prenatal oral tablet 15 mg iron- 1,000 mcg</i> | 2 | |
| <i>pnv 29-1 oral tablet 29 mg iron- 1 mg</i> | 2 | |
| <i>pnv prenatal plus multivit tab gluten-free (rx) 27 mg iron- 1 mg</i> | (pnv,calcium 72-iron-folic acid) | 2 |
| <i>pnv-dha + docusate oral capsule 27-1.25-55-300 mg</i> | 2 | |
| <i>pnv-omega softgel 28-1-300 mg</i> | 2 | |
| <i>pr natal 400 combo pack 29-1-400 mg</i> | 2 | |
| <i>pr natal 400 ec combo pack 29-1-400 mg</i> | 2 | |
| <i>pr natal 430 combo pack 29 mg iron- 1 mg -430 mg</i> | 2 | |
| <i>pr natal 430 ec combo pack 29-1-430 mg</i> | 2 | |
| <i>prena1 true combo pack 30 mg iron- 1.4 mg-300 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| prenaissance oral capsule 29-1.25-55-325 mg | 2 | |
| prenaissance plus oral capsule 28-1-50-250 mg | 2 | |
| prenatabs fa tablet 29-1 mg | 2 | |
| prenatal 19 (with docusate) oral tablet 29 mg iron- 1 mg-25 mg | 2 | |
| prenatal 19 chewable tablet 29 mg iron- 1 mg | 2 | |
| prenatal low iron oral tablet 27 mg iron- 1 mg | 2 | |
| prenatal plus iron tablet (rx) 29 mg iron- 1 mg (pnv,calcium 72-iron,carb-folic) | 2 | |
| prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg (pnv,calcium 72-iron-folic acid) | 2 | |
| prenatal-u capsule 106.5-1 mg | 2 | |
| preplus oral tablet 27 mg iron- 1 mg (pnv,calcium 72-iron-folic acid) | 2 | |
| pretab oral tablet 29-1 mg | 2 | |
| r-natal ob softgel 20 mg iron- 1 mg-320 mg | 2 | |
| select-ob chewable caplet 29 mg iron- 1 mg | 2 | |
| select-ob chewable caplet 29 mg iron- 1 mg | 2 | |
| se-natal 19 chewable tablet 29 mg iron- 1 mg | 2 | |
| taron-c dha capsule 35-1-200 mg | 2 | |
| taron-prex prenatal-dha oral capsule 30 mg iron-1.2 mg-55 mg-265 mg | 2 | |
| triveen-duo dha oral combo pack 29-1-400 mg | 2 | |
| virt-c dha oral capsule 35-1-200 mg | 2 | |
| virt-nate dha softgel 28 mg iron-1 mg -200 mg | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>virt-pn dha softgel (rx) 27 mg iron-1 mg -300 mg</i> | 2 | |
| <i>virt-pn plus oral capsule 28-1-300 mg</i> | 2 | |
| <i>vitafol gummies 3.33 mg iron- 0.33 mg</i> | 2 | |
| <i>vitafol nano oral tablet 18 mg iron- 1 mg</i> | 2 | |
| <i>vitafol-ob+dha combo pack 65-1-250 mg</i> | 2 | |
| <i>vp-ch-pnv oral capsule 30 mg iron-1 mg -50 mg-260 mg</i> | 2 | |
| <i>vp-pnv-dha oral capsule 28 mg iron- 1 mg-200 mg</i> | 2 | |
| <i>zatean-pn dha capsule 27 mg iron-1 mg -300 mg</i> | 2 | |
| <i>zatean-pn plus softgel 28-1-300 mg</i> | 2 | |
| <i>zingiber tablet 1.2 mg-40 mg- 124.1 mg-100 mg</i> | 2 | |

You can find information on what the symbols and abbreviations in this table mean by going to the introduction pages of this document

INDEX

| | | | | | |
|------------------------------|---------|---------------------------|----------|---------------------------------------|--------|
| 1ST TIER UNIFINE PENTIPS | 123 | ADVOCATE PEN NEEDLE | 124 | <i>amikacin</i> | 11 |
| 1ST TIER UNIFINE PENTIPS | | ADVOCATE SYRINGES | 123, 124 | <i>amiloride</i> | 95 |
| PLUS | 123 | <i>afirmelle</i> | 105 | <i>amiloride-hydrochlorothiazide</i> | 95 |
| <i>abacavir</i> | 74 | AIMOVIG AUTOINJECTOR | 60 | <i>amiodarone</i> | 90 |
| <i>abacavir-lamivudine</i> | 74 | AIRSUPRA | 212, 213 | <i>amitriptyline</i> | 47 |
| ABELCET | 57 | AJOVY AUTOINJECTOR | 60 | <i>amitriptyline-chlordiazepoxide</i> | 47 |
| <i>abigale</i> | 184 | AJOVY SYRINGE | 61 | <i>amlodipine</i> | 95 |
| <i>abigale lo</i> | 184 | AKEEGA | 20 | <i>amlodipine-atorvastatin</i> | 97 |
| ABILIFY ASIMTUFII | 67 | <i>ala-cort</i> | 119 | <i>amlodipine-benazepril</i> | 95 |
| ABILIFY MAINTENA | 67 | <i>ala-scalp</i> | 119 | <i>amlodipine-olmesartan</i> | 95 |
| <i>abiraterone</i> | 20 | <i>albendazole</i> | 64 | <i>amlodipine-valsartan</i> | 95 |
| <i>abirtega</i> | 20 | <i>albuterol sulfate</i> | 213, 214 | <i>amlodipine-valsartan-hcthiazid</i> | 95 |
| ABOUTTIME PEN NEEDLE | 123 | <i>alclometasone</i> | 119 | <i>ammonium lactate</i> | 117 |
| ABRYSVO (PF) | 198 | ALCOHOL PADS | 124 | <i>amoxapine</i> | 47 |
| <i>acamprosate</i> | 8 | ALCOHOL PREP PADS | 145 | <i>amoxicil-clarithromy-lansopraz</i> | |
| <i>acarbose</i> | 51 | ALCOHOL PREP SWABS | 124 | | 177 |
| <i>accutane</i> | 117 | ALCOHOL SWABS | 124 | <i>amoxicillin</i> | 16 |
| <i>acebutolol</i> | 91 | ALCOHOL WIPES | 124 | <i>amoxicillin-pot clavulanate</i> | 16, 17 |
| <i>acetaminophen-codeine</i> | 3 | ALECENSA | 20 | <i>amphotericin b</i> | 57 |
| <i>acetazolamide</i> | 209 | <i>alendronate</i> | 205 | <i>amphotericin b liposome</i> | 57 |
| <i>acetazolamide sodium</i> | 209 | <i>alfuzosin</i> | 182 | <i>ampicillin</i> | 17 |
| <i>acetic acid</i> | 173 | <i>aliskiren</i> | 99 | <i>ampicillin sodium</i> | 17 |
| <i>acetylcysteine</i> | 215 | <i>allopurinol</i> | 59 | <i>ampicillin-sulbactam</i> | 17 |
| <i>acitretin</i> | 117 | <i>alosetron</i> | 204 | <i>anagrelide</i> | 85 |
| ACTEMRA | 190 | <i>alprazolam</i> | 9, 10 | <i>anastrozole</i> | 20 |
| ACTEMRA ACTPEN | 190 | ALREX | 176 | ANDEMBRY | |
| ACTHAR | 187 | <i>altavera (28)</i> | 105 | AUTOINJECTOR | 206 |
| ACTHAR SELFJECT | 187 | ALTRENO | 122 | ANKTIVA | 20 |
| ACTHIB (PF) | 198 | ALUNBRIG | 20 | ANORO ELLIPTA | 214 |
| ACTIMMUNE | 206 | ALVAIZ | 83 | <i>apomorphine</i> | 65 |
| <i>acyclovir</i> | 81, 117 | <i>alyacen 1/35 (28)</i> | 106 | <i>apractonidine</i> | 173 |
| <i>acyclovir sodium</i> | 81 | <i>alyacen 7/7/7 (28)</i> | 106 | <i>aprepitant</i> | 63 |
| ADACEL(TDAP | | ALYFTREK | 215 | APRETUDE | 75 |
| ADOLESN/ADULT)(PF) | 198 | <i>alyq</i> | 218 | <i>apri</i> | 106 |
| <i>adapalene</i> | 122 | <i>amabelz</i> | 184 | APTIVUS | 75 |
| <i>adefovir</i> | 81 | <i>amantadine hcl</i> | 65 | AQINJECT PEN NEEDLE | 124 |
| ADEMPAS | 218 | <i>ambrisentan</i> | 218 | <i>aranelle (28)</i> | 106 |
| <i>adrucil</i> | 20 | <i>amethia</i> | 106 | ARCALYST | 190 |
| ADVAIR HFA | 212 | <i>amethyst (28)</i> | 106 | AREXVY (PF) | 198 |

| | | | | | |
|--------------------------------------|--------|--------------------------------------|----------|--------------------------------------|----------|
| ARIKAYCE | 11 | AUVELITY | 47 | BD SAFETYGLIDE SYRINGE | 126 |
| ariPIPrazole | 67, 68 | aviane | 106 | BD ULTRA-FINE MICRO PEN NEEDLE | 127 |
| ARISTADA | 68 | AVMAPKI | 20 | BD ULTRA-FINE MINI PEN NEEDLE | 127 |
| ARISTADA INITIO | 68 | AVMAPKI-FAKZYNJA | 20 | BD ULTRA-FINE NANO PEN NEEDLE | 127 |
| armodafinil | 218 | AVONEX | 101 | BD ULTRA-FINE SHORT PEN NEEDLE | 127 |
| ARNURITY ELLIPTA | 212 | AVSOLA | 190 | BD VEO INSULIN SYR (HALF UNIT) | 127 |
| ascomp with codeine | 3 | AXTLE | 20 | BD VEO INSULIN SYRINGE UF | 127 |
| asenapine maleate | 68 | ayuna | 106 | BELSOMRA | 218 |
| ashlyna | 106 | AYVAKIT | 21 | benazepril | 89 |
| aspirin-dipyridamole | 85 | azacitidine | 21 | benazepril-hydrochlorothiazide .. | 89 |
| ASSURE ID DUO PRO SFTY PEN NDL | 124 | azathioprine | 190 | bendamustine | 21 |
| ASSURE ID DUO-SHIELD | 125 | azathioprine sodium | 190 | BENDAMUSTINE | 21 |
| ASSURE ID INSULIN SAFETY | 125 | azelastine | 173 | BENDEKA | 21 |
| ASSURE ID PEN NEEDLE | 125 | azithromycin | 14, 15 | BENLYSTA | 191 |
| ASSURE ID PRO PEN NEEDLE | 125 | aztreonam | 15 | benztropine | 65 |
| ASTAGRAF XL | 190 | azurette (28) | 106 | bepotastine besilate | 173 |
| atazanavir | 75 | bacitracin | 173 | BESREMI | 191 |
| atenolol | 91 | bacitracin-polymyxin b | 174 | betaine | 206 |
| atenolol-chlorthalidone | 91 | baclofen | 217 | betamethasone dipropionate .. | 119 |
| atomoxetine | 100 | bal-care dha | 219 | betamethasone valerate | 119, 120 |
| atorvastatin | 97 | bal-care dha essential | 219 | BETASERON | 101 |
| atovaquone | 64 | balsalazide | 204 | betaxolol | 91, 209 |
| atovaquone-proguanil | 64 | BALVERSA | 21 | bethanechol chloride | 182 |
| atropine | 173 | balziva (28) | 106 | bexarotene | 21 |
| ATROVENT HFA | 214 | BAQSIMI | 206 | BEXSERO | 198 |
| aubra eq | 106 | BCG VACCINE, LIVE (PF) | 198 | bicalutamide | 21 |
| AUGTYRO | 20 | BD ALCOHOL SWABS | 127 | BICILLIN L-A | 17 |
| auranofin | 190 | BD AUTOSHIELD DUO PEN NEEDLE | 125 | BIKTARVY | 75 |
| aurovela 1.5/30 (21) | 106 | BD ECLIPSE LUER-LOK | 125 | bimatoprost | 209 |
| aurovela 1/20 (21) | 106 | BD INSULIN SYRINGE | 126 | bisoprolol fumarate | 91 |
| aurovela 24 fe | 106 | BD INSULIN SYRINGE | 125 | bisoprolol-hydrochlorothiazide .. | 91 |
| aurovela fe 1.5/30 (28) | 106 | (HALF UNIT) | 125 | BIZENGRI | 21 |
| aurovela fe 1-20 (28) | 106 | BD INSULIN SYRINGE SLIP TIP | 126 | | |
| AUSTEDO | 100 | BD INSULIN SYRINGE ULTRA-FINE | 125, 126 | | |
| AUSTEDO XR | 100 | BD NANO 2ND GEN PEN NEEDLE | 126 | | |
| AUSTEDO XR TITRATION KT(WK1-4) | 101 | BD SAFETYGLIDE INSULIN SYRINGE | 126, 127 | | |
| AUTOSHIELD DUO PEN NEEDLE | 125 | | | | |

| | | | | | |
|--------------------------------------|----------|---------------------------------------|----------|--------------------------------------|----------|
| <i>bleomycin</i> | 21 | <i>cabotegravir</i> | 75 | <i>cefprozil</i> | 14 |
| <i>blisovi 24 fe</i> | 107 | <i>calcipotriene</i> | 117 | <i>ceftazidime</i> | 14 |
| <i>blisovi fe 1.5/30 (28)</i> | 107 | <i>calcitonin (salmon)</i> | 205 | <i>ceftriaxone</i> | 14 |
| <i>blisovi fe 1/20 (28)</i> | 107 | <i>calcitriol</i> | 205 | <i>cefuroxime axetil</i> | 14 |
| BOOSTRIX TDAP | 198 | <i>calcium acetate(phosphat bind)</i> | 181 | <i>cefuroxime sodium</i> | 14 |
| BORDERED GAUZE | 127 | CALQUENCE | 22 | <i>celecoxib</i> | 6 |
| <i>bortezomib</i> | 21 | CALQUENCE | | <i>cephalexin</i> | 14 |
| BORUZU | 21 | (ACALABRUTINIB MAL) | 22 | CERDELGA | 171 |
| <i>bosentan</i> | 218 | <i>camila</i> | 107 | <i>cevimeline</i> | 116 |
| BOSULIF | 21, 22 | CAMZYOS | 93 | <i>chateal eq (28)</i> | 107 |
| BRAFTOVI | 22 | <i>candesartan</i> | 88 | <i>chlordiazepoxide hcl</i> | 10 |
| BREO ELLIPTA | 212 | <i>candesartan-hydrochlorothiazid</i> | 88 | <i>chlorhexidine gluconate</i> | 116 |
| <i>breyna</i> | 212 | CAPLYTA | 68 | <i>chloroquine phosphate</i> | 64 |
| BREZTRI AEROSPHERE | 214 | CAPRELSA | 22 | <i>chlorpromazine</i> | 68 |
| <i>briellyn</i> | 107 | <i>captopril</i> | 89 | <i>chlorthalidone</i> | 96 |
| BRILINTA | 85 | <i>carbamazepine</i> | 40, 41 | <i>chlorzoxazone</i> | 217 |
| <i>brimonidine</i> | 209 | <i>carbidopa</i> | 65 | <i>cholestyramine (with sugar)</i> | 97 |
| <i>brimonidine-timolol</i> | 209 | <i>carbidopa-levodopa</i> | 65, 66 | <i>cholestyramine light</i> | 97 |
| <i>brinzolamide</i> | 209 | <i>carbidopa-levodopa-</i> | | <i>ciclopirox</i> | 57 |
| BRIVIACT | 40 | <i>entacapone</i> | 66 | <i>cilostazol</i> | 85 |
| <i>bromfenac</i> | 176 | <i>carbinoxamine maleate</i> | 59 | CIMDUO | 75 |
| <i>bromocriptine</i> | 65 | <i>carboplatin</i> | 22 | <i>cimetidine</i> | 177, 178 |
| BRONCHITOL | 215 | CAREFINE PEN NEEDLE | | <i>cimetidine hcl</i> | 177 |
| BRUKINSA | 22 | PREP PAD | 128 | CIMZIA | 191 |
| <i>budesonide</i> | 204, 212 | CARETOUCH ALCOHOL | | CIMZIA POWDER FOR | |
| <i>budesonide-formoterol</i> | 213 | CARETOUCH INSULIN | | RECONST | 191 |
| <i>bumetanide</i> | 95 | SYRINGE | 128, 129 | <i>cinacalcet</i> | 205 |
| <i>buprenorphine</i> | 3 | CARETOUCH PEN NEEDLE | 128 | CINQAIR | 215 |
| <i>buprenorphine hcl</i> | 8 | <i>carglumic acid</i> | 179 | CINRYZE | 83 |
| <i>buprenorphine-naloxone</i> | 8, 9 | <i>carteolol</i> | 209 | <i>ciprofloxacin hcl</i> | 18, 174 |
| <i>bupropion hcl</i> | 47 | <i>cartia xt</i> | 92 | <i>ciprofloxacin in 5 % dextrose</i> | 18 |
| <i>bupropion hcl (smoking deter)</i> | 9 | <i>carvedilol</i> | 91 | <i>ciprofloxacin-dexamethasone</i> | 174 |
| <i>buspirone</i> | 206 | CAYSTON | 15 | <i>citalopram</i> | 48 |
| <i>butalbital-acetaminop-caf-cod</i> | 3 | <i>cefaclor</i> | 13 | <i>cladribine</i> | 22 |
| <i>butalbital-acetaminophen</i> | 3 | <i>cefadroxil</i> | 13 | <i>clarithromycin</i> | 15 |
| <i>butalbital-acetaminophen-caff</i> | 3 | <i>cefazolin</i> | 13 | <i>clemastine</i> | 60 |
| <i>butalbital-aspirin-caffeine</i> | 3 | <i>cefdinir</i> | 13 | <i>clemasz</i> | 60 |
| <i>butorphanol</i> | 3 | <i>cefepime</i> | 13 | <i>clemsza</i> | 60 |
| CABENUVA | 75 | <i>cefixime</i> | 13 | CLENPIQ | 181 |
| <i>cabergoline</i> | 65 | <i>cefoxitin</i> | 13 | CLICKFINE PEN NEEDLE | |
| CABLIVI | 85 | <i>cefpodoxime</i> | 14 | | 129, 141 |
| CABOMETYX | 22 | | | <i>clindamycin hcl</i> | 12 |

| | | | | | |
|---------------------------------------|-------------|-------------------------------------|---------------|---------------------------------------|----------|
| <i>clindamycin pediatric</i> | 12 | <i>clozapine</i> | 68 | <i>cyclobenzaprine</i> | 217 |
| <i>clindamycin phosphate</i> | 12, 60, 118 | <i>c-nate dha</i> | 219 | <i>cyclophosphamide</i> | 23 |
| <i>clindamycin-benzoyl peroxide</i> | 118 | <i>COARTEM</i> | 64 | <i>cyclosporine</i> | 176, 191 |
| CLINIMIX 5%/D15W | | <i>COBENFY</i> | 69 | <i>cyclosporine modified</i> | 191 |
| SULFITE FREE | 86 | <i>COBENFY STARTER PACK</i> | 69 | CYLTEZO(CF) | 192 |
| CLINIMIX 4.25%/D10W | | <i>codeine sulfate</i> | 3 | CYLTEZO(CF) PEN | 192 |
| SULF FREE | 86 | <i>codeine-butalbital-asa-caff</i> | 4 | CYLTEZO(CF) PEN | |
| CLINIMIX 4.25%/D5W | | <i>colchicine</i> | 59 | CROHN'S-UC-HS | 192 |
| SULFIT FREE | 86 | <i>colesevelam</i> | 97 | CYLTEZO(CF) PEN | |
| CLINIMIX 5%-D20W(SULFITE-FREE) | 86 | <i>colestipol</i> | 97 | PSORIASIS-UV | 192 |
| CLINIMIX 6%-D5W(SULFITE-FREE) | 86 | <i>colistin (colistimethate na)</i> | 12 | <i>cyproheptadine</i> | 60 |
| CLINIMIX 8%-D10W(SULFITE-FREE) | 86 | COMBIVENT RESPIMAT | 214 | <i>cyred eq</i> | 107 |
| CLINIMIX 8%-D14W(SULFITE-FREE) | 86 | <i>COMETRIQ</i> | 22 | <i>d5 % (d-glucose)-0.9 % sodchl</i> | |
| CLINIMIX E 2.75%/D5W | | COMFORT EZ INSULIN | | | 210 |
| SULF FREE | 86 | SYRINGE | 129, 130, 131 | <i>d5 % and 0.9 % sodium chloride</i> | |
| CLINIMIX E 4.25%/D10W | | COMFORT EZ PEN | | | 210 |
| SUL FREE | 86 | NEEDLES | 129, 130 | <i>d5 %-0.45 % sodium chloride</i> | 210 |
| CLINIMIX E 4.25%/D5W | | COMFORT EZ PRO SAFETY | | <i>dabigatran etexilate</i> | 82 |
| SULF FREE | 86 | PEN NDL | 130 | <i>dalfampridine</i> | 101 |
| CLINIMIX E 5%/D15W | | COMFORT TOUCH PEN | | <i>danazol</i> | 183 |
| SULFIT FREE | 86 | NEEDLE | 131, 132 | <i>dantrolene</i> | 217 |
| CLINIMIX E 5%/D20W | | <i>completenate</i> | 219 | DANYELZA | 23 |
| SULFIT FREE | 87 | <i>compro</i> | 63 | DANZITEN | 23 |
| CLINIMIX E 8%-D10W | | <i>constulose</i> | 179 | <i>dapsone</i> | 62 |
| SULFITEFREE | 87 | COPIKTRA | 22 | DAPTACEL (DTAP PEDIATRIC) (PF) | 199 |
| CLINIMIX E 8%-D14W | | CORLANOR | 94 | <i>daptomycin</i> | 12 |
| SULFITEFREE | 87 | CORTROPHIN GEL | 187 | <i>darunavir</i> | 75 |
| <i>clobazam</i> | 41 | COSENTYX | 191, 207 | DARZALEX | 23 |
| <i>clobetasol</i> | 120 | COSENTYX (2 SYRINGES) | 191 | DARZALEX FASPRO | 23 |
| <i>clobetasol-emollient</i> | 120 | COSENTYX PEN (2 PENS) | 191 | <i>dasatinib</i> | 23 |
| <i>clomipramine</i> | 48 | COSENTYX UNOREADY | | <i>dasetta 1/35 (28)</i> | 107 |
| <i>clonazepam</i> | 10 | PEN | 191 | <i>dasetta 7/7/7 (28)</i> | 107 |
| <i>clonidine</i> | 87 | COTELLIC | 22 | DATROWAY | 23 |
| <i>clonidine hcl</i> | 87, 101 | CREON | 171 | DAURISMO | 23 |
| <i>clopidogrel</i> | 85 | CRESEMBA | 57 | <i>daysee</i> | 107 |
| <i>clorazepate dipotassium</i> | 10 | <i>cromolyn</i> | 173, 179, 215 | <i>deblitane</i> | 107 |
| <i>clotrimazole</i> | 57 | <i>cryselle (28)</i> | 107 | <i>decitabine</i> | 23 |
| <i>clotrimazole-betamethasone</i> | 57 | CURAD GAUZE PAD | 132 | <i>deferasirox</i> | 183 |
| | | CURITY ALCOHOL SWABS | 132 | <i>deferiprone</i> | 183 |
| | | CURITY GAUZE | 132 | DELSTRIGO | 75 |
| | | <i>cyclafem 1/35 (28)</i> | 107 | <i>demeclacycline</i> | 18 |
| | | <i>cyclafem 7/7/7 (28)</i> | 107 | | |

| | | | | | |
|---|----------|---|---------------|---|---------------|
| DENGVAXIA (PF)..... | 199 | <i>dilt-xr</i> | 93 | <i>drospirenone-ethinyl estradiol</i> | 107, 108 |
| <i>denta 5000 plus</i> | 116 | <i>dimethyl fumarate</i> | 102 | DROXIA | 85 |
| <i>dentagel</i> | 116 | DIPENTUM | 204 | <i>droxidopa</i> | 87 |
| DEPO-SUBQ PROVERA 104. | 189 | <i>diphenoxylate-atropine</i> | 179 | DUAVEE | 184 |
| DERMACEA | 132 | <i>dipyridamole</i> | 85 | <i>duloxetine</i> | 48 |
| DERMACEA NON-WOVEN .. | 132 | <i>disopyramide phosphate</i> | 90 | DUPIXENT PEN | 192 |
| <i>dermacinrx lidocan</i> | 8 | <i>disulfiram</i> | 9 | DUPIXENT SYRINGE | 192 |
| DESCOVERY | 75 | <i>divalproex</i> | 41 | <i>dutasteride</i> | 182 |
| <i>desipramine</i> | 48 | <i>dofetilide</i> | 90 | <i>dutasteride-tamsulosin</i> | 182 |
| <i>desmopressin</i> | 187 | <i>dolishale</i> | 107 | EASY COMFORT ALCOHOL | |
| <i>desog-e.estriadiol/e.estriadiol</i> | 107 | <i>donepezil</i> | 46 | PAD | 136 |
| <i>desogestrel-ethinyl estradiol</i> | 107 | DOPTELET (10 TAB PACK) | 83 | EASY COMFORT INSULIN | |
| <i>desonide</i> | 120 | DOPTELET (15 TAB PACK) | 83 | SYRINGE | 136, 137 |
| <i>desoximetasone</i> | 120 | DOPTELET (30 TAB PACK) | 83 | EASY COMFORT PEN | |
| <i>desvenlafaxine succinate</i> | 48 | <i>dorzolamide</i> | 209 | NEEDLES | 137 |
| <i>dexamethasone</i> | 186 | <i>dorzolamide-timolol</i> | 209 | EASY COMFORT SAFETY | |
| <i>dexamethasone sodium</i> | | <i>dotti</i> | 184 | PEN NEEDLE | 136 |
| <i>phosphate</i> | 176, 186 | DOVATO | 75 | EASY GLIDE INSULIN | |
| <i>dexamethylphenidate</i> | 101 | <i>doxazosin</i> | 87 | SYRINGE | 137 |
| <i>dextroamphetamine sulfate</i> | 101 | <i>doxepin</i> | 48 | EASY GLIDE PEN NEEDLE .. | 138 |
| <i>dextroamphetamine-</i> | | <i>doxercalciferol</i> | 205 | EASY TOUCH | 139, 140 |
| <i>amphetamine</i> | 101, 102 | <i>doxorubicin, peg-liposomal</i> | 23 | EASY TOUCH ALCOHOL | |
| <i>dextrose 5 % in water (d5w)</i> | 87 | <i>doxy-100</i> | 18 | PREP PADS | 138 |
| DIACOMIT | 41 | <i>doxycycline hyclate</i> | 18, 19 | EASY TOUCH FLIPLOCK | |
| <i>diazepam</i> | 10, 41 | <i>doxycycline monohydrate</i> | 19 | INSULIN | 139 |
| <i>diazepam intensol</i> | 10 | DRIZALMA SPRINKLE | 48 | EASY TOUCH FLIPLOCK | |
| <i>diazoxide</i> | 207 | <i>dronabinol</i> | 63 | SYRINGE | 138 |
| <i>diclofenac epolamine</i> | 6 | DROPLET INSULIN | | EASY TOUCH INSULIN | |
| <i>diclofenac potassium</i> | 6 | SYR(HALF UNIT) | 132, 133 | SAFETY SYR | 138 |
| <i>diclofenac sodium</i> | 6, 176 | DROPLET INSULIN | | EASY TOUCH INSULIN | |
| <i>diclofenac-misoprostol</i> | 6, 7 | SYRINGE | 132, 133, 134 | SYRINGE | 138, 139, 140 |
| <i>dicloxacillin</i> | 17 | DROPLET MICRON PEN | | EASY TOUCH LUER LOCK | |
| <i>dicyclomine</i> | 179 | NEEDLE | 134 | INSULIN | 139 |
| <i>didanosine</i> | 75 | DROPLET PEN NEEDLE | | EASY TOUCH PEN NEEDLE | 139 |
| DIFICID | 15 | | 134, 135 | EASY TOUCH SAFETY PEN | |
| <i>diflorasone</i> | 120 | DROPSAFE ALCOHOL PREP | | NEEDLE | 140 |
| <i>dilfusal</i> | 7 | PADS | 135 | EASY TOUCH | |
| <i>difluprednate</i> | 176 | DROPSAFE INSULIN | | SHEATHLOCK INSULIN | |
| <i>digoxin</i> | 94 | SYRINGE | 135 | | 138, 139 |
| <i>dihydroergotamine</i> | 61 | DROPSAFE PEN NEEDLE | 135 | EASY TOUCH UNI-SLIP | 140 |
| DILANTIN | 41 | | | <i>econazole nitrate</i> | 57 |
| <i>diltiazem hcl</i> | 92, 93 | | | | |

| | | | | | |
|---|----------|--|----------|---|-----|
| EDURANT | 75 | ENGERIX-B PEDIATRIC (PF) | 199 | <i>ethambutol</i> | 62 |
| EDURANT PED | 75 | <i>enilloring</i> | 108 | <i>ethosuximide</i> | 42 |
| <i>efavirenz</i> | 76 | <i>enoxaparin</i> | 82 | <i>ethynodiol diac-eth estradiol</i> | 108 |
| <i>efavirenz-emtricitabin-tenofovir</i> | 76 | <i>enpresse</i> | 108 | <i>etodolac</i> | 7 |
| <i>efavirenz-lamivu-tenofovir disop</i> ... | 76 | <i>enskyce</i> | 108 | <i>etonogestrel-ethinyl estradiol</i> ... | 108 |
| EGRIFTA SV | 187 | ENSPLYNG | 102 | ETOPOPHOS | 24 |
| EGRIFTA WR | 187 | <i>entacapone</i> | 66 | <i>etoposide</i> | 25 |
| ELAHERE | 23 | <i>entecavir</i> | 81 | <i>etravirine</i> | 76 |
| ELEPSIA XR | 41 | ENTRESTO SPRINKLE | 88 | EUCRISA | 120 |
| ELIGARD | 24 | <i>enulose</i> | 179 | EULEXIN | 25 |
| ELIGARD (3 MONTH) | 24 | EPCLUSA | 80, 81 | <i>everolimus (antineoplastic)</i> | 25 |
| ELIGARD (4 MONTH) | 24 | EPIDIOLEX | 41 | <i>everolimus (immunosuppressive)</i> | 192 |
| ELIGARD (6 MONTH) | 24 | <i>epinastine</i> | 173 | EVOTAZ | 76 |
| <i>elinet</i> | 108 | <i>epinephrine</i> | 94 | EVRYSDI | 207 |
| ELIQUIS | 82 | <i>epitol</i> | 41 | <i>exemestane</i> | 25 |
| ELIQUIS DVT-PE TREAT 30D START | 82 | EPIVIR HBV | 76 | EXTENCILLINE | 17 |
| ELMIRON | 207 | EPKINLY | 24 | EYSUVIS | 176 |
| ELREXFIO | 24 | <i>eplerenone</i> | 99 | EZALLOR SPRINKLE | 97 |
| <i>eltrombopag olamine</i> | 84 | EPRONTIA | 41 | <i>ezetimibe</i> | 97 |
| <i>eluryng</i> | 108 | ERBITUX | 24 | <i>ezetimibe-simvastatin</i> | 97 |
| EMBRACE PEN NEEDLE | 140, 141 | <i>ergoloid</i> | 46 | FAKZYNJA | 25 |
| EMCYT | 24 | ERIVEDGE | 24 | <i>falmina (28)</i> | 108 |
| EMEND | 63 | ERLEADA | 24 | <i>famciclovir</i> | 81 |
| EMGALITY PEN | 61 | <i>erlotinib</i> | 24 | <i>famotidine</i> | 178 |
| EMGALITY SYRINGE | 61 | <i>errin</i> | 108 | FANAPT | 69 |
| <i>emoquette</i> | 108 | <i>ertapenem</i> | 15 | FANAPT TITRATION PACK A | 69 |
| EMRELIS | 24 | <i>ery pads</i> | 118 | FANAPT TITRATION PACK B | 69 |
| EMSAM | 48 | <i>erythromycin</i> | 15, 174 | FANAPT TITRATION PACK C | 69 |
| <i>emtricitabine</i> | 76 | <i>erythromycin ethylsuccinate</i> | 15 | FARXIGA | 51 |
| <i>emtricitabine-tenofovir (tdf)</i> | 76 | <i>erythromycin with ethanol</i> | 118 | FASENRA | 216 |
| <i>emtricitabine-rilpivirine-tenofovir (df)</i> | 76 | <i>erythromycin-benzoyl peroxide</i> | 119 | FASENRA PEN | 215 |
| EMTRIVA | 76 | ERZOFRI | 69 | <i>febuxostat</i> | 59 |
| <i>emzahh</i> | 108 | <i>escitalopram oxalate</i> | 48 | <i>feirza</i> | 108 |
| <i>enalapril maleate</i> | 89 | <i>eslicarbazepine</i> | 41, 42 | <i>felbamate</i> | 42 |
| <i>enalapril-hydrochlorothiazide</i> | 89 | <i>esomeprazole magnesium</i> | 178 | <i>felodipine</i> | 95 |
| ENBREL | 192 | <i>estarrylla</i> | 108 | FEMRING | 185 |
| ENBREL MINI | 192 | <i>estazolam</i> | 10 | <i>femynor</i> | 108 |
| ENBREL SURECLICK | 192 | <i>estradiol</i> | 184, 185 | <i>fenofibrate</i> | 98 |
| <i>endocet</i> | 4 | <i>estradiol valerate</i> | 185 | | |
| ENGERIX-B (PF) | 199 | <i>estradiol-norethindrone acet</i> | 185 | | |
| | | <i>eszopiclone</i> | 218 | | |

| | | | | | |
|---------------------------------------|---------|---------------------------------------|---------------|--------------------------------------|--------------|
| <i>fenofibrate micronized</i> | 97 | <i>flutamide</i> | 25 | <i>generlac</i> | 179 |
| <i>fenofibrate nanocrystallized</i> | 98 | <i>fluticasone propionate</i> | 121, 177, 213 | <i>gengraf</i> | 193 |
| <i>fenofibric acid (choline)</i> | 98 | <i>fluticasone propion-salmeterol</i> | 213 | <i>gentak</i> | 174 |
| <i>fenoprofen</i> | 7 | <i>fluvastatin</i> | 98 | <i>gentamicin</i> | 11, 119, 174 |
| <i>fentanyl</i> | 4 | <i>fluvoxamine</i> | 49 | <i>gentamicin sulfate (ped) (pf)</i> | 11 |
| <i>fentanyl citrate</i> | 4 | <i>folivane-ob</i> | 219 | <i>gentamicin sulfate (pf)</i> | 11 |
| FERRIPROX | 183 | <i>fondaparinux</i> | 82, 83 | GENVOYA | 76 |
| <i>fesoterodine</i> | 182 | <i>fosamprenavir</i> | 76 | GILOTrif | 26 |
| FETZIMA | 48, 49 | <i>fosinopril</i> | 89 | <i>glatiramer</i> | 102 |
| FIASP FLEXTOUCH U-100 | | <i>fosinopril-hydrochlorothiazide</i> | 89 | <i>glatopa</i> | 102 |
| INSULIN | 54 | <i>fosphenytoin</i> | 42 | GLEOSTINE | 26 |
| FIASP PENFILL U-100 | | <i>FOTIVDA</i> | 25 | <i>glimepiride</i> | 56 |
| INSULIN | 54 | FREESTYLE PRECISION | 141 | <i>glipizide</i> | 56 |
| FIASP U-100 INSULIN | 54 | FRUZAQLA | 25 | <i>glipizide-metformin</i> | 56 |
| <i>fidaxomicin</i> | 15 | <i>fulvestrant</i> | 25 | <i>glutamine (sickle cell)</i> | 207 |
| <i>finasteride</i> | 183 | <i>furosemide</i> | 96 | <i>glyburide</i> | 57 |
| <i> fingolimod</i> | 102 | FUZEON | 76 | <i>glyburide micronized</i> | 56 |
| FINTEPLA | 42 | FYARRO | 26 | <i>glyburide-metformin</i> | 57 |
| <i>fioricet</i> | 4 | <i>fyavolv</i> | 185 | <i>glycopyrrolate</i> | 179 |
| FIRMAGON KIT W | | FYCOMPRA | 42 | <i>glydo</i> | 8 |
| DILUENT SYRINGE | 25 | FYLNETRA | 84 | GLYXAMBI | 51 |
| <i>flavoxate</i> | 182 | <i> gabapentin</i> | 42 | GOMEKLI | 26 |
| <i>flecainide</i> | 90 | GALAFOLD | 172 | <i>granisetron hcl</i> | 63 |
| <i> floxuridine</i> | 25 | <i> galantamine</i> | 46 | <i>griseofulvin microsize</i> | 58 |
| <i> fluconazole</i> | 57, 58 | <i> gallifrey</i> | 189 | <i>griseofulvin ultramicrosize</i> | 58 |
| <i> fluconazole in nacl (iso-osm)</i> | 57 | GAMMAGARD S-D (IGA < 1 | | <i>guanfacine</i> | 87, 102 |
| <i> flucytosine</i> | 58 | MCG/ML) | 193 | GVOKE | 207 |
| <i> fludrocortisone</i> | 186 | GAMMAPLEX | 193 | GVOKE HYPOPEN 2-PACK | 207 |
| <i> flunisolide</i> | 176 | GAMUNEX-C | 193 | GVOKE PFS 1-PACK | |
| <i> fluocinolone</i> | 121 | GARDASIL 9 (PF) | 199 | SYRINGE | 207 |
| <i> fluocinolone acetonide oil</i> | 176 | <i> gatifloxacin</i> | 174 | HAEGARDA | 84 |
| <i> fluocinonide</i> | 121 | GATTEX 30-VIAL | 179 | <i>hailey 24 fe</i> | 109 |
| <i> fluocinonide-emollient</i> | 121 | GAUZE PAD | 141 | <i>hailey fe 1.5/30 (28)</i> | 109 |
| <i> fluoride (sodium)</i> | 117 | <i> gavilyte-c</i> | 181 | <i>hailey fe 1/20 (28)</i> | 109 |
| <i> fluorometholone</i> | 176 | <i> gavilyte-g</i> | 181 | <i>halobetasol propionate</i> | 121 |
| <i> fluorouracil</i> | 25, 117 | <i> gavilyte-n</i> | 181 | <i>haloette</i> | 109 |
| <i> fluoxetine</i> | 49 | GAVRETO | 26 | <i>haloperidol</i> | 70 |
| <i> fluphenazine decanoate</i> | 69 | <i> gefitinib</i> | 26 | <i>haloperidol decanoate</i> | 70 |
| <i> fluphenazine hcl</i> | 69, 70 | <i> gemcitabine</i> | 26 | <i>haloperidol lactate</i> | 70 |
| <i> flurazepam</i> | 10 | <i> gemfibrozil</i> | 98 | HARVONI | 81 |
| <i> flurbiprofen</i> | 7 | <i> gemmily</i> | 108 | HAVRIX (PF) | 199 |
| <i> flurbiprofen sodium</i> | 176 | | | | |

| | | | | | |
|-----------------------------------|---------------|-----------------------------|--------|---------------------------------------|----------|
| HEALTHWISE INSULIN SYRINGE | 142 | <i>hydromorphone</i> | 4 | INFLECTRA | 194 |
| HEALTHWISE PEN NEEDLE | 142 | <i>hydromorphone (pf)</i> | 4 | <i>infliximab</i> | 194 |
| HEALTHY ACCENTS UNIFINE PENTIP | 143 | <i>hydroxychloroquine</i> | 64 | INGREZZA | 102 |
| <i>heather</i> | 109 | <i>hydroxyurea</i> | 26 | INGREZZA INITIATION | |
| HEMADY | 186 | <i>hydroxyzine hcl</i> | 60 | PK(TARDIV) | 102 |
| <i>heparin (porcine)</i> | 83 | <i>hydroxyzine pamoate</i> | 207 | INGREZZA SPRINKLE | 103 |
| HEPLISAV-B (PF) | 199 | <i>ibandronate</i> | 205 | INLYTA | 27 |
| HERCEPTIN HYLECTA | 26 | IBRANCE | 26, 27 | INPEN (FOR HUMALOG) | |
| HERNEXEOS | 26 | IBTROZI | 27 | BLUE | 143 |
| HERZUMA | 26 | <i>ibu</i> | 7 | INPEN (NOVOLOG OR | |
| HETLIOZ LQ | 218 | <i>ibuprofen</i> | 7 | FIASP) BLUE | 143 |
| HIBERIX (PF) | 199 | <i>ibuprofen-famotidine</i> | 7 | INQOVI | 27 |
| HUMIRA | 193 | <i>icatibant</i> | 94 | INREBIC | 28 |
| HUMIRA PEN | 193 | <i>iclevia</i> | 109 | <i>insulin asp prt-insulin aspart</i> | 54 |
| HUMIRA PEN CROHNS-UC-HS START | 193 | ICLUSIG | 27 | <i>insulin aspart u-100</i> | 54 |
| HUMIRA PEN PSOR-UVEITS-ADOL HS | 193 | <i>icosapent ethyl</i> | 98 | <i>insulin glargine-yfgn</i> | 54 |
| HUMIRA(CF) | 194 | IDHIFA | 27 | INSULIN SYR/NDL U100 | |
| HUMIRA(CF) PEDICROHNS-STARTER | 193 | <i>ifosfamide</i> | 27 | HALF MARK | 143 |
| HUMIRA(CF) PEN | 194 | ILARIS (PF) | 194 | INSULIN SYRINGE | 126 |
| HUMIRA(CF) PEN CROHNS-UC-HS | 193 | ILEVRO | 177 | INSULIN SYRINGE | |
| HUMIRA(CF) PEN | 193 | ILUMYA | 194 | MICROFINE | 126 |
| PEDIATRIC UC | 193 | <i>imatinib</i> | 27 | INSULIN SYRINGE | |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS | 193 | IMBRUVICA | 27 | NEEDLELESS | 144 |
| HUMULIN R U-500 (CONC) | | IMDELLTRA | 27 | INSULIN SYRINGE-NEEDLE | |
| INSULIN | 54 | <i>imipenem-cilastatin</i> | 16 | U-100 | |
| HUMULIN R U-500 (CONC) | | <i>imipramine hcl</i> | 49 | 141, 143, 144, 149, 151, 153, 158, | |
| KWIKPEN | 54 | <i>imipramine pamoate</i> | 49 | 162, 163 | |
| <i>hydralazine</i> | 94 | <i>imiquimod</i> | 117 | INSULIN U-500 SYRINGE- | |
| <i>hydrochlorothiazide</i> | 96 | IMJUDO | 27 | NEEDLE | 145 |
| <i>hydrocodone-acetaminophen</i> | 4 | IMKELDI | 27 | INSUPEN PEN NEEDLE | 145 |
| <i>hydrocodone-ibuprofen</i> | 4 | IMOVAX RABIES VACCINE | | INTELENCE | 76 |
| <i>hydrocortisone</i> | 121, 186, 204 | (PF) | 199 | INTRON A | 81 |
| <i>hydrocortisone butyrate</i> | 121 | IMPAVIDO | 64 | <i>introvale</i> | 109 |
| <i>hydrocortisone valerate</i> | 122 | INBRIJA | 66 | INVEGA HAFYERA | 70 |
| <i>hydrocortisone-acetic acid</i> | 174 | <i>incassia</i> | 109 | INVEGA SUSTENNA | 70, 71 |
| | | INCONTROL ALCOHOL | | INVEGA TRINZA | 71 |
| | | PADS | 143 | INVELTYS | 177 |
| | | INCONTROL PEN NEEDLE | 143 | IPOL | 200 |
| | | INCRELEX | 188 | <i>ipratropium bromide</i> | 173, 214 |
| | | <i>indapamide</i> | 96 | <i>ipratropium-albuterol</i> | 214 |
| | | <i>indomethacin</i> | 7 | IQIRVO | 179 |
| | | INFANRIX (DTAP) (PF) | 200 | <i>irbesartan</i> | 88 |

| | | | | | |
|---------------------------------------|--------|---------------------------------------|--------|---------------------------------------|--------|
| <i>irbesartan-hydrochlorothiazide</i> | 88 | <i>junel fe 1.5/30 (28)</i> | 109 | <i>lamivudine</i> | 77 |
| <i>irinotecan</i> | 28 | <i>junel fe 1/20 (28)</i> | 110 | <i>lamivudine-zidovudine</i> | 77 |
| ISENTRESS | 76, 77 | <i>junel fe 24</i> | 110 | <i>lamotrigine</i> | 42, 43 |
| ISENTRESS HD | 76 | JUXTAPID | 98 | <i>lanreotide</i> | 188 |
| <i>isibloom</i> | 109 | JYLMAMVO | 28 | <i>lansoprazole</i> | 178 |
| ISOLYTE S PH 7.4 | 210 | JYNNEOS (PF) | 200 | <i>lanthanum</i> | 181 |
| ISOLYTE-P IN 5 % | | KALETRA | 77 | LANTUS SOLOSTAR U-100 | |
| DEXTROSE | 210 | KALYDECO | 216 | INSULIN | 55 |
| ISOLYTE-S | 210 | KANJINTI | 28 | LANTUS U-100 INSULIN | 55 |
| <i>isoniazid</i> | 62 | <i>kariva (28)</i> | 110 | <i>lapatinib</i> | 29 |
| ISOPROPYL ALCOHOL | 118 | KATERZIA | 95 | <i>larin 1.5/30 (21)</i> | 110 |
| <i>isosorbide dinitrate</i> | 99 | <i>kelnor 1/35 (28)</i> | 110 | <i>larin 1/20 (21)</i> | 110 |
| <i>isosorbide mononitrate</i> | 99 | <i>kelnor 1/50 (28)</i> | 110 | <i>larin 24 fe</i> | 110 |
| <i>isosorbide-hydralazine</i> | 100 | KERENDIA | 99 | <i>larin fe 1.5/30 (28)</i> | 110 |
| <i>isradipine</i> | 95 | KESIMPTA PEN | 103 | <i>larin fe 1/20 (28)</i> | 110 |
| ITOVEBI | 28 | <i>ketoconazole</i> | 58 | <i>larissia</i> | 110 |
| <i>itraconazole</i> | 58 | <i>ketoprofen</i> | 7 | <i>latanoprost</i> | 209 |
| IV PREP WIPES | 145 | <i>ketorolac</i> | 7, 177 | LAZCLUZE | 29 |
| <i>ivabradine</i> | 94 | KEYTRUDA | 28 | <i>leflunomide</i> | 194 |
| <i>ivermectin</i> | 64 | KIMMTRAK | 28 | <i>lenalidomide</i> | 29 |
| IWILFIN | 28 | KINERET | 194 | LETOCILIN S | 17 |
| IXIARO (PF) | 200 | KINRIX (PF) | 200 | LENVIMA | 29 |
| <i>jaimiess</i> | 109 | <i>kionex (with sorbitol)</i> | 179 | <i>lessina</i> | 111 |
| JAKAFI | 28 | KISQALI | 29 | <i>letrozole</i> | 29 |
| <i>jantoven</i> | 83 | KISQALI FEMARA CO- | | <i>leucovorin calcium</i> | 207 |
| JANUMET | 51 | PACK | 28, 29 | LEUKERAN | 29 |
| JANUMET XR | 51 | KLISYRI (250 MG) | 118 | LEUKINE | 84 |
| JANUVIA | 51 | <i>klor-con m10</i> | 210 | <i>leuprolide</i> | 29 |
| JARDIANCE | 51 | <i>klor-con m15</i> | 211 | <i>leuprolide (3 month)</i> | 29 |
| <i>jasmiel (28)</i> | 109 | <i>klor-con m20</i> | 211 | <i>levetiracetam</i> | 43 |
| <i>javygtor</i> | 172 | KLOXXADO | 9 | <i>levobunolol</i> | 209 |
| JAYPIRCA | 28 | KOSELUGO | 29 | <i>levocarnitine</i> | 207 |
| JEMPERLI | 28 | <i>kosher prenatal plus iron</i> | 219 | <i>levocarnitine (with sugar)</i> | 207 |
| <i>jencycla</i> | 109 | KRAZATI | 29 | <i>levocetirizine</i> | 60 |
| JENTADUETO | 51 | <i>kurvelo (28)</i> | 110 | <i>levofloxacin</i> | 18 |
| JENTADUETO XR | 51 | KYLEENA | 110 | <i>levofloxacin in d5w</i> | 18 |
| <i>jinteli</i> | 185 | KYNMOBI | 66 | <i>levonest (28)</i> | 111 |
| <i>jolessa</i> | 109 | <i>l norgest/e.estradiol-e.estrad</i> | 110 | <i>levonorgest-eth.estradiol-iron</i> | 111 |
| <i>juleber</i> | 109 | <i>labetalol</i> | 91 | <i>levonorgestrel-ethinyl estrad</i> | 111 |
| JULUCA | 77 | <i>lacosamide</i> | 42 | <i>levonorg-eth estrad triphasic</i> | 111 |
| <i>junel 1.5/30 (21)</i> | 109 | <i>lactulose</i> | 179 | <i>levora-28</i> | 111 |
| <i>junel 1/20 (21)</i> | 109 | <i>lagevrio (eua)</i> | 81 | <i>levothyroxine</i> | 190 |

| | | | | |
|---------------------------------------|----------|--------------------------|----------|----------------------------------|
| LEXIVA | 77 | <i>lubiprostone</i> | 180 | MAVENCLAD (6 TABLET |
| LIBERVANT | 43 | LUMAKRAS | 30 | PACK).....103 |
| <i>lidocaine</i> | 8 | LUMIGAN | 209 | MAVENCLAD (7 TABLET |
| <i>lidocaine hcl</i> | 8 | LUNSUMIO | 30 | PACK).....103 |
| <i>lidocaine viscous</i> | 8 | LUPRON DEPOT | 30, 188 | MAVENCLAD (8 TABLET |
| <i>lidocaine-prilocaine</i> | 8 | LUPRON DEPOT (3 MONTH) | 30, 188 | PACK).....103 |
| <i>lidocan iii</i> | 8 | LUPRON DEPOT (4 MONTH) | 30 | MAVENCLAD (9 TABLET |
| LILETTA | 111 | LUPRON DEPOT (6 MONTH) | 30 | PACK).....103 |
| <i>llow (28)</i> | 111 | LUPRON DEPOT-PED | 188 | MAVYRET |
| <i>linezolid</i> | 12 | LUPRON DEPOT-PED (3 | | MAXICOMFORT II PEN |
| <i>linezolid in dextrose 5%</i> | 12 | MONTH) | 188 | NEEDLE.....147 |
| LINZESS | 179 | <i>lurasidone</i> | 71 | MAXICOMFORT INSULIN |
| <i>liothyronine</i> | 190 | <i>lutera (28)</i> | 111 | SYRINGE.....147 |
| LISCO | 145 | LUTRATE DEPOT (3 | | MAXI-COMFORT INSULIN |
| <i>lisinopril</i> | 90 | MONTH) | 188 | SYRINGE.....147 |
| <i>lisinopril-hydrochlorothiazide</i> | 90 | LYBALVI | 71 | MAXICOMFORT SAFETY |
| LITE TOUCH INSULIN PEN | | <i>lyeq</i> | 111 | PEN NEEDLE.....147 |
| NEEDLES | 145, 146 | <i>lyllana</i> | 185 | MAYZENT |
| LITE TOUCH INSULIN | | LYNOZYFIC | 30 | 103 |
| SYRINGE | 145, 146 | LYNPARZA | 31 | MAYZENT STARTER(FOR |
| <i>lithium carbonate</i> | 103 | LYSODREN | 31 | 1MG MAINT).....103 |
| <i>lithium citrate</i> | 103 | LYTGOBI | 31 | MAYZENT STARTER(FOR |
| LIVDELZI | 179 | <i>lyza</i> | 111 | 2MG MAINT).....104 |
| LIVTENCITY | 80 | MAGELLAN INSULIN | | <i>meclizine</i> |
| LOKELMA | 179 | SAFETY SYRNG | 147 | 63 |
| LONSURF | 30 | MAGELLAN SYRINGE. | 146, 147 | <i>medroxyprogesterone</i> |
| <i>loperamide</i> | 180 | <i>magnesium sulfate</i> | 211 | 189 |
| <i>lopinavir-ritonavir</i> | 77 | <i>malathion</i> | 123 | <i>mefenamic acid</i> |
| LOQTORZI | 30 | <i>maraviroc</i> | 77 | 7 |
| <i>lorazepam</i> | 10 | MARGENZA | 31 | <i>mefloquine</i> |
| <i>lorazepam intensol</i> | 10 | <i>marlissa (28)</i> | 112 | 64 |
| LORBRENA | 30 | <i>marnatal-f</i> | 219 | <i>megestrol</i> |
| <i>loryna (28)</i> | 111 | MARPLAN | 49 | 31, 189 |
| <i>losartan</i> | 88 | MATULANE | 31 | MEKINIST |
| <i>losartan-hydrochlorothiazide</i> | 88 | <i>matzim la</i> | 93 | 31 |
| LOTEMAX | 177 | MAVENCLAD (10 TABLET | | MEKTOVI |
| LOTEMAX SM | 177 | PACK) | 103 | <i>meleya</i> |
| <i>loteprednol etabonate</i> | 177 | MAVENCLAD (4 TABLET | | 112 |
| <i>lovastatin</i> | 98 | PACK) | 103 | <i>meloxicam</i> |
| <i>low-ogestrel (28)</i> | 111 | MAVENCLAD (5 TABLET | | 7 |
| <i>loxapine succinate</i> | 71 | PACK) | 103 | <i>memantine</i> |
| <i>lo-zumandimine (28)</i> | 111 | | | 46, 47 |
| | | | | <i>memantine-donepezil</i> |
| | | | | 47 |
| | | | | MENACTRA (PF).....200 |
| | | | | MENQUADFI (PF).....200 |
| | | | | MENVEO A-C-Y-W-135-DIP |
| | | | | (PF).....200 |
| | | | | <i>mercaptopurine</i> |
| | | | | 31 |
| | | | | <i>meropenem</i> |
| | | | | 16 |
| | | | | <i>merzee</i> |
| | | | | 112 |
| | | | | <i>mesalamine</i> |
| | | | | 204 |
| | | | | <i>mesna</i> |
| | | | | 207 |

| | | | | | |
|---------------------------------------|-------------|---------------------------------------|----------|--------------------------------------|-----|
| <i>metadate er</i> | 104 | MINI ULTRA-THIN II | 148 | <i>mynatal plus</i> | 220 |
| <i>metformin</i> | 51, 52 | <i>minitran</i> | 100 | <i>mynatal-z</i> | 220 |
| <i>methadone</i> | 4, 5 | <i>minocycline</i> | 19 | <i>mynate 90 plus</i> | 220 |
| <i>methazolamide</i> | 209 | <i>minoxidil</i> | 100 | MYRBETRIQ | 182 |
| <i>methenamine hippurate</i> | 12 | MIPLYFFA | 171 | <i>nabumetone</i> | 7 |
| <i>methimazole</i> | 190 | MIRENA | 112 | <i>nadolol</i> | 92 |
| <i>methocarbamol</i> | 217 | <i>mirtazapine</i> | 49 | <i>nafcillin</i> | 17 |
| <i>methotrexate sodium</i> | 31 | <i>misoprostol</i> | 178 | <i>naloxone</i> | 9 |
| <i>methotrexate sodium (pf)</i> | 31 | <i>mitoxantrone</i> | 31 | <i>naltrexone</i> | 9 |
| <i>methoxsalen</i> | 118 | M-M-R II (PF) | 200 | NAMZARIC | 47 |
| <i>methscopolamine</i> | 180 | <i>m-natal plus</i> | 220 | NANO 2ND GEN PEN NEEDLE | 149 |
| <i>methsuximide</i> | 43 | <i>modafinil</i> | 218 | NANO PEN NEEDLE | 149 |
| <i>methylphenidate hcl</i> | 104, 105 | MODEYSO | 31 | <i>naproxen</i> | 7 |
| <i>methylprednisolone</i> | 186 | <i>moexipril</i> | 90 | <i>naratriptan</i> | 61 |
| <i>methylprednisolone acetate</i> | 186 | <i>molindone</i> | 71 | NATACYN | 174 |
| <i>metoclopramide hcl</i> | 180 | <i>mometasone</i> | 122, 177 | <i>nateglinide</i> | 52 |
| <i>metolazone</i> | 96 | MONOJECT INSULIN SAFETY SYRING | 149 | NATPARA | 205 |
| <i>metoprolol succinate</i> | 91 | MONOJECT INSULIN SYRINGE | 148, 149 | NAYZILAM | 43 |
| <i>metoprolol ta-hydrochlorothiaz</i> | 91 | MONOJECT ULTRA COMFORT INSULIN | 148, 149 | <i>nebivolol</i> | 92 |
| <i>metoprolol tartrate</i> | 92 | <i>mono-linyah</i> | 112 | <i>nefazodone</i> | 49 |
| <i>metronidazole</i> | 12, 60, 119 | <i>montelukast</i> | 213 | <i>neomycin</i> | 11 |
| <i>metronidazole in nacl (iso-os)</i> | 12 | <i>morphine</i> | 5 | <i>neomycin-bacitracin-poly-hc</i> | 174 |
| <i>metyrosine</i> | 94 | MORPHINE | 5 | <i>neomycin-bacitracin-polymyxin</i> | 174 |
| <i>mexiletine</i> | 90 | <i>morphine concentrate</i> | 5 | <i>neomycin-polymyxin b-dexameth</i> | 174 |
| <i>micafungin</i> | 58 | MOUNJARO | 52 | <i>neomycin-polymyxin-gramicidin</i> | 174 |
| <i>miconazole-3</i> | 58 | MOVANTIK | 180 | <i>neomycin-polymyxin-hc</i> | 175 |
| MICRODOT INSULIN PEN NEEDLE | 147 | <i>moxifloxacin</i> | 18, 174 | <i>neo-polycin</i> | 175 |
| MICRODOT READYGARD PEN NEEDLE | 147 | <i>moxifloxacin-sod.ace,sul-water</i> | 18 | <i>neo-polycin hc</i> | 175 |
| <i>microgestin 1.5/30 (21)</i> | 112 | <i>moxifloxacin-sod.chloride(iso)</i> | 18 | NERLYNX | 32 |
| <i>microgestin 1/20 (21)</i> | 112 | MRESVIA (PF) | 200 | <i>neuac</i> | 119 |
| <i>microgestin 24 fe</i> | 112 | MULTAQ | 90 | NEULASTA ONPRO | 84 |
| <i>microgestin fe 1.5/30 (28)</i> | 112 | <i>mupirocin</i> | 119 | NEUPRO | 66 |
| <i>microgestin fe 1/20 (28)</i> | 112 | MVASI | 32 | <i>nevirapine</i> | 77 |
| <i>midodrine</i> | 88 | <i>mycophenolate mofetil</i> | 194 | <i>newgen</i> | 220 |
| MIEBO (PF) | 173 | <i>mycophenolate mofetil (hcl)</i> | 194 | NEXLETOL | 98 |
| <i>mifepristone</i> | 52 | <i>mycophenolate sodium</i> | 194 | NEXLIZET | 98 |
| <i>miglitol</i> | 52 | <i>mynatal</i> | 220 | NEXPLANON | 112 |
| <i>miglustat</i> | 172 | <i>mynatal advance</i> | 220 | <i>niacin</i> | 98 |
| <i>mihi</i> | 112 | | | <i>niacor</i> | 98 |
| <i>mimvey</i> | 185 | | | | |

| | | | |
|--|----------|---------------------------------------|---------------------------|
| <i>nicardipine</i> | 95 | NOVOLIN R REGULAR U100 | OMNIPOD 5 (G6/LIBRE 2 |
| NICOTROL | 9 | INSULIN | PLUS)..... |
| NICOTROL NS | 9 | NOVOTWIST | 150 |
| <i>nifedipine</i> | 95 | NOXAFILE | OMNIPOD 5 G6-G7 INTRO |
| <i>nikki (28)</i> | 112 | NUBEQA | KT(GEN5)..... |
| NIKTIMVO | 194 | NUCALA | 150 |
| <i>nilutamide</i> | 32 | NULOJIX | OMNIPOD 5 G6-G7 PODS |
| NINLARO | 32 | NUPLAZID | (GEN 5)..... |
| <i>nitazoxanide</i> | 65 | NURTEC ODT | 150 |
| <i>nitisinone</i> | 172 | <i>nyamyc</i> | OMNIPOD 5 |
| <i>nitrofurantoin macrocrystal</i> | 12 | <i>nylia 1/35 (28)</i> | INTRO(G6/LIBRE2PLUS)..... |
| <i>nitrofurantoin monohyd/m-cryst.</i> | 12 | <i>nylia 7/7/7 (28)</i> | 150 |
| <i>nitroglycerin</i> | 100, 207 | <i>nymyo</i> | OMNIPOD CLASSIC PDM |
| <i>niva-plus</i> | 220 | <i>nystatin</i> | KIT(GEN 3)..... |
| NIVESTYM | 84 | <i>nystatin-triamcinolone</i> | 150 |
| <i>nizatidine</i> | 178 | <i>nystop</i> | OMNIPOD CLASSIC PODS |
| NORDITROPIN FLEXPRO | 188 | NYVEPRIA | (GEN 3)..... |
| <i>norelgestromin-ethin.estradiol.</i> | 112 | <i>obstetrix dha</i> | 150 |
| <i>norethindrone (contraceptive)</i> | 112 | <i>obstetrix dha prenatal duo</i> | OMNIPOD DASH INTRO KIT |
| <i>norethindrone acetate</i> | 189 | <i>o-cal prenatal</i> | (GEN 4)..... |
| <i>norethindrone ac-eth estradiol</i> | | OCALIVA | 150 |
| | 112, 185 | OCREVUS | OMNIPOD DASH PODS |
| <i>norethindrone-e.estradiol-iron.</i> | 113 | OCREVUS ZUNOVO | (GEN 4)..... |
| <i>norgestimate-ethinyl estradiol</i> | 113 | <i>octreotide acetate</i> | 150 |
| <i>norlyda</i> | 113 | ODEFSEY | ONAPGO..... |
| <i>nortrel 1/35 (21)</i> | 113 | ODOMZO | 66 |
| <i>nortrel 1/35 (28)</i> | 113 | OFEV | ondansetron |
| <i>nortrel 7/7/7 (28)</i> | 113 | <i>ofloxacin</i> | 63 |
| <i>nortriptyline</i> | 49 | OGIVRI | ONGENTYS..... |
| NORVIR | 77, 78 | OGSIVEO | ONTRUZANT..... |
| NOVOFINE 30 | 149 | OJEMDA | ONUREG..... |
| NOVOFINE 32 | 149 | OJJAARA | OPDIVO..... |
| NOVOFINE PLUS | 149 | <i>olanzapine</i> | OPDIVO QVANTIG..... |
| NOVOLIN 70/30 U-100 | | <i>olmesartan</i> | OPDUALAG..... |
| INSULIN | 55 | <i>olmesartanamlodipin-hctiazid</i> | OPIPZA..... |
| NOVOLIN 70-30 FLEXPEN | | <i>olmesartan-hydrochlorothiazide</i> | OPSUMIT..... |
| U-100 | 55 | <i>olopatadine</i> | ORENCIA..... |
| NOVOLIN N FLEXPEN | 55 | <i>omega-3 acid ethyl esters</i> | ORENCIA (WITH MALTOSE) |
| NOVOLIN N NPH U-100 | | <i>omeprazole</i> | 195 |
| INSULIN | 55 | <i>omeprazole-sodium bicarbonate</i> | ORENCIA CLICKJECT..... |
| NOVOLIN R FLEXPEN | 55 | | 172 |
| | | | ORFADIN..... |
| | | | ORGOVYXX..... |
| | | | ORILISSA..... |
| | | | ORKAMBI..... |
| | | | orquidea..... |
| | | | ORSERDU..... |
| | | | oseltamivir..... |
| | | | OSENVELT..... |
| | | | OSMOLEX ER..... |

| | | | | | |
|------------------------------------|----------|-----------------------------------|----------|---------------------------------------|----------|
| OTEZLA | 195 | <i>penicillamine</i> | 183 | <i>pitavastatin calcium</i> | 98 |
| OTEZLA STARTER | 195 | <i>penicillin g potassium</i> | 17 | <i>PLASMA-LYTE A</i> | 211 |
| <i>oxaliplatin</i> | 33 | <i>penicillin g procaine</i> | 17 | <i>PLEGRIDY</i> | 105 |
| <i>oxandrolone</i> | 183 | <i>penicillin v potassium</i> | 17 | <i>pnv 29-1</i> | 220 |
| <i>oxazepam</i> | 11 | PENMENVY MEN A-B-C-W- | | <i>pnv-dha + docusate</i> | 220 |
| <i>oxcarbazepine</i> | 43 | Y (PF) | 201 | <i>pnv-omega</i> | 220 |
| <i>oxybutynin chloride</i> | 182 | PENMENVY MENACWY | | <i>podofilox</i> | 118 |
| <i>oxycodone</i> | 5 | COMPONENT(PF) | 201 | <i>polycin</i> | 175 |
| <i>oxycodone-acetaminophen</i> | 5 | PENMENVY MENB | | <i>polymyxin b sulfate</i> | 12 |
| <i>oxymorphone</i> | 5 | COMPONENT (PF) | 201 | <i>polymyxin b sulf-trimethoprim</i> | 175 |
| OZEMPIC | 52 | PENTACEL (PF) | 201 | <i>POMALYST</i> | 34 |
| <i>pacerone</i> | 91 | <i>pentamidine</i> | 65 | <i>portia 28</i> | 114 |
| <i>paclitaxel</i> | 33 | PENTIPS PEN NEEDLE | 151 | <i>posaconazole</i> | 59 |
| <i>paclitaxel protein-bound</i> | 33 | <i>pentoxifylline</i> | 85 | <i>potassium chloride</i> | 211 |
| <i>paliperidone</i> | 72 | <i>perampanel</i> | 43 | <i>potassium chloride-0.45 % nacl</i> | |
| PALYNZIQ | 172 | <i>perindopril erbumine</i> | 90 | <i>potassium citrate</i> | 211, 212 |
| PANRETIN | 118 | <i>periogard</i> | 117 | <i>pr natal 400</i> | 220 |
| <i>pantoprazole</i> | 178 | <i>permethrin</i> | 123 | <i>pr natal 400 ec</i> | 220 |
| <i>paricalcitol</i> | 205 | <i>perphenazine</i> | 72 | <i>pr natal 430</i> | 220 |
| <i>paromomycin</i> | 65 | <i>perphenazine-amitriptyline</i> | 49 | <i>pr natal 430 ec</i> | 220 |
| <i>paroxetine hcl</i> | 49 | PERSERIS | 72 | <i>pramipexole</i> | 66 |
| PAXLOVID | 80 | <i>phenelzine</i> | 50 | <i>prasugrel hcl</i> | 85 |
| <i>pazopanib</i> | 33 | <i>phenobarbital</i> | 44 | <i>pravastatin</i> | 98 |
| PEDIARIX (PF) | 200 | PHENYTEK | 44 | <i>praziquantel</i> | 65 |
| PEDVAX HIB (PF) | 200 | <i>phenytoin</i> | 44 | <i>prazosin</i> | 88 |
| <i>peg 3350-electrolytes</i> | 181 | <i>phenytoin sodium</i> | 44 | <i>prednisolone</i> | 186 |
| PEGASYS | 81 | <i>phenytoin sodium extended</i> | 44 | <i>prednisolone acetate</i> | 177 |
| <i>peg-electrolyte soln</i> | 181 | <i>philith</i> | 113 | <i>prednisolone sodium phosphate</i> | |
| PEMAZYRE | 33 | PIFELTRO | 78 | <i>177, 186</i> | |
| <i>pemetrexed disodium</i> | 33 | <i>pilocarpine hcl</i> | 117, 209 | <i>prednisone</i> | 187 |
| PEMRYDI RTU | 33 | <i>pimecrolimus</i> | 122 | <i>pregabalin</i> | 44 |
| PEN NEEDLE | 150, 151 | <i>pimozide</i> | 72 | PREHEVBARIO (PF) | 201 |
| PEN NEEDLE, DIABETIC | | <i>pimtrea (28)</i> | 113 | PREMARIN | 185 |
| 131, 142, 147, 148, 150, 153 | | <i>pindolol</i> | 92 | PREMPHASE | 186 |
| PEN NEEDLE, DIABETIC, | | <i>pioglitazone</i> | 52 | PREMPRO | 186 |
| SAFETY | 154 | <i>pioglitazone-metformin</i> | 52 | <i>prena1 true</i> | 220 |
| PENBRAYA (PF) | 200 | PIP PEN NEEDLE | 151 | <i>prenaissance</i> | 221 |
| PENBRAYA MENACWY | | <i>piperacillin-tazobactam</i> | 17 | <i>prenaissance plus</i> | 221 |
| COMPONENT(PF) | 201 | PIQRAY | 33 | <i>prenatabs fa</i> | 221 |
| PENBRAYA MENB | | <i>pirfenidone</i> | 216 | <i>prenatal 19</i> | 221 |
| COMPONENT (PF) | 201 | <i>pirmella</i> | 114 | <i>prenatal 19 (with docusate)</i> | 221 |
| <i>penciclovir</i> | 118 | <i>piroxicam</i> | 7, 8 | | |

| | | | | | |
|--|------------|--------------------------------------|----------|---------------------------------|--------|
| <i>prenatal low iron</i> | 221 | <i>propranolol</i> | 92 | REPATHA SURECLICK | 99 |
| <i>prenatal plus</i> | 221 | <i>propylthiouracil</i> | 190 | REPATHA SYRINGE | 99 |
| <i>prenatal plus (calcium carb)</i> | 220 | PROQUAD (PF) | 201 | RETACRIT | 84, 85 |
| <i>prenatal vitamin plus low iron.</i> | 221 | PROSOL 20 % | 87 | RETEVMO | 34 |
| <i>prenatal-u</i> | 221 | <i>protriptyline</i> | 50 | RETROVIR | 78 |
| <i>preplus</i> | 221 | PULMOZYME | 172 | REVCovi | 172 |
| <i>pretab</i> | 221 | PURE COMFORT ALCOHOL | | REVUFORJ | 34 |
| <i>prevalite</i> | 99 | PADS | 152 | REXULTI | 72 |
| PREVENT DROPSAFE PEN | | PURE COMFORT PEN | | REYATAZ | 78 |
| NEEDLE | 151 | NEEDLE | 153 | REZLIDHIA | 34 |
| <i>previfem</i> | 114 | PURE COMFORT SAFETY | | REZUROCK | 195 |
| PREVYMIS | 80 | PEN NEEDLE | 152 | RHOPRESSA | 210 |
| PREZCOBIX | 78 | <i>pyrazinamide</i> | 62 | RIABNI | 34 |
| PREZISTA | 78 | <i>pyridostigmine bromide</i> | 207, 208 | <i>ribavirin</i> | 82 |
| PRIFTIN | 62 | <i>pyrimethamine</i> | 65 | RIDAURA | 195 |
| PRIMAQUINE | 65 | QINLOCK | 34 | <i>rifabutin</i> | 62 |
| <i>primidone</i> | 44 | QUADRACEL (PF) | 202 | <i>rifampin</i> | 62 |
| PRIORIX (PF) | 201 | <i>quetiapine</i> | 72 | <i>rilpivirine</i> | 78 |
| PRO COMFORT ALCOHOL | | <i>quinapril</i> | 90 | <i>riluzole</i> | 105 |
| PADS | 152 | <i>quinapril-hydrochlorothiazide</i> | 90 | <i>rimantadine</i> | 80 |
| PRO COMFORT INSULIN | | <i>quinidine gluconate</i> | 91 | RINVOQ | 195 |
| SYRINGE | 151, 152 | <i>quinidine sulfate</i> | 91 | RINVOQ LQ | 195 |
| PRO COMFORT PEN | | <i>quinine sulfate</i> | 65 | <i>risedronate</i> | 206 |
| NEEDLE | 152 | QULIPTA | 61 | <i>risperidone</i> | 73 |
| PROAIR RESPICLICK | 214 | RABAVERT (PF) | 202 | <i>risperidone microspheres</i> | 72, 73 |
| <i>probenecid</i> | 59 | <i>rabeprazole</i> | 179 | <i>ritonavir</i> | 78 |
| <i>probenecid-colchicine</i> | 59 | RALDESY | 50 | RITUXAN HYCELA | 34 |
| PROCALAMINE 3% | 87 | <i>raloxifene</i> | 186 | <i>rivaroxaban</i> | 83 |
| <i>prochlorperazine</i> | 63 | <i>ramipril</i> | 90 | <i>rivastigmine</i> | 47 |
| <i>prochlorperazine edisylate</i> | 63, 72 | <i>ranolazine</i> | 94 | <i>rivastigmine tartrate</i> | 47 |
| <i>prochlorperazine maleate</i> | 63 | <i>rasagiline</i> | 66 | RIVFLOZA | 208 |
| <i>procto-med hc</i> | 122 | RASUVO (PF) | 195 | <i>rizatriptan</i> | 61 |
| <i>proctosol hc</i> | 122 | RAVICTI | 180 | <i>r-natal ob</i> | 221 |
| <i>proctozone-hc</i> | 122 | RAYALDEE | 206 | ROCKLATAN | 210 |
| PRODIGY INSULIN | | <i>reclipsen (28)</i> | 114 | <i>roflumilast</i> | 216 |
| SYRINGE | 152 | RECOMBIVAX HB (PF) | 202 | ROLVEDON | 85 |
| <i>progesterone micronized</i> | 189 | REGRANEX | 118 | ROMVIMZA | 34 |
| PROGRAF | 195 | RELENZA DISKHALER | 80 | <i>ropinirole</i> | 67 |
| PROLIA | 205 | RELISTOR | 180 | <i>rosadan</i> | 119 |
| <i>promethazine</i> | 60, 63, 64 | RENFLEXIS | 195 | <i>rosuvastatin</i> | 99 |
| <i>promethegan</i> | 64 | <i>repaglinide</i> | 52 | <i>rosyrah</i> | 114 |
| <i>propafenone</i> | 91 | REPATHA PUSHTRONEX | 99 | ROTARIX | 202 |

| | | | | | |
|-------------------------------|----------|---------------------------------------|--------|--------------------------------------|----------|
| ROTATEQ VACCINE | 202 | SEZABY | 44 | <i>ssd</i> | 119 |
| ROZLYTREK | 34 | <i>sf 5000 plus</i> | 117 | <i>stavudine</i> | 78 |
| RUBRACA | 35 | <i>sharobel</i> | 114 | STELARA | 196 |
| <i>rufinamide</i> | 44 | SHINGRIX (PF) | 202 | STERILE PADS | 154 |
| RUKOBIA | 78 | SIGNIFOR | 189 | STIMUFEND | 85 |
| RUXIENCE | 35 | <i>sildenafil (pulm.hypertension)</i> | 219 | STIOLTO RESPIMAT | 215 |
| RYBELSUS | 52 | <i>silver sulfadiazine</i> | 119 | STIVARGA | 35 |
| RYBREVANT | 35 | SIMBRINZA | 210 | STOBOCLO | 206 |
| RYDAPT | 35 | <i>simliya (28)</i> | 114 | STRENSIQ | 172 |
| RYKINDO | 73 | <i>simpesse</i> | 114 | <i>streptomycin</i> | 11 |
| RYTELO | 35 | SIMPLI PEN NEEDLE | 141 | STRIBILD | 78 |
| <i>sacubitril-valsartan</i> | 88 | <i>simvastatin</i> | 99 | STRIVERDI RESPIMAT | 215 |
| SAFESNAP INSULIN | | <i>sirolimus</i> | 196 | <i>subvenite</i> | 45 |
| SYRINGE | 153, 154 | SIRTURO | 62 | <i>sucralfate</i> | 179 |
| SAFETY PEN NEEDLE | 154 | SKY SAFETY PEN NEEDLE | 154 | <i>sulfacetamide sodium</i> | 175 |
| <i>sajazir</i> | 94 | SKYLA | 114 | <i>sulfacetamide sodium (acne)</i> | 119 |
| SANTYL | 118 | SKYRIZI | 196 | <i>sulfacetamide-prednisolone</i> | 175 |
| <i>sapropterin</i> | 172 | SLYND | 114 | <i>sulfadiazine</i> | 18 |
| SAVELLA | 105 | <i>sodium chloride 0.45 %</i> | 212 | <i>sulfamethoxazole-trimethoprim</i> | 18 |
| SCEMBLIX | 35 | <i>sodium chloride 0.9 %</i> | 212 | <i>sulfasalazine</i> | 205 |
| <i>scopolamine base</i> | 64 | <i>sodium fluoride-pot nitrate</i> | 117 | <i>sulindac</i> | 8 |
| SECUADO | 73 | <i>sodium oxybate</i> | 218 | <i>sumatriptan</i> | 61 |
| SECURESAFE INSULIN | | <i>sodium phenylbutyrate</i> | 180 | <i>sumatriptan succinate</i> | 61, 62 |
| SYRINGE | 154 | <i>sodium polystyrene sulfonate</i> | 180 | <i>sumatriptan-naproxen</i> | 62 |
| SECURESAFE PEN NEEDLE | 154 | <i>sodium,potassium,mag sulfates</i> | 181 | <i>sunitinib malate</i> | 35 |
| SELARSDI | 195, 196 | <i>solifenacin</i> | 182 | SUNLENCA | 79 |
| <i>select-ob</i> | 221 | SOLIQUA 100/33 | 55 | SURE COMFORT ALCOHOL | |
| <i>select-ob (folic acid)</i> | 221 | SOLTAMOX | 35 | PREP PADS | 155 |
| <i>selegiline hcl</i> | 67 | SOMATULINE DEPOT | 189 | SURE COMFORT INS. SYR. | |
| <i>selenium sulfide</i> | 119 | SOMAVERT | 189 | U-100 | 154 |
| SELZENTRY | 78 | <i>sorafenib</i> | 35 | SURE COMFORT INSULIN | |
| SEMGLEE(INSULIN | | <i>sorine</i> | 92 | SYRINGE | 155 |
| GLARGINE-YFGN) | 55 | <i>sotalol</i> | 92 | SURE COMFORT PEN | |
| SEMGLEE(INSULIN GLARG- | | <i>sotalol af</i> | 92 | NEEDLE | 155, 156 |
| YFGN)PEN | 55 | SPIRIVA RESPIMAT | 214 | SURE COMFORT SAFETY | |
| <i>se-natal 19 chewable</i> | 221 | <i>spironolactone</i> | 96, 99 | PEN NEEDLE | 154 |
| SEREVENT DISKUS | 214 | <i>spironolacton-hydrochlorothiaz</i> | 96 | SURE-FINE PEN NEEDLES | 156 |
| SEROSTIM | 189 | SPRAVATO | 50 | SURE-JECT INSULIN | |
| <i>sertraline</i> | 50 | <i>sprintec (28)</i> | 114 | SYRINGE | 156 |
| <i>setlakin</i> | 114 | SPRITAM | 44 | SURE-PREP ALCOHOL PREP | |
| <i>sevelamer carbonate</i> | 181, 182 | <i>sps (with sorbitol)</i> | 180 | PADS | 156 |
| <i>sevelamer hcl</i> | 182 | <i>sronyx</i> | 114 | SUTAB | 181 |

| | | | | |
|--------------------------------|----------|---------------------------------------|---------------------------------------|----------|
| <i>syeda</i> | 114 | TECHLITE INSULIN | TIBSOVO | 36 |
| SYMDEKO | 217 | SYRINGE | <i>ticagrelor</i> | 85 |
| SYMJEPI | 94 | TECHLITE INSULN | TICE BCG | 36 |
| SYMLINPEN 120 | 52 | SYR(HALF UNIT) | TICOVAC | 203 |
| SYMLINPEN 60 | 53 | TECHLITE PEN NEEDLE | <i>tigecycline</i> | 19 |
| SYMPAZAN | 45 | TECHLITE PLUS PEN | <i>tilia fe</i> | 115 |
| SYMTUZA | 79 | NEEDLE | <i>timolol</i> | 210 |
| SYNAREL | 189 | TECVAYLI | <i>timolol maleate</i> | 92, 210 |
| SYNERCID | 12 | TEFLARO | <i>tinidazole</i> | 65 |
| SYNJARDY | 53 | <i>telmisartan</i> | <i>tiopronin</i> | 183 |
| SYNJARDY XR | 53 | <i>telmisartan-amldipine</i> | <i>tiotropium bromide</i> | 215 |
| SYNRIBO | 35 | <i>telmisartan-hydrochlorothiazid</i> | TIVDAK | 36 |
| SYRINGE WITH NEEDLE, | | <i>temazepam</i> | TIVICAY | 79 |
| SAFETY | 154 | TEMIXYS | TIVICAY PD | 79 |
| TABLOID | 35 | <i>tencon</i> | <i>tizanidine</i> | 217, 218 |
| TABRECTA | 35 | TENIVAC (PF) | TOBI PODHALER | 11 |
| <i>tacrolimus</i> | 122, 196 | <i>tenofovir disoproxil fumarate</i> | <i>tobramycin</i> | 11, 175 |
| <i>tadalafil</i> | 219 | TEPMETKO | <i>tobramycin in 0.225 % nacl</i> | 11 |
| TAFINLAR | 35 | <i>terazosin</i> | <i>tobramycin sulfate</i> | 11 |
| <i>tafluprost (pf)</i> | 210 | <i>terbinafine hcl</i> | <i>tobramycin-dexamethasone</i> | 175 |
| TAGRISSO | 35 | <i>terbutaline</i> | <i>tolterodine</i> | 182 |
| TAKHZYRO | 208 | <i>terconazole</i> | <i>tolvaptan (polycys kidney dis)</i> | 96 |
| TALVEY | 36 | <i>teriflunomide</i> | TOPCARE CLICKFINE | 158 |
| TALZENNA | 36 | <i>teriparatide</i> | TOPCARE ULTRA | |
| <i>tamoxifen</i> | 36 | TERUMO INSULIN | COMFORT | 159 |
| <i>tamsulosin</i> | 183 | SYRINGE | <i>topiramate</i> | 45 |
| <i>tarina 24 fe</i> | 114 | <i>testosterone</i> | <i>toposar</i> | 36 |
| <i>tarina fe 1-20 eq (28)</i> | 114 | <i>testosterone cypionate</i> | <i>toremifene</i> | 36 |
| <i>taron-c dha</i> | 221 | <i>testosterone enanthate</i> | <i>torpenz</i> | 37 |
| <i>taron-prex prenatal-dha</i> | 221 | TETANUS,DIPHTHERIA | <i>torsemide</i> | 96 |
| TASIGNA | 36 | TOX PED(PF) | TOUJEO MAX U-300 | |
| <i>tasimelteon</i> | 218 | <i>tetrabenazine</i> | SOLOSTAR | 56 |
| TAVALISSE | 85 | <i>tetracycline</i> | TOUJEO SOLOSTAR U-300 | |
| TAVNEOS | 196 | TEVIMBRA | INSULIN | 56 |
| <i>taysofy</i> | 115 | THALOMID | TRADJENTA | 53 |
| <i>tazarotene</i> | 122 | <i>theophylline</i> | <i>tramadol</i> | 6 |
| <i>tazicef</i> | 14 | THINPRO INSULIN | <i>tramadol-acetaminophen</i> | 6 |
| <i>taztia xt</i> | 93 | SYRINGE | <i>trandolapril</i> | 90 |
| TAZVERIK | 36 | <i>thioridazine</i> | <i>trandolapril-verapamil</i> | 90 |
| TDVAX | 202 | <i>thiothixene</i> | <i>tranexamic acid</i> | 85 |
| TECENTRIQ | 36 | <i>tiadylt er</i> | <i>tranylcypromine</i> | 50 |
| TECENTRIQ HYBREZA | 36 | <i>tiagabine</i> | TRAVASOL 10 % | 87 |

| | | | | | |
|---------------------------------------|---------------|--------------------------------|----------|-------------------------------|-------------------------|
| <i>travoprost</i> | 210 | <i>tri-sprintec</i> (28) | 115 | ULTICARE | 162, 163 |
| TRAZIMERA | 37 | TRIUMEQ | 79 | ULTICARE INSULIN | |
| <i>trazodone</i> | 50 | TRIUMEQ PD | 79 | SYRINGE | 162 |
| TRECATOR | 62 | <i>triveen-duo dha</i> | 221 | ULTICARE INSULN | |
| TRELEGY ELLIPTA | 215 | <i>trivora</i> (28) | 115 | SYR(HALF UNIT) | 162 |
| TRELSTAR | 37 | <i>tri-vylibra</i> | 115 | ULTICARE PEN NEEDLE | 162 |
| TREMFYA | 196, 197 | <i>tri-vylibra lo</i> | 115 | ULTICARE SAFETY PEN | |
| TREMFYA PEN | 197 | TRIZIVIR | 79 | NEEDLE | 162, 163 |
| TREMFYA PEN INDUCTION | | TROGARZO | 79 | ULTIGUARD SAFEPACK- | |
| PK-CROHN | 196 | TROPHAMINE 10 % | 87 | INSULIN SYR | 163, 164 |
| <i>treprostinil sodium</i> | 219 | <i>trospium</i> | 182 | ULTIGUARD SAFEPACK- | |
| TRESIBA FLEXTOUCH U-100 | 56 | TRUE COMFORT ALCOHOL PADS | 159 | PEN NEEDLE | 163, 164 |
| TRESIBA FLEXTOUCH U-200 | 56 | TRUE COMFORT INSULIN SYRINGE | 159 | ULTILET ALCOHOL SWAB | 164 |
| TRESIBA U-100 INSULIN | 56 | TRUE COMFORT PEN NEEDLE | 159, 160 | ULTILET INSULIN SYRINGE | |
| <i>tretinooin</i> | 122, 123 | TRUE COMFORT PRO ALCOHOL PADS | 160 | | 144, 164 |
| <i>tretinooin (antineoplastic)</i> | 37 | TRUE COMFORT PRO INS SYRINGE | 159, 160 | ULTILET PEN NEEDLE | 164 |
| <i>tri-femynor</i> | 115 | TRUE COMFORT SAFE INSULIN SYRG | 159, 160 | ULTRA CMFT INS SYR | |
| <i>triamcinolone acetonide</i> | | TRUE COMFORT SAFETY PEN NEEDLE | 159 | (HALF UNIT) | 141, 154 |
| | 117, 122, 187 | TRUEPLUS INSULIN | 161 | ULTRA COMFORT INSULIN SYRINGE | 136, 141, 142, 164, 165 |
| <i>triamterene-hydrochlorothiazid</i> | 96 | TRUEPLUS PEN NEEDLE | 161 | ULTRA FLO INSUL | |
| <i>triazolam</i> | 11 | TRULICITY | 53 | SYR(HALF UNIT) | 165 |
| <i>trientine</i> | 183 | TRUMENBA | 203 | ULTRA FLO INSULIN | |
| <i>tri-estarrylla</i> | 115 | TRUQAP | 37 | SYRINGE | 165 |
| <i>trifluoperazine</i> | 73 | TRUXIMA | 37 | ULTRA FLO PEN NEEDLE | 165 |
| <i>trifluridine</i> | 176 | TUKYSA | 37 | ULTRA THIN PEN NEEDLE | 165 |
| <i>trihexyphenidyl</i> | 67 | TURALIO | 37 | ULTRACARE INSULIN | |
| TRIJARDY XR | 53 | <i>turqoz</i> (28) | 115 | SYRINGE | 165, 166 |
| TRIKAFTA | 217 | TWINRIX (PF) | 203 | ULTRACARE PEN NEEDLE | 166 |
| <i>tri-legest fe</i> | 115 | TYBOST | 208 | ULTRA-FINE INS SYR | |
| <i>tri-linyah</i> | 115 | TYENNE | 197 | (HALF UNIT) | 166, 167 |
| <i>tri-lo-estarrylla</i> | 115 | TYENNE AUTOINJECTOR | 197 | ULTRA-FINE INSULIN | |
| <i>tri-lo-marzia</i> | 115 | TYMLOS | 206 | SYRINGE | 166, 167 |
| <i>tri-lo-mili</i> | 115 | TYPHIM VI | 203 | ULTRA-FINE PEN NEEDLE | 167 |
| <i>tri-lo-sprintec</i> | 115 | TYVASO | 219 | ULTRA-THIN II (SHORT) | |
| <i>trimethoprim</i> | 12 | UBRELVY | 62 | INS SYR | 167, 168 |
| <i>tri-mili</i> | 115 | | | ULTRA-THIN II (SHORT) | |
| <i>trimipramine</i> | 50 | | | PEN NDL | 168 |
| TRINTELLIX | 50 | | | ULTRA-THIN II INS PEN | |
| <i>tri-nymyo</i> | 115 | | | NEEDLES | 168 |
| <i>tri-previfem</i> (28) | 115 | | | ULTRA-THIN II INSULIN | |
| | | | | SYRINGE | 167, 168 |

| | | | | | |
|---|----------|--|----------|----------------------------|--------|
| UNIFINE OTC PEN NEEDLE | 168 | VENCLEXTA STARTING PACK | 38 | VIVIMUSTA | 38 |
| UNIFINE PEN NEEDLE..... | 168 | <i>venlafaxine</i> | 50 | VIVOTIF | 204 |
| UNIFINE PENTIPS..... | 150, 168 | <i>venlafaxine besylate</i> | 50 | VIZIMPRO | 38 |
| UNIFINE PENTIPS MAXFLOW..... | 168 | VEOZAH..... | 208 | VOCABRIA | 79 |
| UNIFINE PENTIPS PLUS | 168, 169 | <i>verapamil</i> | 93 | <i>volnea</i> (28)..... | 116 |
| UNIFINE PENTIPS PLUS MAXFLOW..... | 168 | VERIFINE INSULIN SYRINGE..... | 170, 171 | VONJO | 38 |
| UNIFINE PROTECT..... | 169 | VERIFINE PEN NEEDLE..... | 170 | VORANIGO | 38 |
| UNIFINE SAFECONTROL PEN NEEDLE..... | 169 | VERIFINE PLUS PEN NEEDLE..... | 170 | <i>voriconazole</i> | 59 |
| UNIFINE ULTRA PEN NEEDLE..... | 169, 170 | VERIFINE PLUS PEN NEEDLE-SHARP..... | 171 | VOSEVI | 81 |
| UPTRAVI..... | 219 | VERQUVO..... | 94 | VOWST | 208 |
| <i>ursodiol</i> | 180 | VERSACLOZ..... | 74 | <i>vp-ch-pnv</i> | 222 |
| UZEDY..... | 73, 74 | VERSALON..... | 171 | <i>vp-pnv-dha</i> | 222 |
| <i>valacyclovir</i> | 82 | VERZENIO..... | 38 | VRAYLAR | 74 |
| VALCHLOR..... | 118 | <i>vestura</i> (28)..... | 116 | VUMERTY | 105 |
| <i>valganciclovir</i> | 82 | V-GO 20..... | 171 | VYALEV | 67 |
| <i>valproate sodium</i> | 45 | V-GO 30..... | 171 | <i>vyfemla</i> (28)..... | 116 |
| <i>valproic acid</i> | 45 | V-GO 40..... | 171 | <i>vylibra</i> | 116 |
| <i>valproic acid (as sodium salt)</i> | 45 | vienna..... | 116 | VYLOY | 38 |
| <i>valsartan</i> | 89 | vigabatrin..... | 45 | VYZULTA | 210 |
| <i>valsartan-hydrochlorothiazide</i> | 89 | vigadrone..... | 45 | <i>warfarin</i> | 83 |
| VALTOCO..... | 45 | vigpoder..... | 45 | WEBCOL | 171 |
| <i>valtya</i> | 116 | vilazodone..... | 50 | WELIREG | 38 |
| <i>vancomycin</i> | 13 | VIMKUNYA..... | 203 | WINREVAIR | 217 |
| VANFLYTA..... | 37 | vinblastine..... | 38 | <i>wixela inhub</i> | 213 |
| VANISHPOINT INSULIN SYRINGE..... | 170 | <i>vincasar pfs</i> | 38 | XALKORI | 38, 39 |
| VANISHPOINT SYRINGE..... | 170 | <i>vincristine</i> | 38 | <i>xarah fe</i> | 116 |
| VAQTA (PF)..... | 203 | vinorelbine..... | 38 | XARELTO | 83 |
| <i>varenicline tartrate</i> | 9 | <i>viorele</i> (28)..... | 116 | XARELTO DVT-PE TREAT | |
| VARIVAX (PF)..... | 203 | VIRACEPT..... | 79 | 30D START | 83 |
| VAXCHORA VACCINE..... | 203 | VIREAD..... | 79 | XATMEP | 39 |
| VEGZELMA..... | 37 | <i>virt-c dha</i> | 221 | XCOPRI | 46 |
| <i>velivet triphasic regimen</i> (28).... | 116 | <i>virt-nate dha</i> | 221 | XCOPRI MAINTENANCE PACK | 46 |
| VELTASSA..... | 181 | <i>virt-pn dha</i> | 222 | XCOPRI TITRATION PACK | 46 |
| VEMLIDY..... | 79 | <i>virt-pn plus</i> | 222 | XDEMVY | 176 |
| VENCLEXTA..... | 37 | <i>vitafol gummies</i> | 222 | XELJANZ | 197 |
| | | <i>vitafol nano</i> | 222 | XELJANZ XR | 197 |
| | | <i>vitafol-ob+dha</i> | 222 | XERMELO | 181 |
| | | VITRAKVI..... | 38 | XGEVA | 206 |
| | | | | XIFAXAN | 13 |
| | | | | XIGDUO XR | 53 |
| | | | | XIIDRA | 177 |

| | | | |
|-----------------------------|--------|-------------------------|--------|
| XOLAIR | 217 | <i>zolpidem</i> | 218 |
| XOSPATA | 39 | ZONISADE | 46 |
| XPOVIO | 39 | <i>zonisamide</i> | 46 |
| XTANDI | 39 | <i>zovia 1/35e (28)</i> | 116 |
| <i>xulane</i> | 116 | <i>zovia 1-35 (28)</i> | 116 |
| XULTOPHY 100/3.6 | 56 | ZTALMY | 46 |
| XYOSTED | 184 | ZTLIDO | 8 |
| <i>yargesa</i> | 172 | <i>zumandimine (28)</i> | 116 |
| YERVOY | 39 | ZURZUVAE | 50, 51 |
| YESINTEK | 197 | ZYDELIG | 40 |
| YF-VAX (PF) | 204 | ZYKADIA | 40 |
| YONSA | 39 | ZYLET | 176 |
| YUFLYMA(CF) | 198 | ZYMFENTRA | 208 |
| YUFLYMA(CF) AI CROHN'S- | | ZYNLONTA | 40 |
| UC-HS | 197 | ZYNYZ | 40 |
| YUFLYMA(CF) AUTOINJECTOR | 198 | ZYPREXA RELPREVV | 74 |
| <i>yuvafem</i> | 186 | | |
| <i>zafemy</i> | 116 | | |
| <i>zafirlukast</i> | 213 | | |
| <i>zaleplon</i> | 218 | | |
| ZARXIO | 85 | | |
| <i>zatean-pn dha</i> | 222 | | |
| <i>zatean-pn plus</i> | 222 | | |
| <i>zebutal</i> | 6 | | |
| ZEGALOGUE | | | |
| AUTOINJECTOR | 208 | | |
| ZEGALOGUE SYRINGE | 208 | | |
| ZEJULA | 39 | | |
| ZELBORAF | 40 | | |
| <i>zenatane</i> | 118 | | |
| ZENPEP | 172 | | |
| <i>zidovudine</i> | 79, 80 | | |
| ZIIHERA | 40 | | |
| <i>zingiber</i> | 222 | | |
| <i>ziprasidone hcl</i> | 74 | | |
| <i>ziprasidone mesylate</i> | 74 | | |
| ZIRABEV | 40 | | |
| ZIRGAN | 176 | | |
| ZOLADEX | 40 | | |
| ZOLINZA | 40 | | |
| <i>zolmitriptan</i> | 62 | | |



GOLD KIDNEY HEALTH PLAN

P.O. Box 285, Portsmouth, NH 03802

www.goldkidney.com



This formulary was updated on 10/01/2025. For more recent information or other questions, please contact Gold Kidney Health Plan Member Services at **1 (844) 294-6535 (TTY users should call 711)**. Our office hours are 8 a.m. to 8 p.m., local time, 7 days a week from October 1 – March 31 (except holidays), and 8 a.m. to 8 p.m., local time, Monday through Friday, April 1 – September 30 (except holidays), or visit www.goldkidney.com.

Gold Kidney Health Plan, Inc., is an HMO-POS and HMO-POS C-SNP with a Medicare contract. Enrollment in Gold Kidney Health Plan depends on contract renewal.